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Abstract
Gene expression is controlled by transcription factors that regulate the rates at which 
genes are expressed either by recruiting or inhibiting protein complexes that bind to the 
promoters or enhancers of target genes. Molecules that can specifically modulate these 
protein-DNA interfaces show promise as tools for understanding gene regulation pathways 
and may have application in human medicine. Hairpin pyrrole-imidazole polyamides 
are programmable oligomers that bind the DNA minor groove in a sequence-specific 
manner with affinities comparable to those of natural DNA-binding proteins. These 
cell-permeable small molecules have been shown to enter the nuclei of live cells, disrupt 
protein-DNA interactions, and downregulate endogenous gene expression. This thesis 
describes the use of polyamides to modulate gene expression in order to probe gene 
regulation mechanisms of several different biologically relevant systems. A polyamide 
is designed to target the glucocorticoid receptor transcription factor DNA binding site 
located in the promoter of the glucocorticoid-induced leucine zipper gene. This polyamide 
is shown to bind with high affinity to the promoter sequence, modulate the expression of 
this gene, and disrupt the binding of the protein to the gene’s promoter. Examination of 
the global effects of this polyamide on mRNA transcription is used to elucidate a list of 
genes that are regulated by a glucocorticoid receptor protein-DNA dependent mechanism. 
Also in this thesis, the specificities of a Cy3-labeled polyamide known to downregulate 
expression of the Vascular Endothelial Growth Factor is examined using DNA microarrays 
composed of hairpins harboring all 524,800 unique 10 base pair DNA sequences. We 
experimentally verify the correlation of Cy3 fluorescence intensity with quantitative 
DNase I footprint-derived binding affinities. Additionally, progress is made towards the 
polyamide-mediated inhibition of Myc/Max transcription factor gene regulation. 
viii
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1.1 Gene expression and the central dogma 
In 1958 the means by which life as we know it persists and thrives was enumerated 
in the form of the central dogma of molecular biology.1 In its simplest form, the dogma 
states that each living cell holds the blueprint to life in the form of genes, and that this 
genomic information is transcribed from DNA to RNA, which is then translated into 
proteins. Over half a century later, innumerable advances in technology have expanded 
this simple view to include a host of mechanisms by which each step of this process is 
influenced and modulated in response to cellular needs. The genome is not a blueprint 
of a static cellular state but actually encompasses all the instructions needed for a cell to 
respond to environmental stimuli. Sequencing of the human genome estimates that humans 
possess 20,000 to 30,000 genes,2,3 all of which are maintained folded within chromosome 
structures and are accessed as needed by the cell to maintain normal function. Information 
encoding the structure, regulation, and expression of each of these genes as well as their 
expressed products is encoded in the nucleotide sequences of the base pairs of the DNA 
molecules that make up the genome. 
Gene expression is the process by which a gene’s coded information is converted from 
these nucleotide sequences into functioning gene products. This process is used by all 
known life forms to generate the RNAs, proteins, and various macromolecular machineries 
needed for life. In eukaryotic cells, gene expression is a complex process involving a variety 
of steps prior to the actual synthesis of a protein. These include the transcription of the gene 
into the primary RNA product, processing of this initial gene transcript to remove intron 
sequences and create the mature 3’ terminus, transport of the processed mRNA transcript to 
the cytoplasm, and then, finally, translation of the messenger RNA into protein. With very 
few exceptions, all of the genes that encode proteins follow this pathway.4
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1.2 Regulation of gene expression: transcriptional modulation
Any step of the gene expression process is subject to modulation, from the transcription 
of DNA into RNA all the way through the post-translational modification of the final 
protein.  Every cell in any given organism contains the exact same genes, yet the multitude 
of cell types in a human body each display a different phenotype, produce different 
proteins at different stages of the life cycle, and somehow display different programs of 
gene expression. At the most fundamental level, regulation of gene expression is what 
allows genotype to be converted into phenotype. Modulation of the amount and timing of 
the appearance of the final gene product allows the cell to maintain control over structure 
and function and provides the basis for the versatility and adaptability of a living organism. 
A cell’s ability to regulate and control the expression of each gene product allows the cell the 
flexibility to respond to environmental stimuli such as chemical signaling, environmental 
variation, cell damage, etc. 
Regulation at the transcriptional level is a key element in the regulation of gene 
expression and can be divided into three general categories of influence: 1) Regulation at 
the genetic level involves direct interaction of a control factor with the gene in question, 
2) Regulation via interaction of a control factor with the transcription machinery that results 
in modulation of gene expression, and 3) Epigenetic regulation involving global alterations 
in DNA structure that influence transcription. Direct interaction with DNA is the simplest 
and most direct method by which a protein can modulate the level of gene transcription. In 
general, genes harbor several protein binding sites specifically utilized for the regulation 
of transcription. These protein binding sites include enhancers, insulators, repressors, and 
silencers and the mechanisms for regulating transcription through these binding sites are 
complex and vary from activating transcription by recruiting RNA polymerase to blocking 
key RNA polymerase binding sites to hinder gene transcription. 
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Transcription Factors
Transcription factor proteins constitute a major class of DNA-binding molecules that 
participate in the transcriptional control of gene expression. Transcription factors bind to 
DNA in gene promoters or enhancer regions, generally upstream of the transcription start 
site, and modulate the frequency of RNA polymerase binding to the gene and subsequent 
transcription. Transcription factors vary widely in architecture, as the small sample of 
transcription factors shown in Figure 1.1 illustrates. While different transcription factors 
accomplish their tasks via different means, all transcription factors display two critical 
abilities—the ability to bind to DNA in a sequence-specific manner, and the ability to cause 
a modulation of transcription once bound.4 Most transcription factors possess a specific 
DNA-binding domain that is responsible for recognition and interaction with a specific 
DNA sequence, typically four to eight nucleotides in length, often located in an enhancer 
or promoter region of a given gene.
Myc/Max Glucocorticoid 
Receptor
NF-κB p50/p65
Lef-1 Oct4/Sox2TBP
Figure 1.1 X-ray crystal structures of transcription factor–DNA complexes
Myc/Max (PDB 1NKP),5 Glucocorticoid Receptor (PDB 1R40),6 NF-κB (PDB 1LE5),7 Lef-1 (PDB 2LEF),8 
TBP (PDB 1TGH),9 Oct4/Sox2 (PDB 1O4X).10
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1.3 Molecular recognition of DNA 
Deoxyribonucleic acid (DNA):
A single strand of DNA consists of four different bases linked by a phosphodiester 
deoxyribose sugar backbone. Two strands of DNA intertwine to form a double helix 
associated by hydrogen bonds between the Watson-Crick base pairs such that thymine (T) 
pairs with adenine (A), and cytosine (C) pairs with guanine (G) (Figure 1.2). In a DNA 
double helix the direction of the nucleotides in one strand is opposite to their direction in 
the other strand, thus the strands are antiparallel.  The helix of B-form DNA, the average 
conformation adopted by the majority of biologically active DNA sequences, is right handed 
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Figure 1.2 The structure of DNA
Left) X-ray crystal structure of B-form DNA. The phosphodiester-linked deoxyribose backbone is 
shown in blue, and the Watson-Crick base pairs are shown in gray (PDB 1BNA).11 Highlighted: 
adenine (red) thymine (blue) cytosine (magenta) and guanine (green). Right) Chemical structures of 
phosphodiester-linked hydrogen-bonded base pairs. Adenine (A) is bonded to thymine (T) and cytosine (C) is 
bonded to guanine (G) Dashed lines indicate hydrogen bonds. 
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and displays ten base pairs per turn with the plane of each hydrogen-bonded base pair 
lying perpendicular to the helical axis. This helix is not symmetrical, instead a wide major 
groove and a narrow minor groove line the helix and DNA sequences can be distinguished 
by the pattern of functional groups, e.g., hydrogen bond donors and acceptors, displayed 
on the edges of the base pairs in either groove.
Sequence-specific recognition of DNA:
Proteins and small molecules can recognize B-form DNA through interactions with the 
major groove, minor groove, and phosphate backbone, or a combination of these elements. 
These interactions can be mediated through electrostatics, hydrogen bonding, van der 
Waals interactions, and, in the case of intercalators, via base pair stacking. The DNA base 
pair edges in the major groove and minor groove provide a sequence-specific array of 
functionality for hydrogen bonding, hydrophobic interactions, and steric complementarity 
with proteins and small molecule binders.12-16 It is these patterns of hydrogen donors and 
acceptors that allow for sequence-specific recognition of DNA by proteins and small 
Figure 1.3 Major and minor groove hydrogen bonding patterns of the four Watson-Crick base pairs
Circles with dots represent lone pairs on purine N3 or pyrimidine O2, and circles with an H represent the 
2-aminogroup of guanine (G-NH2). A)Major and minor groove hydrogen bonding patterns of each base pair 
B) Hydrogen bonding pattern offered to the major groove by the sequence 5’-GTAC-3’. C)Hydrogen bonding 
pattern offered to the minor groove by the sequence 5’-GTAC-3’
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molecules that can form hydrogen bonds with the functional groups present in the grooves. 
In a formal sense, the four Watson-Crick base pairs can be differentiated on the groove 
floor by the specific positions of hydrogen bond donors and acceptors, as well as by subtle 
differences in molecular shape. Figure 1.3 depicts the differences in these hydrogen bond 
donors and acceptors as seen on the floor of each groove.
1.4 Sequence-specific DNA-binding small molecules
In addition to DNA-binding proteins such as the transcription factors described 
above, there are also small molecule natural products that recognize and bind specific 
DNA sequences. Four particular examples are shown in Figure 1.4: calicheamicin 
oligosaccharide, chromomycin, actinomycin D, and distamycin A. Calicheamicin 
oligosaccharide has been shown to recognize and bind the minor groove monomerically 
at 5’-TCCT-3’ sequences.17 Chromomycin targets the sequence 5’-GGCC-3’ and binds in 
the minor groove of DNA in a 2:1 ligand:DNA stoichiometry. Chromomycin’s biological 
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Figure 1.4 Chemical structures of DNA-binding small molecule natural products
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activity has been attributed to interference of replication and transcription.18 Actinomycin D 
intercalates DNA preferentially at 5’-GC-3’ sequences in a 1:1 ligand:DNA stoichiometry. 
Actinomycin D is known to inhibit transcription and potentially DNA replication 
and has been used as a chemotherapeutic as well.19,20 Distamycin A is an A,T-binding 
oligopeptide of three N-methylpyrrole (Py) carboxamide units. As can be seen in 
Figure 1.5, X-ray and NMR structural studies of Distamycin A reveal that this 
crescent-shaped molecule can bind DNA in either a 1:1 or 2:1 stoichiometry relative to 
DNA. The 2:1 complex forms in an antiparallel orientation and results in expansion of the 
minor groove relative to the 1:1 ligand-DNA complex.21-23
A B
Figure 1.5 X-ray crystal structures of distamycin bound to DNA
 
A) Distamycin bound with a 1:1 ligand:DNA stoichiometry to the sequence 5’-CGCAAATTGCG’ 
(PBD 2DND) B) Distamycin bound with a 2:1 stoichiometry to the sequence 5’GTATATAC-3’(PDB 378D) 
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The simple A,T binding natural product distamycin A has evolved over the past 
two decades into a new class of programmable heterocyclic oligomers that demonstrate 
high affinity and sequence specificity for the DNA minor groove.12,13 Incorporation of 
alternative heterocycles such as imidazole (Im) or hydroxypyrrole (Hp) expanded the 
sequence-recognition capabilities of polyamides and a set of pairing rules has been 
developed to allow for the programmable targeting of desired DNA sequences. 
Sequence-specific recognition of the minor groove of DNA by polyamides arises from 
the pairing of three different aromatic amino acids, pyrrole (Py), imidazole (Im), and 
hydroxypyrrole (Hp).24-26 The targeted binding surface of a crescent-shaped polyamide 
may be programmed by the incremental change of atoms on the corners of the ring pairs 
presented to the DNA minor groove floor. Stabilizing and, importantly, destabilizing 
interactions with the different edges of the four Watson-Crick bases are modulated by shape 
complementarity and specific hydrogen bonds.27-29 An Im/Py pair distinguishes G•C from 
C•G, T•A, and A•T, and likewise a Py/Im pair distinguishes C•G from G•C, T•A, and A•T. 
Im presents a lone pair of electrons to the DNA minor groove and can accept a hydrogen 
bond from the exocyclic amine of guanine.5 Additionally, the Hp/Py pair distinguishes T•A 
from A•T, G•C, and C•G.4–6 Hp projects an exocyclic OH group toward the minor groove 
floor that is sterically accommodated in the cleft of the T•A base pair, preferring to lie over 
T not A.25 
As can be seen in Figure 1.6, in addition to developing the pairing rules, another key 
step of the evolution of Im/Py polyamides is the covalent linkage of the two antiparallel 
heterocyclic strands by a gamma amino butyric acid (GABA) unit, forming a “hairpin” 
polyamide, demonstrating a 100-3600-fold increase in affinity relative to to the unlinked 
homodimeric motif.30,31 Additionally, the incorporation of the turn linkage in the form of a 
GABA or substituted GABA turn allows the incorporation of unsymmetrical ring pairs for 
the targeting of non-palindromic DNA sequences.32  
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1.5 Polyamide inhibition of gene regulation in live cell culture
Given the fact that transcription is the key first step in gene expression, and the fact 
that the binding of trans-acting factors to promoter elements is critical for transcription, 
a key route to regulating gene expression lies in controlling the activity of these 
trans-acting factors. The programmability of Py-Im polyamides combined with the 
subnanomolar increases in affinity achieved by linking the two oligomeric strands 
provides polyamides with affinity competing with and often rivaling that of endogenous 
DNA-binding proteins.12,13 By using Py-Im polyamides to displace or prevent the binding of 
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Figure 1.6 Recognition of the DNA minor groove by polyamides
A)Schematic illustration of the polyamide ImHpPyPy-γ-ImHpPyPy-β-Dp binding its target sequence, 
5’-AGTACT-3’. Putative hydrogen bonds are shown as dashed lines. Hairpin turn and tail moieties, as 
indicated in illustration, tolerate T•A and A•T base pairs. B) A ball-and-stick representation of the polyamide 
shown in a. c) ball-and-stick symbols as well as abbreviations are listed below the chemical structures. This 
nomenclature will be used throughout this dissertation.
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transcription factors to their respective promoter DNA sequences, it is possible to modulate the 
expression of particular genes. Critical to this goal is the ability of polyamides to enter a live 
cell and permeate the nucleus in order to bind DNA and successfully regulate gene expression. 
Confocal microscopy studies have confirmed the positive nuclear uptake profiles of a variety of 
polyamide-fluorophore conjugates in a panel of cell lines.33,34 Additionally, the presence of an 
isophthalic acid (IPA) moiety in the tail region has been shown to yield high-affinity conjugates 
with improved nuclear permeability.35 
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Figure 1.7 Polyamides as regulators of gene expression in cell culture
A) Schematic diagram of the VEGF promoter showing inhibition of HRE binding by HIF-1 (shown as 
HIF-1α/HIF-1β heterodimer), binding sequence of the HRE enhancer shown with match polyamide 
1, and chemical structures and ball-and-stick models of match polyamide 1 and mismatch polyamide 2. 
B) Schematic diagram of the androgen receptor transcription complex, binding sequence of the consensus 
ARE targeted by match polyamide 3, and chemical structures and ball-and-stick models of match polyamide 
3 and mismatch polyamide 4.
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The culmination of the technological advances in this field has resulted in high affinity, 
sequence-specific, cell-permeable Py-Im hairpin polyamides that have successfully 
been utilized in several instances to modulate gene expression in cell culture. In a 
seminal example, a polyamide designed to bind to the hypoxia response element (HRE) 
was shown to disrupt the binding of hypoxia-inducible factor (HIF) to the HRE. Polyamide 
treatment was shown to decrease the transcription of vascular endothelial growth factor 
(VEGF) in cultured HeLa cells.35,36  In another example, a polyamide designed to target the 
androgen response element (ARE) has been shown to downregulate prostate-specific antigen 
(PSA) and other androgen responsive genes in prostate cancer cells.37
The hypoxia inducible factor 1α (HIF-1α) transcription factor drives the expression 
of many genes in response to a low oxygen environment. HIF-1α recognizes and binds 
a consensus sequence 5’-TACGTG-3’ termed the Hypoxic Response Element (HRE). 
Polyamide 1 (Figure 1.7A) targets a subset of known HREs. One particular gene whose 
modulation is particularly interesting is vascular endothelial growth factor (VEGF), a gene 
responsible for the vascularization of tumors.  When HeLa and U251 cells were treated with 
micromolar concentrations of polyamide 1, a reduction in the deferoxamine (DFO) induction 
of VEGF gene was noted, while dosing with a non-HRE binding polyamide 2 did not produce 
a statistically significant change in gene expression. On a global scale, microarray experiments 
have shown that polyamide 1 downregulates a subset of genes upregulated by DFO induction. 
Furthermore, chromatin immunoprecipitation (ChIP) experiments demonstrated a reduced 
occupancy of HIF-1α at the VEGF HRE in the presence of polyamide 1. 35,36,38 
The androgen receptor (AR) transcription factor binds as a homodimer to the androgen 
response element (ARE), 5’-GGTACAnnnTGTTCT-3’, in response to induction by steroid 
hormones such as testosterone. AR-regulated gene expression is critical in the development and 
progression of prostate cancer. One key AR-regulated gene is prostate specific antigen (PSA), 
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a well-studied marker gene that correlates highly with the presence of prostate cancer. LnCap 
(prostate cancer) cells treated with a Py-Im hairpin polyamide 3 (Figure 1.7B) targeted to 
the consensus ARE half-site 5’-WGWWCW-3’ demonstrate a suppressed dihydrotestosterone 
(DHT) induction of PSA mRNA transcription. This gene regulation modulation is not seen 
with treatment by a mismatch control polyamide targeting 5’-WGWCGW-3’. Microarray 
experiments assessing the global mRNA transcription in LnCap cells when treated with 3 
and 4 indicate that 3 is able to disrupt induction by DHT for a subset of the DHT induced 
genes in a manner that is differential from treatment by 4 and likely is sequence-specific. ChIP 
experiments on 3 and 4 again suggest the disruption of a protein-DNA interface as a potential 
mechanism for polyamide activity.37
1.6 An allosteric model for polyamide inhibition of steroid hormone receptors
Allosteric modulation of protein-DNA interactions
Both HIF-1α and AR are major groove-binding proteins, yet minor groove-binding 
Py-Im polyamides are able to successfully disrupt protein DNA-binding and alter the 
gene regulation of the given transcription factor. A likely model for this inhibition is that 
allosteric modulation of the DNA occurs upon polyamide binding that renders the major 
groove of the DNA no longer capable of binding the transcription factor.39,40 The process 
of promoter recognition and utilization involves a stepwise interaction of a complex 
series of transcription factors with the promoter to create a stable DNA-protein complex 
that allows RNA polymerase to initiate transcription. There are as many as 100,000 
protein-encoding genes in the mammalian genome, and rather than generate a unique 
transcription factor to regulate each gene, nature appears to have developed a limited 
number of transcription factors responsible for DNA recognition and that the high degree of 
specificity demonstrated is generated by specific protein-protein interactions that stabilize 
otherwise weak interactions on a promoter. Protein-DNA interactions are generally fairly 
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weak and will readily dissociate.41 The capacity to stabilize this otherwise weak interaction 
is likely a critical aspect of transcription control in which multiple factors must interact on 
the DNA to stabilize a functional complex.4
Transcription factors often posess domain that is critical for mediation of 
protein-protein interactions with other components of the transcriptional machinery. 
In addition, transcription factors are also known to communicate indirectly through allosteric 
modulation of DNA resulting in cooperative assembly with very little direct protein-protein 
interaction. In this model, the sequence-specific binding of a transcription factor induces 
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Figure 1.8 Atomic model of the cooperative assembly of interferon-β enhancesome
A composite model of allosterically driven protein–DNA recognition created from overlayed X-ray crystal 
structures (PDB 2O6G, 2O61) showing 4-6 base pair transcription factor binding sites along the highly 
conserved composite DNA interface of 55 base pairs spanning approximately 160 Å in length.
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perturbations in the DNA that modulate the binding of the next transcription factor. An 
elegant example of allosterically modulated protein–DNA specificity on a gene enhancer 
is the interferon-beta enhanceosome (Figure 1.8). In this protein complex, eight different 
transcription factors (ATF-2/c-Jun, IRF-3A, IRF-7B, IRF-3C, IRF-7D, p50, and RelA) 
cooperatively assemble on the enhancer, yet there are no protein-protein contacts between any 
of the proteins on this DNA sequence. Thus, it has been proposed that structural alterations 
to the DNA, such as widening or narrowing of the major or minor groove by individual 
protein–DNA interactions, create optimum binding shape and structure for other proteins, 
in a cooperative interaction.42 Each transcription factor binds four to eight base pairs 
and inhibition of the binding of any one of the proteins may result in interruption of the 
transcriptional activation activity of the protein complex as a whole.
Allosteric modulation of DNA by Py-Im polyamides
A recent high-resolution X-ray crystal structure of a β-amino turn-linked 
eight-ring cyclic Py-Im polyamide bound to the central six base pairs of the steroid hormone 
receptor consensus sequence reveals that significant modulation of DNA shape occurs 
upon polyamide binding. Cyclic polyamide 5, comprised of two antiparallel ImPyPyPy 
strands capped by (R)-β-amino-γ turn units codes for the sequence 5′-WGWWCW-3’. 
The high-resolution crystal structure of the polyamide in complex with the 
10 base pair DNA oligonucleotide sequence 5′-CCAGTACTGG-3′, containing an 
ARE/GRE consensus DNA sequence demonstrates that structural alterations of DNA by 
these major groove-binding proteins and minor groove-binding cyclic polyamides operate 
in opposite directions.40 
Binding of cyclic polyamide 5 induces significant (>4 Å) widening of the DNA 
minor groove and compression of the major groove by more than 4 Å as compared to 
unliganded DNA (Figure 1.9 C, D).43 Additionally, polyamide binding induces bending of 
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Figure 1.9 Comparison of native DNA to polyamide/DNA complex
A) chemical structure of cyclic polyamide 5 which targets 5’WGWWCW-3’ B) ball-and-stick model 
superimposed over the binding site on the dsDNA oligonucleotide sequence used for crystallization.C) Native 
DNA crystal structure at 0.98 Å resolution (PDB 1D8G) D) DNA/polyamide co-crystal structure at 0.95 Å 
resolution. (PDB 3OMJ) E) Significant DNA bending is observed for polyamide-bound DNA (blue) versus 
unbound DNA (yellow). F) top: Comparison of the minor-groove width for DNA in the absence of polyamide 
(yellow) and in the presence of bound polyamide (blue). bottom: Comparison of the major-groove width 
for DNA in the absence of polyamide (yellow) and in the presence of bound polyamide (blue). In E and F, 
polyamide has been removed from the blue complex for clarity.39,40
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the DNA helix by >15° towards the major groove, resulting in major groove compression 
(Figure 1.9E). A slice through the short axis of the DNA helix, showing the minor and 
major groove geometry at the center of the polyamide binding site for uncomplexed and 
complexed DNA shows this distortion clearly (Figure 1.9F).40 
Ultimately, the perturbation in the major-groove geometry that occurs upon polyamide 
binding converts the wide, shallow surface of the major groove from a functionally exposed 
protein recognition domain to a narrow, deep cleft too small to accommodate the width of a 
standard protein α-helical domain or β-sheet from a transcription factor. A detailed analysis 
of the structure of DNA bound by the androgen receptor and the related glucocorticoid 
receptor reveals that the cyclic polyamide 5 is an allosteric modulator that perturbs the 
DNA structure in such a way that nuclear receptor protein binding is no longer compatible. 
This allosteric perturbation of the DNA helix provides a molecular basis for disruption of 
transcription factor−DNA interfaces by sequence-specific DNA binding polyamides.39,40
37
1.7 Scope of this work
The work presented in this thesis is focused on the further development of 
Py-Im polyamides as tools for understanding the mechanisms behind gene regulation. 
By perturbing gene regulation in endogenous systems we can begin to understand the 
molecular basis for the difference between normal gene function and those alterations 
in gene control events that underlie certain disease states. In Chapter 2, we utilize a 
Py-Im polyamide targeted to bind 5’-WGWWCW-3’ to probe the dual mechanism of 
transcriptional action displayed by the glucocorticoid receptor (GR) transcription factor. 
This sequence-specific small molecule probe is used to separate and identify a list of 
genes that are regulated by a protein-DNA interaction from those genes that are generally 
regulated by the GR in both DNA-binding-dependent and DNA-binding-independent 
mechanisms. In Chapter 3 we utilize polyamides to validate a new microarray-based tool 
for use in determining the DNA-sequence binding preferences of small molecules and 
proteins and in doing so examine the binding preferences of two polyamides that have 
been demonstrated to modulate gene expression in cell culture. The binding preferences 
for the polyamides assayed validate the polyamide pairing rules in an unbiased fashion. 
Chapter 4 presents progress towards divesting a group of genes regulated by the Myc-Max 
heterodimeric transcription factor. Our goal is to regulate genes bound at 5’-CACGTG-3’ 
Myc-Max heterodimer binding sites while leaving Max-Max homodimer binding sites 
unbound. We anticipate that this will modulate the expression of Myc-regulated genes 
without inducing a Myc-upregulation feedback loop. In this chapter, a library of small 
molecules is developed to target the binding site, demonstrate that they bind with high 
affinity and specificity to the targeted site, and have positive uptake properties in a variety 
of live cells. While modulation of gene expression was not demonstrated in these cell lines, 
work is ongoing to probe this system further.
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Repression of DNA-Binding-Dependent  
Glucocorticoid Receptor-Mediated Gene Expression
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The text of this chapter was taken in part from a manuscript co-authored with 
Nicholas G. Nickols and Peter B. Dervan (California Institute of Technology)
42
Abstract
The glucocorticoid receptor (GR) affects the transcription of genes involved in 
diverse processes including energy metabolism and the immune response through 
DNA-binding-dependent and -independent mechanisms. The DNA-binding-
dependent mechanism occurs by direct binding of GR to glucocorticoid response 
elements (GREs) at regulatory regions of target genes; the DNA-binding-independent 
mechanism involves binding of GR to transcription factors and co-activators that in turn 
contact DNA. A small molecule that competes with GR for binding to GREs could be 
expected to selectively affect the DNA-binding-dependent pathway by interfering with the 
protein–DNA interface. We show that a DNA-binding polyamide that targets the consensus 
GRE sequence binds the glucocorticoid induced zipper (GILZ) GRE, inhibits expression 
of GILZ and several other known GR target genes, and reduces GR occupancy at the GILZ 
promoter.  Genome-wide expression analysis of the effects of this polyamide on a set of 
glucocorticoid induced and repressed genes could help elucidate the mechanism of GR 
regulation for these genes.
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2.1 Introduction
Glucocorticoids are a major subclass of steroid hormones known to modulate a large 
number of metabolic, cardiovascular, immune, and behavioral functions and play diverse 
roles in growth, development, and maintenance of basal and stress-related homeostasis. 
Glucocorticoids exert a major influence on inflammatory processes and approximately 
20% of the genes expressed in human leukocytes are regulated positively or negatively by 
glucocorticoids.1  Glucocorticoids are among the most widely prescribed drugs worldwide, 
primarily used as anti-inflammatory and immunosuppressive agents.
Figure 2.1 Crystallographic structures of the glucocorticoid receptor
A)DNA binding domain bound to DNA (PDB 1R4O) with consensus DNA binding site depicted below. 
B) Ligand binding domain bound to dexamethasone (PDB 1M2Z) 
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 At the cellular level, the actions of glucocorticoids are mediated by a 94-kDa intracellular 
receptor protein, the glucocorticoid receptor (GR). The GR belongs to the superfamily of 
steroid/thyroid/retinoic acid receptor proteins that function as ligand-dependent 
transcription factors and binds with high affinity to glucocorticoids (GCs) such as cortisol 
44
and dexamethasone.  As a member of the same class of transcription factors, GR is 
structurally similar to the androgen and progesterone receptors, containing a zinc-finger 
motif DNA binding domain, a dimerization domain, and a ligand binding domain.2 In the 
absence of ligand, GR resides in the cytoplasm of cells as part of a complex of proteins 
including chaperon heat shock proteins (hsps) 90, 70, and 50. Hsp90 regulates ligand 
binding, as well as cytoplasmic retention of GR by exposing the ligand binding site and 
masking the  two nuclear localization sequences contained within the protein.3-5 Ligand 
binding releases GR from sequestration by cytoplasmic heat shock proteins5 and activates 
a series of cellular activities, which leads to nuclear localization and homodimerization 
(Figure 2.2). 
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GR GR
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Figure 2.2 Simplified model for the response of glucocorticoid receptor to steroid hormone stimulus
The glucocorticoid hormone, cortisol, passes through the plasma membrane into the cytoplasm where it 
binds to the specific, high-affinity glucocorticoid receptor (GR), releasing it from sequestration by heat shock 
proteins. The activated GR forms a homodimer and is translocated to the nucleus where the receptor complex 
binds to specific DNA-responsive elements to activate gene transcription.
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Like other steroid hormone receptors, GR is known to modulate gene transcription 
via the binding of receptor dimers to specific palindromic sequences called glucocorticoid 
response elements (GREs), usually located in the cis-regulatory region of target genes—
this mode of action is termed transactivation. Additionally, the GR has been shown to exert 
its actions through an indirect, non-DNA-binding mechanism, termed transrepression, in 
which transcriptional modulation is achieved through crosstalk between GR and other 
transcription factors such as nuclear factor-κB (NF-κB),6 activator protein-1 (AP-1),7,8 
Sma and Mad-related protein (Smad), and signal transduction and activator of transcription 
(STAT).9 This protein-protein cross talk does not require the DNA-binding activity of the 
GR, as GR mutants that are deficient in dimerization function have been shown to lose 
DNA binding ability as well as simple GRE-mediated transcription function but retain their 
transrepression activity.7,10 
Because many GR target genes are immune modulators, synthetic GR agonists such 
as dexamethasone are among the most effective anti-inflammatory drugs available for the 
treatment of a variety of chronic and acute inflammatory diseases. Unfortunately, because 
of the functions of other GR target genes, long term treatment with corticosteroids results 
in metabolic and behavioral derangements that can be treatment limiting. While the GR 
targets involved in inflammatory and immune regulation have not been comprehensively 
defined, there is a great deal of evidence suggesting that transrepression—that is, GR 
interaction with NF-kB and/or AP-1 and the subsequent suppression of their target genes—
is  the major mechanism by which glucocorticoids achieve their desired anti-inflamatory 
effect.8,11,12
An understanding of the mechanisms of GR activity on target genes has been explored 
using a variety of approaches including microarray analysis,13,14 ChIP-scanning,15 and 
modulation of GR activity using siRNA,16 genetic mutants,7  and ligands with modified 
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structures.17  However, these methods would not be expected to explicitly differentiate 
between the direct and indirect mechanisms of GR action.  A small molecule that competes 
with GR for binding to the consensus GRE could be expected to specifically disrupt 
GR-DNA binding and be used as a tool to identify GR target genes whose regulation 
mechanism depends on a direct protein–DNA interface.  This differentiation of 
mechanisms of GR target gene regulation could contribute to efforts to develop more 
specific GR modulators that retain immunosuppressant functions while minimizing side 
effects resulting from other GR targets.18 Py-Im polyamides have previously been used to 
modulate gene expression in cell culture via inhibition of the transcription factor–DNA 
interface of both  hypoxia inducible factor19,20 and androgen receptor21 to their respective 
DNA response elements. Because Py-Im polyamides can be selectively programmed to 
recognize the known DNA-binding sequence of the GR, interruption of the GR–DNA 
binding interaction by polyamides represents a unique opportunity to inhibit the 
DNA-binding-dependent activity of endogenous GR while leaving the 
protein–protein- mediated activity unaffected (Figure 2.3).
GR GR
TF
GR GR
GR GR
GR GR
TF
+
+
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+
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DNA-binding dependent transcriptional control
DNA-binding independent  transcriptional control
polyamide
polyamide
GRE
TFRE
GRE
TFRE
Figure 2.3 Effect of polyamide-DNA binding on GR gene regulation
Top: Direct mechanism is dependent upon GR-DNA binding at the GR response element (GRE). Bottom: 
Indirect mechanism is dependent upon GR binding to another protein, indicated here as a general transcription 
factor TF (with binding site TF response element TFRE). A sequence-specific polyamide designed to bind to 
the GRE but not to the TFRE would alter gene expression controlled by the DNA-binding-dependent but not 
the DNA-binding-independent mechanism.
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In this study we designed a polyamide targeted to the sequence 5’-WGWWCW-3’ 
(where W represents either a T•A or an A•T base pair), found in the consensus GRE, 
with the goal of disrupting GR-GRE binding (Figure 2.3A, polyamide 1). This 
polyamide binds the two known GREs found in the promoter of the well-characterized 
glucocorticoid-induced leucine zipper (GILZ) gene, inhibits expression of GILZ and 
17% of transcripts induced by dexamethasone in cultured alveolar epithelial cells (A549), 
and reduces GR occupancy at the GILZ promoter in vivo.  A “mismatch” polyamide that 
targets the sequence 5’-WGWCGW-3’ (Figure 2.3A, polyamide 2) is used as a control for 
non-GRE binding polyamide effects.  The subset of GR-regulated genes that are uniquely 
affected by the GRE-targeted polyamide may represent a set of genes that are regulated by 
GR through direct GR-GRE binding. 
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Figure 2.4  Polyamide design and GILZ promoter structure
A) Structure of match polyamide 1 designed to bind 5’-WGWWCW-3’ and mismatch control polyamide 2 
designed to bind 5’-WGWCGW-3’, where W represents a T•A or an A•T basepair. Ball-and-stick models of 
polyamides represent the structure shown, imidazole and pyrrole monomer units are represented by filled and 
open circles, respectively. The isophthalic acid tail moiety is represented by a hexagon. B) Representation of 
the GILZ promoter region with its two functional GRE sites indicated. C) Sequences of the two GILZ GREs 
shown with polyamide 1 bound to its target site.
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2.2 Results
I. Binding affinities of Py-Im polyamides to GRE1 and GRE2 of the GILZ promoter 
The proximal GILZ promoter contains two functional GREs15 
(GRE1: 5’-CCTGCActtTGTTCT-3’  and GRE2: 5’-AAACAccgTGTTCA-3’ spaced 22 
base pairs apart approximately 2500 base pairs upstream of the transcription start site 
(Figure 2.4 B,C). The DNA binding affinity of polyamides 1 and 2 on this sequence was 
measured by quantitative DNase I footprint titrations using a 5’ 32P-labeled PCR fragment 
of pGR_GILZ, which contains a 78 base pair sequence from the promoter encompassing 
both functional GILZ GREs (Figure 2.5). Polyamide 1 has Ka= 1.9 ± 0.8 x 1010 M-1 for 
the GRE1 consensus half-site 5’-TGTTCT-3’ and Ka= 8.8 ± 1.8 x 10
9 M-1 for the GRE2 
consensus half-site 5’-TGTTCA-3’. Binding of polyamide 2, which targets the sequence 
5’-WGWCGW-3’, to the GREs is not measurable by these methods (Ka ≤ 1 x 10
7 M-1). 
Binding of polyamide 2 with a Ka of 6.3 ± 0.4 x 109 M-1 is observed at the site 5’-TGTCTT-3’ 
located between the GREs. This is a single base pair mismatch site for polyamide 2, and 
thus 2 can be expected to demonstrate some binding to this site.22
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3’..ATC GGACGTGAAACAAGA CAGATGATGTGTACAGAATCAC GTTTGTGGCACAAGT CT..5'
1.9 ± 0.8 x 10 
10
M
-1
K             =aGRE1
K           =aGRE2 8.8 ± 1.8 x 10 
9
M
-1
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
10-12 10-11 10-10 10-9 10-8 10-7 10-6
G
R
E
2
G
R
E
1
1
1 2 3 4 5 6 7 8 9 10 11 12 13
In
ta
ct
G A D
N
as
e
1 
pM
10
0 
nM
G
R
E
2
G
R
E
1
2
1 2 3 4 5 6 7 8 9 10 11 12 13
In
ta
ct
G A D
N
as
e
1 
pM
10
0 
nM
+
+
IPA
1
IPA +
+
2
A
B
C D
Θ
[1]
Figure 2.5  DNase I footprinting of GILZ promoter region
A) Sequence of the pGR_GILZ plasmid insert. B) Storage phosphor autoradiograms from quantitative 
DNase I footprint titrations of polyamides 1 and 2. Lane 1: intact DNA, lane 2: G reaction, lane 3: A reaction, 
lane 4: DNase control, lanes 5-13: DNase I digestion products in the presence of 1 pM, 3 pM 10 pM, 30 
pM, 100 pM, 300 pM, 1 nM 3 nM, 10 nM , 30 nM, 100 nM polyamide, respectively. C) binding isotherms for 
polyamides 1 and 2 bound to GRE 1 D) Ball-and-stick models of polyamides 1 and 2.
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II. Electrophoretic mobility shift assay (EMSA) 
The effects of polyamides 1 and 2 on the binding of recombinant human glucocorticoid 
receptor to an oligo containing the GRE1 site of the GILZ promoter were measured by 
an electrophoretic mobility shift assay (Figure 2.6). Incubation of the 32P-labeled GRE 
DNA with recombinant human GR produces a gel shift that is reduced in the presence of 
polyamide 1 at concentrations as low as 10 nM. Polyamide 2 has minimal effect at the same 
concentrations. The shift is abolished by incubation with a 100-fold excess of unlabeled 
GRE DNA but is unaffected by similar treatment with a scrambled control DNA, indicating 
a specific shift resulting from a GR-GRE binding event.
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Figure 2.6  In vitro displacement of GR binding by polyamide 1
Storage phosphor autoradiogram from EMSA of recombinant human glucocorticoid receptor binding to a 
27-bp oligonucleotide duplex containing the GILZ GRE1. Lanes represent the following conditions, where * 
represents 32P labeling: 1) Free *GRE DNA 2) *GRE DNA + GR 3) *GRE DNA+ GR + GRE DNA 4) *GRE 
DNA + GR + scrambled DNA 5-11) *GRE DNA + GR + polyamide 1 (lanes 5-11) or 2 (lanes 12-18) in 
concentrations increasing from 10 pM, 100 pM, 1 nM, 10 nM, 100 nM, 1 µM to 10 µM, respectively.
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III. Inhibition of glucocorticoid-induced GILZ expression
 Induction of GILZ mRNA by dexamethasone in the presence of polyamides 1 and 
2 in A549 cells was measured by quantitative real-time RT-PCR. Polyamide 1 inhibits 
the expression of dexamethasone-induced GILZ mRNA up to 65% at 5 and 10 µM, as 
measured in this assay (Figure 2.7A). Polyamide 2 does not show a measurable effect 
on GILZ expression at these concentrations. The GR antagonist mifepristone was used 
as a control and inhibits the expression of GILZ up to 79% at 3 µM. GR occupancy at 
the GILZ promoter was assessed by chromatin immunoprecipitation (Figure 2.7B). 
Six hour dexamethasone treatment results in a 15-fold increase in GR occupancy at the 
GILZ promoter, treatment of the cells with polyamide 1 for 48 hours prior to harvest reduces 
this occupancy, while treatment with the mismatch polyamide 2 shows a more modest 
effect. While polyamide 2 does not bind the GRE sites we cannot exclude the possibility 
that it may bind to other regions of the GILZ promoter. While polyamide 2 affects GILZ 
promoter occupancy, albeit significantly less so that 1, it is somewhat surprising that 2 only 
minimally affects GILZ mRNA.  However, it is not known what degree of occupancy is 
necessary for maximal induction of GILZ under these conditions. Treatment of cells by 
both polyamides 1 and 2 modestly affects cell proliferation and viability in a concentration 
and time dependent manner (Figure 2.7C). 
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Figure 2.7  Inhibition of dexamethasone-induced GILZ expression by 1 and 2
A) Induction of GILZ mRNA in the presence of mifepristone (mif), 1 and 2, as measured by quantitative 
real-time PCR. Polyamide 1 inhibits expression of GILZ mRNA up to 65% at 5 and 10 µM while polyamide 
2 shows no effect. 3 µM mifepristone control inhibits expression up to 79%. Error bars represent SD. 
B) Chromatin immunoprecipitation assays with anti-GR or mock antibody treatment expressed as 
fold-enrichment (specific/mock) of DNA sequences at the GILZ promoter. GR occupancy at the GILZ 
promoter is decreased in the presence of 1 (10 µM) and to a lesser extent by 2. Error bars represent SD. 
C) WST-1 colorimetric assay of cell viability and proliferation. Cells were treated for 24 and 48 hours 
with either polyamide 1 or 2 and subsequently assayed for cell viability and proliferation by measuring the 
absorbance of the dye at Amax of 450 nm on a multiwell plate reader.
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IV. Genome-wide microarray analysis
Global effects of polyamides 1 and 2 and the GR antagonist mifepristone on gene 
expression in dexamethasone-stimulated A549 cells were monitored with Affymetrix 
high-density Human Genome U133 Plus 2.0 arrays, which interrogate >50,000 transcripts. 
Of these transcripts, 431 were affected greater than 2-fold by dexamethasone compared 
to non-induced control, with 323 transcripts induced while 108 were repressed. An 
agglomerative  clustering analysis of the transcripts affected by dexamethasone demonstrates 
distinctive patterns of genes that are  GC-responsive and GR-mediated but have differential 
response to treatment by polyamide 1 and 2 (Figure 2.8A) at 5 µM concentration. 
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Figure 2.8 Global effects of polyamides on GR-regulated genes
Interrogation by Affymetrix high-density Human Genome U133 Plus 2.0 arrays. A) Agglomerative 
clustering of transcripts induced or repressed by dexamethasone (dex) by at least 2-fold under the four 
specified conditions: no treatment control, mifepristone (mif, 3 µM), 1 (5 µM) and 2 (5 µM). Clustering 
was based on an error-weighted Euclidean correlation of intensity ratios for each treatment as compared 
with dex-induced controls. (B) Venn diagram representing genes affected (|fold change| >2.0, P< 0.01) 
by dex and mif and (C) Venn diagram representing genes affected (|fold change| > 2.0, P< 0.01) by dex 
and mif as well as by dex and 1. Numbers inside the intersections represent transcripts affected by both 
treatments.
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The GR antagonist mifepristone abolishes the activity of GR and therefore was used as a 
control to identify those transcripts that were affected by a GR-related mechanism. 
431 transcripts were either induced or repressed by 2-fold or greater (p < 0.01) by 
dexamethasone treatment. Of these, the effects of dexamethasone were abolished by 
simultaneous treatment by 3 µM mifepristone for 252 transcripts, indicating that these 252 
were a result of GR activity (Figure 2.8B). For 76 transcripts of this set of 252, the effects 
of dexamethasone treatment were abolished by polyamide 1 to a greater extent than by 
polyamide 2, indicating a sequence-specific polyamide effect on those transcripts 
(Figure 2.8C). This set of 76 transcripts corresponds to 67 genes, listed in Table 2.1. 
Gene FoldInduction Gene
Fold
Induction Gene
Fold
Induction Gene
Fold
Repression
CDKN1C (N33167) 20 IGFBP1 (NM_000596) 4 49111_at (N80935) 3 NR4A2 (NM_006186) 6
FKBP5 (NM_004117) 14 CDC42EP3 (AI754416) 4 TIPARP (AL556438) 3 IER2 (NM_004907) 3
DNAJC15 (NM_013238) 14 PLEKHA7 (AA758861) 4 EPB41L4A (AU144565) 3 EREG (NM_001432) 3
FGD4 (AI949549) 11 CEP3 (AI801777) 4 CEBPD (NM_005195) 3 IER3 (NM_003897) 3
CIDEC (NM_022094) 8 LOC153346 (AU157049) 4 EMP1 (NM_001423) 3 NR0B1 (NM_000475) 3
EDN3 (NM_000114) 8 IL6R (NM_000565) 4 LOC54492 (AK026748) 3 MAFK (BG231691) 3
PTGER4 (AA897516) 8 ARRB1 (BE207758) 4 ARRB1 (BC003636) 3 CYP24A1 (NM_000782) 3
METTL7A (NM_014033) 7 CDC42EP3 (AL136842) 4 SOCS1 (AB005043) 3 EDN1 (NM_001955) 2
FAM105A (NM_019018) 7 AKAP13 (NM_006738) 3 SCNN1G (AI985987) 3 NEIL3 (NM_018248) 2
ATAD4 (NM_024320) 6 244650_at (AA581439) 3 EPB41L4B (NM_019114) 3 PTGS2 (AY151286) 2
GOLSYN (NM_017786) 6 PKP2 (NM_004572) 3 ARRB1 (NM_004041) 3 RND1 (U69563) 2
CORO2A (AL515381) 5 FBXL16 (AI613010) 3 IL6R (NM_000565) 3
TFCP2L1 (NM_014553) 5 CEBPD (AV655640) 3 MT1F (BF246115) 2
RASSF4 (N49935) 5 FOXO3 (AV725666) 3 JPH2 (AA716165) 2
CDH16 (NM_004062) 4 FLVCR2 (NM_017791) 3 SLC22A5 (NM_003060) 2
ACSL1 (NM_021122) 4 MT2A (NM_005953) 3 RHOU(AL096776) 2
MT1X (NM_002450) 4 KIAA0146 (AI363213) 3 MAN1C1 (NM_020379) 2
AKAP13 (NM_006738) 4 43511_s_at (AI201594) 3 KIAA0232 (D86985) 2
ACSL1 (NM_001995 4 ETNK2 (NM_018208 3
Table 2.1 Genes affected >2-fold by dexamethasone and mifepristone whose activity is 
modulated by polyamide 1 and not by polyamide 2
These genes may represent glucocorticoid-responsive genes that are controlled via direct GR-binding 
mechanisms.
 We anticipate that the regulation of these genes by GR involves a direct GR-GRE 
interaction. In order to analyze the potential GRE sequence-specific role of polyamide 
treatment within this subset of GR-regulated genes, those genes that showed similar effect 
from both polyamides 1 and 2 were considered to be non-GRE-specific effects and were 
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not included among those analyzed. Many of the genes identified by the microarray as 
dexamethasone-responsive are consistent with those previously identified in this cell line.15 
A list of the effect of all treatment conditions on the GR-regulated genes is available in the 
Materials and Methods section of this chapter. 
2.3 Discussion
A mechanistic understanding of cell signaling is fundamental to the development 
of improved medicines and diagnostics.  Towards this end, the functions of individual 
biomolecules and their involved pathways have been explored using both biological 
and chemical methods.  Genetic approaches include gene knockouts, dominant negative 
proteins, and siRNA to affect the activity of selected genes.  Chemical approaches have 
utilized pre-existing, designed, or discovered small molecules that perturb a particular 
protein or specific protein-protein interaction, and have been employed successfully to 
characterize cell signaling pathways.23-25 
The elucidation of transcription factor, coactivator, and corepressor activation, 
their gene targets, and mechanisms of activity is a focus of intense research interest. 
Genome-wide, high-throughput approaches including mRNA microarray analysis,26 
ChIP-chip,27-29 and more recently ChIP-sequencing30 have been used to define the targets 
of transcription factors. Specific protein-DNA interactions are the interfaces where 
information from protein signaling is converted into programs of gene expression. Used 
in the context of genome-wide analysis, small molecules that perturb this interface 
in a predictable manner could become useful tools for understanding gene expression. 
Programmable, DNA-binding Py-Im polyamides offer a chemical approach to perturbing 
protein-DNA interactions that could be used for characterization of transcription factor-
DNA interactions. We have reported previously that Py-Im polyamide 1, which targets 
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5’-WGWWCW-3’, inhibits androgen receptor (AR) binding to its consensus sequence 
5’-GGTACAnnnTGTTCT-3’.22  As members of the same class of transcription factors, 
AR and GR share highly conserved DNA-binding domains, similar consensus sequences 
and transactivation mode of action.  However, each acts within their individual biological 
contexts and responds to distinct chemical stimuli. The use of polyamide 1 in the context 
of disrupting the GR-GRE interface offers additional perspective in the mechanistic study 
of GR gene-regulatory action and its dual transactivation/transrepression mechanisms. 
Because of the central role of GR in multiple inflammatory response pathways and its 
role as a drug target, mechanistic studies of GR-modulated gene expression are a growing 
field of study. However, the multiple mechanisms by which GR mediates gene expression 
makes identification of GR target genes a challenge.9,18,31 
The complex transcriptional activity of the GR involves DNA-binding-dependent as 
well as DNA-binding-independent mechanisms that result in both gene activation as well 
as repression. In general the most well-understood mechanism is that by which genes are 
activated by direct DNA binding of GR to a GRE in the regulatory region of target genes 
followed by recruitment of coactivators and the general transcriptional machinery. Another 
well-documented, though less understood mechanism is the transrepression mechanism, 
in which GR exerts its influence indirectly by binding to other proteins and transcription 
factors leading to the repression of genes controlled by those proteins. Intriguingly, an 
increasing body of evidence indicates that much of the anti-inflammatory activity of GCs 
is mediated by the transrepression mechanism, a finding that has been attributed largely 
to the repression of key inflammatory transcription factors including AP-1 and NF-κB.6-8 
Meanwhile, many of the reported side effects of GC treatment have been attributed to 
transactivation mechanism.32 Efforts to develop new GC-based drugs that can dissociate 
anti-inflammatory and immunosuppressive effects from side effects have focused largely on 
establishing a method of dissociating the transrepression from the transactivation activity 
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of the GR. Much of the work in this area has centered about the development of new 
GR-binding ligands that display a more selective gene regulation pattern than classical 
GCs. The end result of this body of effort has demonstrated that the problem is complex, 
as slight alterations in ligand structure and chemical reactivity can have a pronounced 
influence on the transcriptional regulatory activity of GR.17
An additional complication to mechanistic study of the GR is the fact that examples 
have also been noted in which genes are repressed through DNA-binding-dependent GR 
action, as well as those in which genes are activated through DNA-binding-independent 
action. Techniques using immunoprecipitated chromatin fragments reveal a great deal of 
useful information about GR target sites, but are not expected to distinguish between sites of 
direct GR-GRE interaction and sites of indirect GR-protein-DNA interaction. Our approach 
utilizes a DNA binding polyamide targeting the consensus GRE that would be expected 
to dissociate the direct DNA-binding from the indirect, DNA-binding-independent GR 
gene-regulatory mechanisms. 
In this study, a sequence-specific polyamide targeted towards the consensus 
DNA-binding sequence of the glucocorticoid receptor was tested on a well-known 
glucocorticoid-induced gene, GILZ, in order to establish its ability to disrupt 
GR-DNA binding and thereby regulate gene transcription. Polyamide 1, designed to target 
the sequence 5’- WGWWCW-3’, has been shown by DNase I footprinting to bind at 
subnanomolar concentrations to the right half-site of each of two different functional GREs 
located in the promoter region of the GILZ gene. Quantitative real-time PCR analysis of 
RNA isolated from A549 cells treated with polyamide 1 demonstrates a 60% reduction in 
dexamethasone-induced GILZ mRNA levels as compared with vehicle control. Chromatin 
immunoprecipitation indicates that in the presence of polyamide 1, the dexamethasone-
induced GR occupancy of the GILZ promoter is reduced, suggesting that it is polyamide 
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occupancy at this site that is responsible for the lowered mRNA expression levels. 
A control polyamide 2 targeted at a different sequence, 5’-WGWCGW-3’, shows reduced 
affect on GR promoter occupancy and no effect on GILZ gene transcription. 
The established ability of polyamide 1 to disrupt the GR-GRE interaction for GILZ 
led us to a genome-wide search for other transcriptional events that are interrupted 
sequence-specifically. Affymetrix microarrays interrogating >50,000 transcripts were 
chosen to examine the global effect of polyamides 1 and 2 at 5 µM concentration on 
dexamethasone-treated cells.  The GR antagonist mifepristone was used as a control in 
order to isolate which of the dexamethasone-responsive transcripts result from GR activity. 
These conditions isolated 252 genes which were considered genuine GR-modulated 
GC-affected transcripts.  Both polyamides had a similar and modest effect on cell 
proliferation under these experimental conditions.
In order to tease out which of these effects is due to a binding event at a 5’-WGWWCW-3’ 
sequence corresponding to a GRE, we have eliminated genes from the list that were affected 
by polyamide 2, as both the footprinting and ChIP data shows that it is possible that this 
compound may have an effect on genes whose promoters contain a 5’-WGWCGW-3’ site. 
Of the list of 252 GR-modulated transcripts, treatment with polyamide 1 had a unique 
effect on 170 transcripts over treatment with polyamide 2. This left us with a final list 
of 170 transcripts whose expression is confidently affected both by GR as well as our 
sequence-specific small molecule. Of this final list of confidently interrogated transcripts 
we find 76 transcripts, corresponding to 67 genes, which are identified as genes whose 
expression was modulated by polyamide 1. We believe this list of genes to represent 67 
genes that are regulated by direct GR-DNA interactions.  While little information exists in 
the literature linking glucocorticoid response with these genes, we note that several genes 
with known functional GRE binding sites are included in the list (Table 2.2). For genes 
59
in which the binding site has been identified, the sequence is listed, with the predicted 
polyamide 1 target binding site underlined. The GREs for the genes listed in this table have 
been determined to have GC-induced GR occupation at the indicated location relative to the 
given gene. For some of these genes, functionality has been confirmed via point mutation 
or a luciferase-driven reporter assay. The fact that these genes contain polyamide 1 binding 
sites and demonstrate responsiveness to polyamide 1 treatment gives us confidence that the 
subset of genes identified here represents a new list of DNA-binding dependent genes to be 
explored by the GR field.
Gene GRE (5` 3’) Location Ref
CDKN1C AGAACAgccTGTCCT Promoter (32)
FKBP5 AGAACAgggTGTTCT Intron (31, 33)
ACSL1 AGCACAtcgAGTTCA Intron (31)
AKAP13 -- Exon (31)
ETNK2 -- Intron (31)
IGFBP1 -- Intron, Upstream (31)
MT2A
AGGACAgccTGTCCT
AGAACAggaTGTTTA
Upstream (31)
IL6R -- Intron (31)
Table 2.2 Genes identified in our study that have previously been shown to have 
 GR-occupied and/or functional GREs
 
 There is still very little known about many of the genes that are affected by 
glucocorticoids, including which genes are activated as a result of transrepressed 
mechanisms or transactivated mechanisms. The lack of identified GREs to be found in the 
literature complicates the search for genes that are regulated by the transactivation 
mechanism. DNA-binding polyamides represent a unique approach to differentiating the 
transrepression from transactivation activity of the GR—the potential to selectively block 
the protein-DNA interactions of endogenous GR while leaving the protein-protein 
interactions unaffected. This approach is limited by the target site degeneracy of both the 
polyamide as well as GR, effects of specific polyamide-DNA binding on programs of other 
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transcription factors, and non-specific effects of polyamides that are independent of 
sequencespecific polyamide-DNA binding. Small molecules that affect specific GR-protein 
interactions represent a complementary approach that is as yet unexplored. It is our hope 
that the list of genes provided by this study serves as a guide towards genes that necessitate 
further exploration in the search to selectively regulate the transactivation mechanism of 
glucocorticoid response.
2.4 Materials and Methods
Materials
Unless otherwise stated, DNA oligonucleotides were ordered PAGE-purified 
from Integrated DNA Technologies. Unless otherwise stated, reagents were 
purchased from Sigma-Aldrich.. All solvents were purchased from Aldrich or 
EMD Biosciences. Trifluoroacetic acid (TFA) was purchased from Halocarbon. 
rac-Dithiothreitol (DTT) was purchased from ICN.  RNase-free DEPC water was purchased 
from US Biochemicals. Water (18.2 MΩ) was purified using a Millipore water purification 
system.
Methods
UV spectra were recorded using an Agilent 8453 UV-Vis spectrophotometer. 
Polyamide concentrations were measured as a solution in water at λ=310 nm using 
an estimated extinction coefficient of ε=69,500 M-1 cm-1 for 8-ring polyamides.39 
LASER desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was 
performed using an Applied Biosystems Voyager DE Pro spectrometer. Analytical and 
preparative high-performance liquid chromatography (HPLC) were performed with a 
Beckman Gold system equipped with a diode array (analytical) or single-wavelength 
(preparative) detector.
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i. Polyamide synthesis  
Pyrole and imidazole monomer units [Boc-Py-OBt (1,2,3-Benzotriazol-1-yl 4-[(tert-
Butoxycarbonyl)amino]-1-methylpyrrole-2-carboxylate) and Boc-Im-OH (4-[(tert-
Butoxycarbonyl)amino]-1-methylimidazole-2-carboxylic acid) respectively] are 
synthesized according to established protocols37 and maintained as general group stock. 
Fmoc-D(Dab)-Boc-OH turn monomer unit  and Boc2O were purchased from Peptides 
International. 
Polyamides 1 and 2 were synthesized by solid-phase methods on Kaiser oxime resin 
(Nova Biochem, Darmstadt, Germany) following established protocols.33 In a typical 
synthesis, 4 molar equivalents (relative to resin loading for the lot of oxime resin used) 
of monomer unit were activated with 4 equivalents of PyBOP (NovaBiochem)  and 
4 equivalents of diisopropylethylamine (DIEA) in a solution of dimethylformamide (DMF) 
(solution was approximately 0.3-0.5 M in monomer unit). In a glass peptide synthesis 
vessel, the resin was shaken with this solution for 2-4 hours at room temperature until the 
reaction was complete, as assessed by analytical HPLC of a cleaved sample of resin. Resin 
was deprotected by shaking in a solution of 20% trifluoroacetic acid (TFA) in methylene 
chloride for 20 minutes at room temperature. After completion of synthesis of the oligomer 
the Fmoc protecting group was removed by 10 minute incubation with 20% piperidine in 
DMF at room temperature. The free amine was subsequently protected by incubation of the 
resin for 1 hour in a solution of Boc2O in DMF.  The polyamide was subsequently cleaved 
from resin by incubation at 55 °C with 3,3-diamino-N-methyl-dipropylamine overnight (8-
14 hours). The cleavage product was purified by reverse-phase HPLC, frozen in LN2 and 
lyophilyzed to dryness. 
62
Isophthalic acid (IPA) was activated with PyBOP (Nova Biochem) and conjugated to 
the polyamides as previously described.34 Briefly:  a 1 M solution of IPA  in DMF and DIEA 
(50eq) was mixed with a 0.75 M solution of PyBOP in DMF. This solution was added to 
a lyophilized aliquot of cleaved polyamide and allowed to sit at room temperature for 
1 hour. Following conjugation the polyamide was precipitated from solution by addition of 
cold diethyl ether and the precipitate was pelleted by centrifugation, the supernatant was 
removed and the pellet was allowed to air-dry. The Boc protecting group was removed by 
the addition of 100 μL of neat TFA to the pellet. The deprotection proceeded for 10 min at 
room temperature before being diluted with 20% acetonitrile/water (0.1% TFA) followed 
by purification by reverse-phase HPLC. Purities and identities of the polyamides were 
assessed by HPLC, UV-visible spectroscopy, and MALDI-TOF MS.
1: (MALDI-TOF) [M+H]+ calcd for C
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H
77
N22O12
+ 1357.6, observed 1357.5
2: (MALDI-TOF) [M+H]+ calcd for C
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H
77
N
23
O12
+ 1358.6, observed 1358.6
ii. Plasmid preparation 
Plasmid pGR_GILZ was constructed by ligating the following hybridized inserts 
(a 78-bp sequence from the GILZ promoter containing GRE1 and GRE2) into the 
BamHI / HindIII polycloning site in pUC19:
5’-GATC CCATA AGTATAGC CTGCACTTTG TTCTGTCT ACTACACATGT 
CTTAGTGC AAACACCGTGT TCAGAGAG GTTGTG-3’
5’-AGCT CACAA CCTCTCTG AACACGGTGT TTGCACTA AGACATGTGTA 
GTAGACAG AACAAAGTGCA GGCTATAC TTATGG-3’
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The ligated plasmid was then transformed into JM109 subcompetent cells 
(Promega) by standard methods (30 minute incubation on ice followed by 45 
second heat shock (42 ºC) followed by 1 hour incubation at 37 ºC). Colonies were 
selected for α-complementation on agar plates containing 50 mg/L ampicillin, 
120 mg/L IPTG, and 40 mg/L X-gal after overnight growth at 37 ºC. Cells were harvested 
after 16 h growth at 37 ºC in LB medium containing 50 mg/L ampicillin. Plasmids were 
then purified by mini-prep kits. The presence of the desired inserts was determined by 
capillary electrophoresis dideoxy sequencing methods (Largen).
iii. Preparation of 5’-labeled DNA for DNase I footprinting 
Two primer oligonucleotides, 5’-AATTCGAGCTCGGTACCCGGG-3’ 
(forward, corresponding to EcoRI restriction enzyme cut site) and 
5’-CTGGCACGACAGGTTTCCCGA-3’ (reverse, corresponding to PvuII restiction 
enzyme cut) were constructed for PCR amplification. The forward primer was 
radiolabeled using [γ-32P]-dATP (MP Biomedicals) and polynucleotide kinase 
(Roche) according to the manufacturer’s protocol, followed by purification using 
ProbeQuant G-50 spin columns. The desired PCR product was generated from the 
plasmid pGR_GILZ using the primer pair and Expand High Fidelity PCR Core Kit 
(Roche) following the manufacturer’s protocol.   The labeled fragment was loaded onto 
a 7% nondenaturing preparatory polyacrylamide gel (5% cross-link), and the desired 
283 base pair band was visualized by autoradiography and isolated. Chemical sequencing 
reactions were performed according to published protocols.38
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iv. Quantitative DNase I footprint titrations 
All reactions were carried out in a volume of 400 mL according to published protocols. 
Polyamides were equilibrated with the radiolabeled DNA for 14 h prior to DNase I 
cleavage at 23 ºC. Quantitation by storage phosphor autoradiography and determination of 
equilibrium association constants were as previously described.35
v. Electrophoretic mobility shift assay (EMSA) 
The oligonucleotide 5’-GTATAGCCTGCACTTTGTTCTGTCTAC-3’ representing 
a 27-bp section of the GILZ promoter containing GRE1 (underlined) was annealed to 
its complement and end-labeled with [γ-32P]dATP and polynucleotide kinase (Roche) 
following the manufacturer’s instructions. Aqueous solutions of polyamides 1 and 2 at 
the indicated concentrations were incubated with the duplex at room temperature for 2 h 
in 5 µL 5x buffer containing 100 mM HEPES, pH 7.9, 300 mM KCl, 25 mM MgCl2, 10 
mM dithiothreitol (DTT), and 50% glycerol. Recombinant human glucocorticoid receptor 
(Affinity Bioreagents, 3.5 mg/ml) was diluted 1:20 with 50 µg/µl bovine serum albumin 
(BSA) and stored as a frozen stock solution. Fresh aliquots of this solution were used 
for each experiment and discarded after use. 2 µL of the diluted GR protein, 1 µL of 
200 ng/µL poly dI-dC, 1 µL of unlabeled DNA (for control lanes) were taken up in water 
to a final volume of 15 µL and incubated at 4 °C for 30 min. This solution was added to the 
polyamide-DNA complex and incubated at room temperature for 1 h before being separated 
on a 6% polyacrylamide gel in 1x TBE. Gels were visualized on a phosphorimager.
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vi. Measurement of dexamethasone-induced mRNA. 
RNA isolation:  
A549 cells (ATCC) were plated in 24-well plates at a density of 20-25 x 103 cells 
per well (40-50 x103 cells per mL) in F12-K medium (ATCC) supplemented with 
10% FBS (Irvine Scientific, Santa Ana, CA) and 4 mM penicillin/streptomycin. After 24 
h, the medium was replaced with F12-K containing 10% charcoal-stripped FBS, 4 mM 
penicillin/streptomycin, and polyamides or mifepristone at the designated concentrations. 
Cells were grown for an additional 48 h and then treated with 100 nM dexamethasone 
for 6 h. (Figure 2.9). The medium was removed, cells were washed with ice-cold PBS and 
immediately lysed with RLT buffer from an RNeasy kit (Qiagen). Further RNA isolation 
was carried out with the RNeasy kit as described in the manufacturer’s manual. The isolated 
total RNA was quantified. The yields were 12-15 μg per well.
Plate Cells
F12-K, 10% FBS
Replace Media, F12-K, 10% CT-FBS
Media contains polyamide, mifepristone, or vehicle control
0 hours 24 hours 72 hours 
dexamethasone 
added
78 hours,
 Harvest
Figure 2.9 Timeline of cell treatment protocol, used for RT-PCR, ChIP and microarray assays
Reverse transcription:  
A 2.5 μg sample of total RNA was used to reverse transcribe cDNA  using  Superscript II 
reverse transcriptase (Invitrogen) according to the manufacturer’s protocol. Random hex-
amers were used as primers. The total volume for each RT reaction was 20 μl.
Real-time quantitative RT-PCR:
Analysis was performed using the GILZ gene primers described below, purchased from 
Integrated DNA Technologies  Quantitative real-time RT-PCR was performed with SYBR 
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Green PCR Master Mix (Applied Biosystems, Foster City, CA) following the manufacturer’s 
suggested protocol. Temperature cycling and detection of the SYBR Green emission were 
performed with an ABI 7300 real-time instrument using Applied Biosystems Sequence 
Detection System version 1.2. Statistical analysis was performed on three independent 
experiments.  mRNA of the genes of interest were measured relative to β-glucuronidase as 
an endogenous control. Primer sequences were designed using Primer3.36 
To amplify the 97-bp fragment from the 3’-translated region of GILZ:
Forward primer: 5’- CTCCCCGTTTGTTTTTCTCA -3’ 
Reverse primer:  5’- TGCTCCTTCAGGATCTCCAC -3’ 
To amplify the β-glucuronidase gene as an endogenous control: 
Forward primer: 5’- CTCATT TGGAATTTTGCCGATT -3’
Reverse primer:  5’- CCGAGTGAAGATCCCCTTTTTA -3’
vii. Measurement of Cell Proliferation and Viability. 
A549 cells were plated in 96-well plates, 100 µL at 20 x 103 cells/mL in F12-K 
medium containing 10% charcoal-stripped FBS and 4 mM penicillin/streptomycin. 
After the indicated time period, 10 µL of Cell Proliferation Reagent WST-1 
(Roche, Cat. No. 05 015 944 001) was added to each well. Reagent was allowed to incubate 
at 37 °C for 30 minutes and absorbance was read at 450 nm on a Perkin-Elmer Victor 3 
multiwell plate reader.
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viii. Chromatin Immunoprecipitation. 
A549 cells were plated in 15 cm diameter plates at a density of 10 x 105 cells per 
plate. Media conditions, polyamide treatment, time course, and dexamethasone stimulation 
were identical to the conditions described above for qPCR. Upon completion of the 6 h 
dexamethasone treatment, cells were cross-linked by treatment with 1% formaldehyde for 
10 minutes. Chromatin was isolated using a ChIP-IT kit (Amersham) following the 
manufacturer’s protocol. Chromatin was sheared and immunoprecipitated by overnight 
incubation  at  4 °C with   anti-GR antibody N499  (A gift from Keith Yamamoto, UCSF). 
A 1:1 mixture of Protein G and Protein A Agarose beads (Upstate) was used to 
isolate the immunoprecipitated material via centrifugation. Cross-links were reversed and 
the DNA was isolated via phenol/chloroform extraction followed by ethanol precipitation. 
qPCR using primers targeted to the GILZ promoter were used to assess enrichment of 
bound fragments as compared with mock-precipitated (no antibody) controls. PCRs were 
monitored with SYBR Green PCR Master Mix (Applied Biosystems) on an ABI 7300 
qPCR instrument. Primer sequences, described below, were designed using Primer3.36 
Detailed procedure can be found in Nicholas Nickols’ PhD dissertation.40 
To amplify the 88-bp fragment from the 5’-promoter region of GILZ:
Forward primer: 5’- GCACTGATTCATGGGTACTGG -3’ 
Reverse primer:  5’- ACCAACTCAGGACCAAAGGAG -3’ 
ix. Analysis of Gene Expression with Oligonucleotide Microarrays. 
A549 cells were plated in 12-well plates at a density of 40-50 x 103 cells per well. 
Media conditions, polyamide treatment, time course, and dexamethasone stimulation were 
identical to the conditions described above for qPCR and ChIP.  Mifepristone was added 
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at the same time as polyamide was added. RNA was isolated as previously described. The 
RNA was submitted to the Millard and Muriel Jacobs Gene Expression Facility at the 
California Institute of Technology where labeled mRNA was hybridized to Affymetrix 
high-density Human Genome U133 Plus 2.0 arrays according to established protocols. 
Gene expression was analyzed by using Resolver (Rosetta Biosoftware, Seattle, WA). Data 
were uploaded to the Gene Expression Omnibus repository (accession no. GSE17307). 
Table 2.3 lists the effect of all treatment conditions on the GR-regulated genes. 
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Table 2.3  Microarray fold changes under all treatment conditions of sequences affected 
≥2-fold by dexamethasone and mifepristone
Accession numbers given are Affymetrix accession numbers.
Sequence Accession # Dex Mif 1 2 Sequence Accession # Dex Mif 1 2
CDKN1C N33167 20.3 -18.9 -5.0 -1.1 STOM M81635 3.5 -2.8 -1.8 -1.5
FKBP5 NM_004117 14.3 -5.0 -5.9 -2.9 AKAP13 NM_006738 3.5 -2.6 -4.1 -3.1
RRAD NM_004165 13.8 -9.6 -1.4 2.0 NEXN AF114264 3.5 -2.9 -4.4 -3.2
DNAJC15 NM_013238 13.7 -12.1 -15.4 -2.4 244650_at AA581439 3.5 -3.1 -2.2 -1.1
TFCP2L1 AI928242 12.9 -5.5 -5.5 -2.0 PKP2 NM_004572 3.4 -3.3 -3.4 -1.5
CDKN1C NM_000076 12.6 -7.8 -3.6 1.0 THBD NM_000361 3.4 -2.3 -1.3 -1.9
FKBP5 W86302 12.1 -5.2 -5.8 -2.1 ANKRD44 AU157224 3.4 -3.1 -5.8 -5.5
RRAD NM_004165 11.4 -11.4 -1.3 1.8 FOXO3 NM_001455 3.4 -2.5 -2.4 -2.1
FKBP5 AI753747 11.2 -4.5 -4.9 -1.8 FGD4 AA296351 3.4 -3.1 -2.6 -2.1
TSC22D3 AL110191 10.9 -6.4 -1.8 -1.3 FOXO3 N25732 3.4 -2.8 -3.3 -2.1
FGD4 AI949549 10.8 -6.1 -7.5 -2.0 LOC283278 AI690465 3.4 -2.6 -5.9 -2.5
CIDEC NM_022094 8.4 -4.7 -5.4 -4.0 KIAA1462 AL553774 3.4 -3.4 -1.9 -2.4
CDKN1C N95363 8.3 -5.8 -2.6 1.3 FBXL16 AI613010 3.4 -3.7 -2.3 -1.2
EDN3 NM_000114 8.2 -4.3 -5.8 -1.3 CEBPD AV655640 3.3 -3.1 -4.4 -2.3
CDKN1C R78668 7.9 -5.7 -3.3 1.1 FOXO3 AV725666 3.3 -2.9 -3.4 -1.9
PTGER4 AA897516 7.6 -4.3 -3.1 -1.9 SNAI2 AI572079 3.3 -3.1 -2.0 -2.0
FGD4 AI277617 7.6 -5.8 -6.9 -1.6 BIRC3 U37546 3.2 -2.8 1.9 1.4
FAM43A AW264102 7.2 -3.9 -1.2 1.5 CALD1 AL577531 3.2 -2.5 -3.0 -2.3
METTL7A NM_014033 6.6 -3.2 -7.2 -1.8 TSC22D3 NM_004089 3.2 -3.0 -1.6 -1.3
UNC5B AK022859 6.6 -4.8 1.1 2.0 227082_at AI760356 3.2 -2.1 -4.1 -3.7
FAM105A NM_019018 6.5 -4.6 -2.8 -1.2 ALPP NM_001632 3.2 -2.7 -1.2 1.7
ANGPTL4 NM_016109 6.3 -3.4 -1.6 -1.5 ANPEP NM_001150 3.2 -2.6 -1.9 1.4
ATAD4 NM_024320 6.2 -2.8 -2.9 -1.0 ZBTB20 AW499525 3.2 -2.1 -8.1 -4.5
GOLSYN NM_017786 5.9 -3.6 -5.1 -1.6 CALD1 NM_018495 3.2 -2.8 -3.1 -2.0
RGS2 NM_002923 5.5 -4.2 -1.4 -1.6 RBM20 AI539118 3.2 -3.1 -4.5 -3.8
CORO2A AL515381 5.4 -3.4 -3.1 1.2 MT1P2 AF333388 3.2 -2.8 -2.4 -2.0
TFCP2L1 NM_014553 5.2 -3.5 -3.2 -1.5 MT1F M10943 3.2 -2.8 -2.5 -1.9
ANGPTL4 AF169312 5.1 -3.0 -1.5 -1.6 FLVCR2 NM_017791 3.1 -2.9 -2.3 -1.4
CDKN1C D64137 5.1 -4.2 -2.5 1.2 SERPINE1 NM_000602 3.1 -2.3 -7.7 -6.2
GMPR NM_006877 5.0 -3.1 -1.1 2.1 213158_at AA045174 3.1 -2.2 -21.5 -5.7
RASSF4 N49935 4.9 -4.4 -6.0 -2.0 MT1H NM_005951 3.1 -2.9 -2.4 -1.9
PER1 NM_002616 4.9 -2.6 1.3 1.1 MT2A NM_005953 3.1 -2.9 -2.3 -2.0
LOC286167 AV721528 4.5 -3.9 -1.2 1.0 KIAA0146 AI363213 3.1 -2.7 -4.1 -1.8
ZFP36 NM_003407 4.5 -3.2 1.0 -1.3 ABHD2 AI557319 3.1 -2.2 -3.6 -3.1
CDH16 NM_004062 4.4 -4.3 -2.6 1.4 GPR115 W67511 3.0 -2.5 -4.6 -4.3
ACSL1 NM_021122 4.3 -2.8 -4.5 -2.0 FOXO3 BE888885 3.0 -2.5 -2.7 -1.8
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Sequence Accession # Dex Mif 1 2 Sequence Accession # Dex Mif 1 2
C13orf15 NM_014059 4.3 -4.4 -2.0 1.2 CHST7 NM_019886 3.0 -2.7 1.7 1.9
MT1X NM_002450 4.3 -3.9 -3.3 -2.2 43511_s_at AI201594 3.0 -2.2 -2.9 -1.1
GRAMD4 AB018310 4.2 -4.3 -1.1 1.4 213156_at BG251521 3.0 -2.0 -10.6 -4.8
SDPR BF982174 4.2 -3.4 1.4 1.3 227121_at BF476076 3.0 -2.2 -6.8 -4.0
AKAP13 M90360 4.2 -2.5 -5.9 -3.3 EPB41L4A NM_022140 3.0 -2.1 -3.2 -2.2
ACSL1 NM_001995 4.1 -2.9 -4.2 -2.0 AKAP13 AW575773 2.9 -2.4 -4.4 -2.4
KCNB1 L02840 4.0 -4.0 -4.5 -4.3 EPB41L4B AB032179 2.9 -2.4 -2.2 -2.1
AKAP13 AK022014 4.0 -2.3 -4.8 -3.1 SLC4A11 AF336127 2.9 -2.8 -1.4 1.1
DUSP1 AA530892 3.9 -2.2 -1.2 -1.4 SH3TC1 NM_018986 2.9 -2.7 -1.6 -1.0
SDPR NM_004657 3.9 -2.9 1.4 1.2 ERRFI1 AL034417 2.9 -2.0 1.2 1.0
MT1X NM_005952 3.9 -3.5 -2.8 -2.2 CALD1 NM_004342 2.9 -2.4 -3.6 -2.2
IGFBP1 NM_000596 3.8 -2.6 -2.5 -1.6 ETNK2 NM_018208 2.9 -2.6 -2.6 -1.5
ABHD2 AI832249 3.8 -2.3 -4.1 -3.7 PALM2-AKAP2 NM_007203 2.9 -2.2 -2.0 -2.5
CDC42EP3 AI754416 3.7 -2.2 -3.6 -1.9 MOBKL2B AI692878 2.9 -2.7 -6.0 -5.1
PLEKHA7 AA758861 3.7 -3.0 -5.8 -2.1 49111_at N80935 2.9 -2.1 -2.7 1.0
STOM AI537887 3.7 -2.7 -1.8 -1.5 BAIAP2 BC002495 2.8 -2.5 -1.2 1.1
CEP3 AI801777 3.7 -2.3 -3.7 -1.6 GADD45A NM_001924 2.8 -2.6 1.2 1.3
REEP1 BE535746 3.6 -3.0 -6.6 -3.8 TIPARP AL556438 2.8 -2.2 -2.3 -1.6
LOC153346 AU157049 3.6 -3.6 -2.2 -1.3 EPB41L4A AU144565 2.8 -2.4 -3.2 -1.5
THBD NM_000361 3.6 -2.3 -1.3 -1.8 CEBPD NM_005195 2.8 -2.3 -2.1 -1.4
IL6R NM_000565 3.6 -2.6 -2.9 -2.1 PRKCD NM_006254 2.8 -2.1 -1.1 1.2
RAB11FIP1 NM_025151 3.6 -2.9 -1.2 1.3 MAOA AA923354 2.8 -2.0 -3.3 -2.0
THBD AW119113 3.6 -2.6 -1.5 -1.9 EMP1 NM_001423 2.8 -2.4 -2.7 -1.5
ABHD2 BE671816 3.6 -2.3 -4.2 -3.3 LOC54492 AK026748 2.8 -2.7 -2.2 -1.0
ARRB1 BE207758 3.5 -2.6 -4.5 -2.2 ARRB1 BC003636 2.7 -2.2 -3.3 -1.7
CDC42EP3 AL136842 3.5 -2.2 -3.3 -2.0 SOCS1 AB005043 2.7 -2.7 -2.0 1.1
BAIAP2 AB017120 2.7 -2.7 -1.4 -1.0 RHOU AB051826 2.2 -2.1 -1.1 -1.0
EPB41L4B NM_019114 2.7 -2.3 -2.3 -1.9 DNER BF059512 2.1 -2.3 -3.4 -2.6
EMP1 BF445047 2.7 -2.7 -2.7 -2.3 COBLL1 NM_014900 2.1 -2.1 -3.0 -2.1
KIAA1462 AL050154 2.7 -3.3 -2.3 -2.5 BAIAP2 NM_017450 2.1 -2.6 -1.3 1.2
ARRB1 NM_004041 2.7 -2.0 -2.7 -1.7 HSD11B2 NM_000196 2.1 -2.0 -1.3 1.6
EMP1 NM_001423 2.7 -2.3 -2.7 -1.5 KIAA1545 AA527531 2.1 -2.2 -1.8 -1.8
B3GNT5 BE672260 2.7 -2.1 1.1 1.1 MAN1C1 NM_020379 2.1 -2.1 -2.0 -1.4
TFCP2L1 AW195353 2.7 -2.2 -2.3 -1.8 PPL NM_002705 2.1 -2.3 -1.9 -1.4
SERPINE1 AL574210 2.6 -2.1 -3.9 -6.0 FLVCR2 AW001026 2.1 -2.1 -1.6 -1.3
NEXN NM_144573 2.6 -2.4 -3.8 -3.0 KIAA0232 D86985 2.1 -2.1 -3.1 -1.4
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IL6R AV700030 2.6 -2.2 -2.2 -1.5 AKAP2 BE879367 2.1 -2.1 -1.9 -2.2
RAB11FIP1 AA143793 2.6 -2.8 -1.1 1.3 GPR37 U87460 -2.0 2.3 1.5 1.8
TNS4 AA158731 2.6 -2.2 -1.1 -1.2 FOXA2 AB028021 -2.0 2.0 1.5 1.3
NDRG1 NM_006096 2.6 -2.4 -1.6 1.2 FZD7 AI333651 -2.0 2.1 3.3 2.1
PLEKHA2 BF347859 2.5 -2.1 -2.8 -2.6 LHX8 BC040321 -2.0 2.0 -1.1 -1.2
ITGB4 AF011375 2.5 -2.1 -2.1 -2.0 VASH2 AI961235 -2.1 2.1 1.5 1.6
STARD13 AA128023 2.5 -2.4 -2.9 -2.9 EDN1 NM_001955 -2.1 2.1 2.3 1.8
KIAA1462 AL553774 2.5 -2.4 -1.6 -1.9 KCNK3 NM_002246 -2.1 2.9 -1.4 -1.3
LIFR AA701657 2.5 -2.2 -2.7 -3.0 SLC40A1 AL136944 -2.2 2.1 -1.4 1.1
RHOB BI668074 2.5 -2.1 -1.1 -1.7 FAM113B BF056901 -2.2 2.0 1.4 -1.1
CORO2A NM_003389 2.5 -2.1 -1.8 1.0 TGFA NM_003236 -2.2 2.2 1.8 2.1
CKB NM_001823 2.5 -2.5 -1.4 -1.1 MYOCD AI093327 -2.3 2.0 -1.0 -1.0
SEC14L2 NM_012429 2.5 -2.4 -2.1 -2.1 TGFB2 NM_003238 -2.3 2.3 -1.1 -1.1
CTGF M92934 2.5 -2.9 -2.9 -2.2 LOC285513 AK026379 -2.3 2.3 1.8 1.3
FOS BC004490 2.5 -2.1 1.1 -1.7 NEIL3 NM_018248 -2.4 2.0 2.7 1.6
MT1F BF246115 2.4 -2.4 -2.2 -1.4 PTGS2 AY151286 -2.4 2.2 3.3 1.8
MT1G NM_005950 2.4 -2.2 -1.8 -1.6 EDN1 J05008 -2.5 2.1 2.7 2.0
SRGN J03223 2.4 -2.0 -1.3 -1.3 RND1 U69563 -2.5 2.3 2.3 1.5
PER2 NM_022817 2.4 -2.1 1.4 1.4 240173_at AI732969 -2.5 2.3 -1.1 -1.2
THBS1 NM_003246 2.4 -2.2 -4.4 -2.7 SLITRK6 AI680986 -2.6 2.7 -1.7 -1.7
KIAA0232 AF143884 2.4 -2.2 -7.4 -1.9 GREM1 AF154054 -2.6 2.3 -1.9 -2.0
JPH2 AA716165 2.4 -2.5 -2.5 -1.9 RBM24 AI677701 -2.6 2.1 1.8 1.4
PACSIN2 BC008037 2.4 -2.1 -2.0 -2.3 PTGS2 NM_000963 -2.7 2.5 3.7 2.0
THBS1 AV726673 2.4 -2.2 -3.8 -2.5 HMOX1 NM_002133 -2.7 2.4 1.2 -1.6
ZBTB20 AW974823 2.4 -2.4 -1.5 -1.1 FAM84B AL039862 -2.7 2.0 8.6 3.6
ARRB1 BF446943 2.4 -2.1 -2.4 -1.8 LONRF2 AV709727 -2.8 2.0 1.3 -1.1
PACSIN2 NM_007229 2.4 -2.0 -2.1 -2.1 IER2 NM_004907 -2.8 2.2 3.1 1.5
AHNAK BG287862 2.3 -2.1 -1.5 -1.4 HLCS AI682088 -2.8 2.1 1.4 1.1
HPCAL1 NM_002149 2.3 -2.2 -3.2 -3.0 SLC7A11 AB040875 -2.9 2.4 1.2 -1.6
213817_at AL049435 2.3 -2.2 -1.9 1.3 EREG NM_001432 -2.9 2.3 4.8 1.6
KLF6 BU683415 2.3 -2.1 -1.2 -1.4 IER3 NM_003897 -3.0 2.3 5.4 3.5
KLF6 BG250721 2.3 -2.0 -1.2 -1.3 GREM1 NM_013372 -3.0 2.5 -1.0 -1.5
LIFR AI680541 2.3 -2.3 -2.8 -2.4 SLC7A11 AA488687 -3.1 2.7 1.2 -1.5
EMP2 NM_001424 2.3 -2.2 -1.2 1.3 NR0B1 NM_000475 -3.2 2.6 2.2 1.2
LRRC8A AK024649 2.3 -2.1 -1.8 -2.1 LOC644943 AA876179 -3.2 2.8 1.8 1.2
SLC19A2 AF153330 2.3 -2.1 -1.2 -1.1 MAFK BG231691 -3.2 2.2 4.0 1.7
Accession numbers given are Affymetrix accession numbers.
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SLC22A5 NM_003060 2.3 -2.2 -2.1 1.0 CYP24A1 NM_000782 -3.3 3.0 2.1 1.0
KLF4 BF514079 2.3 -2.6 1.9 1.4 DIO2 AI038059 -3.3 2.7 1.2 -1.7
S100P NM_005980 2.3 -2.1 1.1 -1.0 ID4 AL022726 -3.4 2.4 -1.5 -1.4
MOBKL2B AI375115 2.3 -2.2 -3.3 -3.5 TGFB2 M19154 -3.6 3.3 1.0 -1.3
TMEM43 W74580 2.3 -2.2 -1.4 -1.3 NAV3 NM_014903 -3.8 2.1 -1.0 -1.2
MT1E AL031602 2.2 -2.3 -1.8 -1.6 NR4A2 AI935096 -3.9 2.5 40.9 5.8
ITGB4 NM_000213 2.2 -2.1 -1.5 -1.5 TM4SF20 NM_024795 -4.2 3.6 -1.0 -1.2
EPB41L4A NM_022140 2.2 -2.1 -1.9 -1.6 SOX2 AI669815 -4.3 2.7 -1.2 -1.1
KLHL29 BE465475 2.2 -2.3 -4.9 -4.1 MYOCD AI452798 -4.6 3.1 -1.5 -1.3
GPR115 NM_153838 2.2 -2.0 -3.1 -2.8 ST8SIA4 AA552969 -5.3 3.8 -1.2 -1.2
RHOU AL096776 2.2 -2.4 -2.5 1.3 ST8SIA4 AA352113 -5.6 5.1 -1.2 -1.4
RHOB AI263909 2.2 -2.4 -1.1 -1.5 NR4A2 NM_006186 -5.7 3.2 53.5 7.0
AKAP2 BG540494 2.2 -2.3 -2.1 -2.0 ST8SIA4 AI422986 -5.9 4.6 -1.3 -1.3
ENTPD2 AW134837 2.2 -2.3 -1.7 -1.5 IL11 NM_000641 -5.9 2.3 -1.1 1.1
KCNG1 AI332979 2.2 -2.1 -1.5 1.1 NR4A2 S77154 -6.0 3.1 63.6 7.0
TMEM43 AA115485 2.2 -2.1 -1.4 -1.3 GDF15 AF003934 -8.4 4.9 16.2 5.7
ST3GAL1 NM_003033 2.2 -2.2 1.0 1.2 229242_at BF439063 -9.2 7.6 2.1 1.9
Accession numbers given are Affymetrix accession numbers.
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Abstract
A high-throughput Cognate Site Identity (CSI) microarray platform interrogating all 
524,800 ten base pair-variable sites is correlated to quantitative DNase I footprinting 
data of DNA-binding pyrrole-imidazole polyamides.  An eight-ring hairpin polyamide 
programmed to target the 5 base pair sequence 5’-TACGT-3’ within the hypoxia 
response element (HRE) yielded a CSI microarray-derived sequence motif of 
5’-WWACGT-3’ (W = A,T). A linear β-linked polyamide programmed to target a (GAA)
3
 
repeat yielded a CSI microarray-derived sequence motif of  5’-AARAARWWG-3’ 
(R = G,A).  Quantitative DNase I footprinting of selected sequences from each microarray 
experiment enabled quantitative prediction of Ka values across the microarray intensity 
spectrum.
Cy3
Cy3
Cy3
[Ligand]
Cy3
Cy3
Cy3
Ka-calibrated
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3.1 Introduction
Cell-permeable small molecules that bind specific DNA sequences and are able to 
interfere with protein-DNA interfaces would be useful in modulating eukaryotic gene 
expression.  For targeting the regulatory elements of eukaryotic genes, knowledge of the 
preferred binding landscape of the ligand and the energetics of each site would guide gene 
regulation studies.  Pyrrole-imidazole polyamides are a class of cell-permeable oligomers 
that can be programmed, based on simple aromatic amino acid pairing rules, to bind a 
broad repertoire of DNA sequences.1  Knowledge of polyamide match sites has allowed 
us to pursue the characterization of the equilibrium association constants and hence, free 
energies, of hairpin polyamides for cognate DNA sites by quantitative footprint titration 
methods.  Despite the predictive power of simple pairing rules, the sequence-dependent 
variability of DNA minor groove shape affords significant variability in the range of 
affinities for match as well as all formal single and double base pair mismatch sites.1
Quantitative footprint titrations
 Characterization of polyamide binding preferences has been studied using quantitative 
DNase I footprinting titrations, affording binding isotherms that enable rigorous 
determination of the equilibrium association constant (Ka).
2  The resolution of footprinting 
is conservatively limited to association constants of 2-fold difference or greater.  Polyamide 
binding preferences have frequently been interrogated using DNA fragments roughly 100 
base pair in size containing as many as four 6-10 base pair binding sites, which are identical 
with the exception of a single position that iteratively exhibits A·T, T·A, C·G, and G·C 
base pairs.  Each binding site is interspersed with an 8 or more base pair spacer region 
to prevent interaction between the binding sites.3  Obtaining high quality data limits a 
32P end-labeled DNA fragment to four unique binding sites due to the resolving power of 
a polyacrylamide gel in a quantitative footprint titration.  While DNase I footprinting has 
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enabled the elucidation of a binding code for hairpin polyamides, a relatively limited set of 
binding sites has been studied.  To comprehensively interrogate all four encoded positions 
of an eight-ring hairpin polyamide, one would need 136 unique binding sites.  In addition, 
interrogation of the base pairs flanking the polyamide core would necessitate 2,080 
(for six base pairs total) or 32,896 (for eight base pairs total) binding sites.
CSI microarray platform
Several high-throughput platforms have been developed to characterize the binding 
properties of ligand-DNA interactions.4  Of these, two have explicitly studied the binding 
preferences of polyamides.  The fluorescence intercalator displacement assay has 
interrogated polyamide binding to 512 unique five base pair sequences in a microplate 
format.4b  The more recently developed cognate site identifier (CSI) microarray platform 
presents all 32,896 unique eight-mers (scalable to all unique ten-mers) to fluorescently 
labeled polyamides, enabling an unbiased interrogation of binding preference.4c  By 
coupling DNase I footprinting with the CSI microarray data, the binding affinities 
(Ka values) of a given DNA-binding molecule (such as a polyamide) for any DNA 
sequence can be determined (Figure 3.1).  To date, CSI microarray intensities of hairpin 
Cy3-polyamide conjugates have been linearly correlated to the Ka values of unlabeled 
polyamides.4c  We will examine whether this relationship between DNase I footprint 
titration-derived Ka values for Cy3-labeled polyamides and the corresponding microarray 
data remains true for additional polyamide binding architectures.  Because the 
Cy3-polyamide conjugate may alter sequence-specificity when compared with its 
biologically active counterpart, the sequence-specificities of fluorophore-labeled polyamide 
and the biologically relevant polyamide will also be determined.  
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Figure 3.1 Methods for analyzing DNA binding specificity
A) Quantitative DNase I footprinting gives rise to a defined equilibrium association constant at a specified 
binding site for a given DNA binding molecule.  B) The CSI microarray platform gives rise to relative binding 
preferences of an entire sequence space for the same molecule with a sequence logo as a standard summary 
output.
A CSI microarray harbors immense sequence specificity data; determining how to best 
represent this data is critical.  The first reported CSI work4c represented binding preferences 
as a sequence logo5 derived from several motif-finding algorithms6 that searched the 
highest Z-score bins (the ~300 highest intensities on the array), assigning equal weight to 
each sequence.  It also examined the relative abundance of each sequence motif mutation 
within its respective Z-score bin.4c  In this paper we observe that Ka-weighting sequence 
motifs does not alter the sequence logo appreciably.  In addition, a comprehensive single 
base pair mutational analysis is performed, which quantifies the specificities encoded by 
the polyamide at each position the polyamide interacts with DNA.
Two Cy3-labeled polyamides of biological interest7 are examined on the CSI 
microarray that displays all unique ten base pair sequences. These polyamides include a 
hairpin structure whose sequence specificities can be predicted from the extensive DNase I 
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footprinting data characterizing other pyrrole-imidazole polyamides1 and a linear β-linked 
structure whose sequence specificity is less well understood.8  In order to correlate the CSI 
relative affinities (intensities) to absolute affinities (Ka values), DNase I footprinting was 
performed on a subset of these sequences for both the Cy3-polyamide conjugates and the 
related, unlabeled polyamides of known biological activity.
3.2 Results
I. Polyamide design
Two polyamide core sequences have been chosen as representative of both hairpin 
and linear β-linked polyamide architectures.  These core recognition sequences exhibit 
biologically significant roles, modulating transcription in cell culture experiments.7 
Hairpin polyamides 1 and 2 (Figure 3.2), were selected based on results from a project in 
which a polyamide-fluorescein conjugate, Ct-Py-Py-Im-(R)-H2N-γ-Py-Im-Py-Py-(+)-FITC 
(1), displaced hypoxia inducible factor-1α (HIF-1α) from the hypoxia response element 
(HRE) of the vascular endothelial growth factor (VEGF) gene, downregulating VEGF 
expression 60% in cell culture experiments.7a,b  This eight-ring hairpin was programmed to 
bind the sequence 5’-WTWCGW-3’ (W = A,T).1,3c  In particular, polyamide 1 was shown 
to bind the HRE sequence, 5’-TACGTG-3’ on the VEGF promoter by footprint titration.7a,b 
The Cy3 moiety was conjugated (2) at the same position as fluorescein for 1 to best mimic 
the binding properties between the two polyamides.  
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Figure 3.2 Polyamides for CSI Studies
Hairpin polyamides 1 and 2 targeted to the hypoxia response element (HRE), 5’-TACGTG-3’.  Linear β-linked 
polyamides 3 and 4 targeted to GAA repeats in Friedreich’s ataxia.
As with polyamide 1, polyamide 3 (Figure 3.2) is known to bind its biologically 
relevant target. Polyamide 3, Im-Py-β-Im-Py-β-Im-β-Dp, targets an intronic 
5’-(GAA)n-3’ repeat hyperexpansion, enabling 2.5-fold upregulation of the frataxin gene, 
whose deficiency causes the neurodegenerative disorder Friedreich’s Ataxia.7c  Limited 
knowledge about the linear β-linked class of polyamides8 precludes the existence of binding 
rules.  The linear β-linked architecture has the added complexity of binding in 1:1 and 
2:1 ligand/DNA stoichiometries, and we would anticipate that this class will be generally 
less useful due to sequence promiscuity resulting from multiple binding modes.  Its 1:1 
binding preferences for purine tracts, such as (GAA)n, likely reflect shape selectivity for 
sequences with narrow DNA minor groove conformations.8c  In a 2:1 binding stoichiometry, 
polyamide 3 would be predicted to target 5’-WGCWGCWGCW-3’.8a  Remarkably, 
relatively few genes are affected from cell culture studies of 3 suggesting that this polyamide 
may be specific for 5’-AAGAAGAAG-3’.7c  The Cy3 fluorophore has been conjugated to 
the C-terminal 3,3’-diamino-N-methyldipropylamine tail (polyamide 4).
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II. CSI microarray design and results
CSI microarrays were synthesized using maskless array synthesis (MAS) technology9 
to display all 524,800 unique ten base pair sites in quadruplicate across six microarrays. 
Replicates of individual hairpins occur on separate microarrays.  Each hairpin on the 
chip consists of a self complementary palindromic sequence interrupted by a central 
5’-GGA-3’ sequence to facilitate hairpin formation: 5’-GCGC-N1N2N3N4N5N6N7N8N9N10-
GCGC-GGA-GCGC-N10’N9’N8’N7’N6’N5’N4’N3’N2’N1’-GCGC-3’ (N = A,T,C,G).  Previous 
experiments have found that 95% of the oligonucleotides on the array form duplexes.4c
0 20 40 60 800
0.5
1
1.5
2
2.5
3
CSI Intensity (× 103) (2)
Fr
eq
ue
nc
y (
× 
10
5 )
0 20 40 60 800
0.5
1
1.5
2
2.5
3
CSI Intensity (× 103) (4)
Fr
eq
ue
nc
y (
× 
10
5 )
A B
Figure 3.3 Histogram of microarray intensities
A) for polyamide 2, B) for polyamide 4
Polyamides 2 and 4 were slowly titrated onto the arrays and imaged at each 
concentration until saturation of the highest intensity binding sites was observed, 
10 nM and 175 nM concentrations, respectively for 2 and 4.  After each small addition 
of polyamide, the arrays were washed prior to imaging.  The data for each of the arrays 
was then normalized as previously described4c to give averaged sequence intensities of the 
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524,800 ten base pair sites for 2 and 4.  As found with previously reported CSI arrays,4c 
histograms of the probe intensities for 2 and 4 display a strong right-handed tail 
(Figure 3.4).  The fractional standard deviations among probe replicates (standard deviation 
of replicates/average normalized intensity) average 0.15 ± 0.09 (polyamides 2 and 4), for 
intensities exceeding 1 × 103 (Figure 3.4).
BA
Fractional Standard Deviation (2)
Fr
eq
ue
nc
y (
× 
10
3 )
2
00 0.2 0.4 0.6 0.8 1 1.2 1.4
4
6
8
10
12
Fractional Standard Deviation (4)
Fr
eq
ue
nc
y (
× 
10
3 )
2
00 0.2 0.4 0.6 0.8 1 1.2 1.4
4
6
8
10
1214
Figure 3.4 Histogram of microarray fractional standard deviations
Fractional standard deviation was calculated as standard deviation of intensities for a specific 
sequence/average sequence intensity for that specific sequence.   A) for polyamide 2, B) for polyamide 4
III. Plasmid design  
Three plasmids have been designed based on output from the CSI microarray intensities 
(Figure 3.5).  Because of our interest in testing the dynamic range of the CSI assay in terms 
of the representative Ka values measured by a broad range of intensities, plasmids pKAM3 
and pJWP17 were constructed to harbor binding sites of equal intensity spacing across 
a broad portion of each array’s intensities, between highest and lowest intensities.  The 
Ka values found using pKAM3 were tightly clustered across the three highest intensities, 
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necessitating further interrogation.  Plasmid pKAM4 was designed to probe three additional 
intensities.  A single binding site (IIIa and Ib) was held constant between pKAM3 and 
pKAM4 to enable interplasmid comparison of binding affinities.  Because pJWP17 afforded 
Ka values broadly spaced across the intensity spectrum, no further study was pursued.
Since our goal is to directly compare footprinting-derived Ka values with 
CSI array-derived intensities, each plasmid binding site mimics the full ten base pair 
binding site from the array in addition to two flanking base pairs on either side of the 
binding site: 5’-GC-(N)10-GC-3’ (N = A,T,C,G).  Attempts to fully replicate the 
5’-GCGC-(N)10-GCGC-3’ binding site from the array exhibited secondary structure 
formation when the respective amplicons were sequenced and separated by denaturing gel 
electrophoresis.
283 bp32P Eco RI Pvu IIpKAM-3
G
A
5'-GCGC TTTTACGGAA GCGC G3'-CGCG AAAATGCCTT CGCG
B
A
C
5'-GATC GGAGC TTTTACGTAA GCGGAGGC TTTTACGTAG GCGGAGGC TTTTACGTGA GCGGAGGC TTTTACGGAA GCGGAT AGCT-3'
3'-CTAG CCTCG AAAATGCATT CGCCTCCG AAAATGCATC CGCCTCCG AAAATGCACT CGCCTCCG AAAATGCCTT CGCCTA TCGA-5'
75.6 51.4 31.3 4.2
Ia IIa IIIa IVa
5'-GATC GGAGC TTTTACGTGA GCGGAGGC AATTTCGTGT GCGGAGGC GCTTTCGTCC GCGGAGGC ACCTTCGTGA GCGGAT AGCT-3'
3'-CTAG CCTCG AAAATGCACT CGCCTCCG TTAAAGCACA CGCCTCCG CGAAAGCAGG CGCCTCCG TGGAAGCACT CGCCTA TCGA-5'
pKAM-4
31.3 20.0 12.0 6.0
Ib IIb IIIb IVb
5'-GATC GGAGC AAGAAGAAGT GCGGAGGC AAGAAGTTCA GCGGAGGC ATGTTGTTGA GCGGAGGC ATGAAGACGA GCGGAT AGCT-3'
3'-CTAG CCTCG TTCTTCTTCA CGCCTCCG TTCTTCAAGT CGCCTCCG TACAACAACT CGCCTCCG TACTTCTGCT CGCCTA TCGA-5'
pJWP-17
75.2 51.2 26.8 4.1
Ic IIc IIIc IVc
Cy3
Cy3
Cy3
Figure 3.5 Insert sequences utilized in plasmids
Binding sites are boxed, labeled with their corresponding CSI array intensity (× 103), and numbered. 
A) pKAM3 is shown, in addition to a microarray schematic demonstrating the relationship between the 
plasmid and a selected microarray sequence.  B) pKAM4.  C) pJWP17
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IV. Quantitative DNase I footprint titrations: affinity and specificity determination  
Hairpin polyamides 1 and 2 were incubated each for 14 h with pKAM3 or pKAM4 
prior to DNase I cleavage.  These two polyamides were found to bind each of seven unique 
ten-base pair binding sites in the same rank-order, preferentially binding 
 5’-TTTTACGTAA-3’ with affinities of 7.5 × 109 M-1 (1) and 4.5 × 109 M-1 (2) 
(Table 3.1 and Figure 3.6).  Replacing the flourescein dye on polyamide 1 with Cy3 
(polyamide 2) introduced an energetic penalty that ranged from 1.5- to 10-fold, with the 
minimum penalty occurring at the two highest CSI intensity binding sites (Table 3.1). 
Polyamide 2 differentiated the highest and lowest affinity binding sites by 70-fold, slightly 
more than the 50-fold differentiation found for the fluorescein-labeled polyamide 1.
Polyamide
CSI Intensity (× 103)
1 +FITC (+)
2 +Cy3 (+)
pKAM-3
pKAM-4
Polyamide
CSI Intensity (× 103)
1 +FITC (+)
2 +Cy3 (+)
TTTTACGTAA
75.6 (±9.9)
7.5 (±1.8) × 109
[1]
4.5 (±1.0) × 109
[1]
TTTTACGTGA
31.3 (±4.8)
5.4 (±0.9) × 109
[1.3]
1.6 (±0.2) × 109
[2.8]
Ia
Ib
TTTTACGTAG
51.4 (±7.4)
5.1 (±0.6) × 109
[1.5]
3.0 (±0.6) × 109
[1.5]
AATTTCGTGT
20.0 (±2.8)
2.3 (±0.1) × 109
[3.2]
4.0 (±0.9) × 108
[11]
IIa
IIb
TTTTACGTGA
31.3 (±4.8)
4.2 (±0.6) × 109
[1.8]
2.1 (±0.3) × 109
[2.1]
GCTTTCGTCC
12.0 (±1.5)
2.8 (±0.2) × 109
[2.6]
5.8 (±0.7) × 108
[7.8]
IIIa
IIIb
TTTTACGGAA
4.2 (±1.4)
1.5 (±0.8) × 108
[50]
6.2 (±2.0) × 107
[73]
ACCTTCGTGA
6.0 (±0.4)
1.5 (±0.2) × 109
[5]
1.3 (±0.2) × 108
[34]
IVa
IVb
The 10 base pair binding sites and corresponding CSI Microarray intensities are found in each column.  All 
footprinting incubations were conducted at a minimum in triplicate at 23 ºC for 14 h.  Standard deviations are 
shown in parentheses.  The bracketed numbers are Ka–max/Ka–current to compare values within each polyamide 
series.
Table 3.1  Quantitative DNase I footprinting-derived Ka values (M–1) for 1 and 2
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Figure 3.6 DNase I footprinting gels and corresponding isotherms of polyamides 1 and 2 on pKAM3 and 
pKAM4
A) Polyamide 1 on pKAM3  B) Polyamide 2 on pKAM3  C) Polyamide 1 on pKAM4  D) Polyamide 2 on 
pKAM4
Linear β-linked polyamides 3 and 4 were each incubated for 14 h with pJWP17 prior 
to DNase I cleavage.  They bound four unique ten base pair sites in the same rank-order, 
preferentially binding 5’-AAGAAGAAGT-3’ (Table 3.2 and Figure 3.7).  
Appending the Cy3 dye to polyamide 3 either had no effect on affinity or reduced 
binding affinity as much as 30-fold (Table 3.2).  Polyamide 3 bound all four binding sites 
over a 2400-fold range in affinity, eight times broader than for polyamide 4.
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pJWP-17
Polyamide
CSI Intensity (× 103)
3
4
+
(+)Cy3
AAGAAGAAGT
75.2 (±9.2)
2.4 (±0.6) × 1010
[1]
3.3 (±0.7) × 109
[1]
Ic
AAGAAGTTCA
51.2 (±6.2)
9.3 (±2.3) × 109
[3]
2.7 (±0.8) × 108
[10]
IIc
ATGTTGTTGA
26.8 (±7.3)
2.9 (±0.7) × 108
[80]
1.1 (±0.4) × 108
[30]
IIIc
ATGAAGACGA
4.1 (±0.4)
1.0 (±0.4) × 107
[2400]
1.0 (±0.2) × 107
[330]
IVc
Table 3.2 Quantitative DNase I footprinting-derived Ka values (M–1) for 1 and 2
The 10 base pair binding sites and corresponding CSI Microarray intensities are found in each column.  All 
footprinting incubations were conducted at a minimum in triplicate at 23 ºC for 14 h.  Standard deviations are 
shown in parentheses.  The bracketed numbers are Ka–max/Ka–current to compare values within each polyamide 
series.
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Figure 3.7 DNase I footprinting gels and corresponding isotherms of polyamides 3 and 4 on pJWP17
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V. Calibrating microarrays for Ka prediction  
Because DNase I footprinting enables the calculation of Ka and the direct comparison 
of four binding sites in a single assay, determining energetics data from CSI microarrays 
is crucial for understanding the global binding specificity of a polyamide.  An eight-ring 
hairpin polyamide targeting 5’-WGWWCW-3’ (W = A,T) and characterized by quantitative 
DNase I footprinting, Im-Py-Py-Py-γ-Im-Py-Py-Py-β-Dp,3c,10 has been compared to its 
Cy3-labeled counterpart studied on the CSI-array platform, demonstrating a linear 
relationship between intensity and Ka.
4c  
Because microarray intensity at a specific microarray feature should be proportional 
to the fractional occupancy of DNA at that feature, the relationship between equilibrium 
association constant (Ka) or dissociation constant (Kd) and background-normalized 
microarray intensity should be:11
Intensity = c × Θ = c × Ka[PA]1+Ka[PA]
[PA]
Kd+ [PA]
= c × (1)
In this relationship, Θ represents the fractional occupancy of DNA at a specific 
feature, c a scalar to reflect that microarray intensity can vary with incident laser intensity, 
and [PA] the free polyamide concentration on the CSI array.  The terms c and [PA] are solved 
for a curve fit to Equation 1 using Ka values derived from DNase I footprint titrations and 
CSI microarray intensity data.  Examining the limiting case where [PA] « Kd being studied 
one observes a simplification to Equation 1:
(2)Intensity = c × [PA]Kd
= c × [PA] × Ka
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Equation  2  represents the linear subset of the more general CSI intensity–Ka 
relationship described in Equation 1.  Fitting the footprinting data of polyamide 2 to its 
corresponding microarray intensities (Table 3.1) using Equation 2 fits well (R2 = 0.94). 
The linearized Equation 2 does not, however, map intensity and Ka with high correlation 
for polyamide 4.  Fitting the data to Equation 1 affords a better fit (R2 = 0.99), indicating 
that [PA] is not insignificant relative to the Kd of the highest intensity microarray data 
(Figure 3.8).12,13
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Figure 3.8 CSI array intensities correlate well with DNase I footprinting-determined Ka values
 
A) Polyamide 2 versus CSI array fit to Eq 2  B) Polyamide 4 versus CSI array fit to Eq 1
 
 The Ka-calibrated microarrays can subsequently be used to interpolate Ka values from 
normalized sequence intensities.  Ka values are derived by rearranging Equation 1 to present 
Ka as a function of microarray intensity:
In the case where [PA] « Kd, Equation 2 rearranged to:
(4)Ka = Intensity[PA] × c
(3)Ka = Intensity[PA] × (c – Intensity)
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Figure 3.9 Correlation of footprinting and CSI data
A) Log-log scale plot of polyamide 2 versus CSI intensity data fit using Equation 2 B) Log-log scale plot of 
polyamide 4 versus CSI intensity data fit using Equation 1e. C) Linear-linear scale plot of polyamide 2 versus 
CSI data using Equation 2e D) Linear-linear scale plot of polyamide 4 versus CSI data using Equation 1 E)
Log-log scale plot of polyamide 2 versus CSI intensity data fit using Equation 2e F) Log-log scale plot of 
polyamide 4 versus CSI intensity data fit using Equation 1e
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VI. Correlating binding between Cy3-labeled and biologically relevant polyamides
While establishing a general Ka–intensity relationship for Cy3-labeled polyamides is 
a crucial first step towards global sequence interrogation of a core polyamide motif, it 
is equally important that the biologically relevant polyamide has sequence preferences 
that correlate with its Cy3-labeled counterpart.  Scatter plots of polyamide 1 vs. 2 and 
polyamide 3 vs. 4 are best fit by a power relationship of y=axn, where (x,y) denotes the Ka 
values for (1, 2) or (3, 4) (Figure 3.10).14  The R2 between 1 and 2 is 0.87, and that between 
3 and 4 is 0.78.
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Figure 3.10 Cy3-labeled polyamides and unlabeled polyamides correlate well
A) Correlation of Ka values for polyamide 1 (fluorescein labeled) and polyamide 2 (Cy3 labeled). 
B) Correlation of Ka values for polyamide 3 (unlabeled) and polyamide 4 (Cy3 labeled)
VII. Sequence Analysis
To graphically represent the binding preferences of polyamides 2 and 4, sequence 
logos have been generated (Figure 3.11 A ,B). In all cases, the motif-finding program 
MEME6a was utilized to extract sequence motifs from the CSI binding intensities.  The 
position-specific probability matrices output by MEME were used as inputs to enoLOGOS15 
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to generate a sequence logo16  The logo for polyamide 2 was created by searching the ~2500 
highest sequence intensities of the CSI microarray.17  These data points span approximately 
a 3-fold range in Ka.  The logo for polyamide 4 interrogated the 48 highest intensity sequences 
(a 7-fold range in Ka) of the CSI microarray.
18  We examined Ka-weighted sequence 
logos for both polyamides 2 and 4 and found minimal differences in the resulting logos 
(Figure 3.11).
The  motif for polyamide 2 has the most information at a site width of six: 5’-WWACGT-3’ 
(Figure 3.11, W = A,T).  The chlorothiophene/pyrrole pair (Ct/Py) specificity cannot be 
globally elucidated using polyamide 2 because of the palindromic nature of the ACGT 
binding site core.  It is evident that the core does specify 5’-ACG-3’ using Py/Py, Py/Im, 
and Im/Py pairings, respectively.  Polyamide 3 specifies nine base pairs based on MPE 
footprinting data.8d  Polyamide 4 elicits a nine base pair motif that is best represented as 
1 2 3 4 5 6
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0.0
1.0
2.0
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ts
5 3
ATATTACAGAT
(+)Cy3
1 2 3 4 5 6 7 8 90.0
1.0
2.0
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T
CAAAGATACAGTATAATG
3ʹ
1 2 3 4 5 6
+Cy3 (+)
0.0
1.0
2.0
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ts
5 3
ATATTACAGATC 1 2 3 4 5 6 7 8 90.01.02.0bits 5ʹCAAAGATACAGTATATG3ʹ
(+)Cy3
D
A B
Figure 3.11 Ka-weighting components of individual sequence logos does not alter the sequence logo
A) Sequence logo for polyamide 2. B) Sequence logo for polyamide 4.  C) Ka-weighted sequence logo for 
polyamide 2.  D) Ka-weighted sequence logo for polyamide 4.
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5’-AARAARWWG-3’ (Figure 3.11, B; R = G,A and W = A,T).  Previous work would 
suggest that Im may have no sequence preferences within linear β-linked polyamides,8 
although this selection of nine base pair high-affinity binding sites for 4 suggests at least 
G·A or A·T specificity, consistent with microarray data from Friedreich’s Ataxia cell culture 
work.7c
VIII. Quantitative profiling of single base pair mismatches
While sequence logos provide a visual representation of sequence specificity, 
traditional studies on polyamides quantitate the specificity of a ring pairing at a selected 
base pair.  We have examined a comprehensive single base pair mutational analysis of 
both polyamides 2 and 4 using Ka values interpolated from the calibrated CSI microarrays 
(Table 3.3, Table 3.4).19 Because the motif-finding algorithm MEME found 
5’-WWACGT-3’ (W = A,T) as a preferred binding sequence for polyamide 2, we utilized 
this core sequence for mutational studies.  Additionally, because of the 5’-ACGT-3’ 
palindromic element of this binding site, we have isolated only binding sites containing 
5’-WWWWWWACGT-3’ and their mutant counterparts to preclude analyzing variants 
where the polyamide may be rotated 180º from the presumed orientation. To determine 
a Ka for 5’-WWWWWWACGT-3’ (for example), the geometric mean of all microarray 
binding site intensities containing this motif was found.  Walking from 5’ to 3’ on 
5’-W1W2A3C4G5T6-3’, we observe that there is 3-fold specificity for W versus S (S = C,G) 
at position 1 (occupied by the linker).  At position 2 (Ct/Py pair), there is 20-fold specificity 
for W versus S, but minimal for T·A versus A·T.  The previous study of Ct/Py specificity 
noted only modest specificity for T·A versus A·T.3c   Position 3 (a Py/Py pair) confirms 
the previously observed W over S specificity.  At position 4 (a Py/Im pair) the polyamide 
encodes the greatest specificity with preference for C·G versus A·T, T·A, or G·C.  It is 
likely that this preference is at least 20-fold.  At position 5, polyamide 2 appears to exhibit
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X·Z
A·T
T·A
C·G
G·C
A·T
T·A
C·G
G·C
A·T
T·A
C·Ga
G·C
A·Ta
T·Aa
C·G
G·Ca
A·T
T·A
C·G
G·C
A·T
T·A
C·Ga
G·Ca
Ka (M-1)
2.0 (1.4) × 109
2.5 (1.2) × 109
6.9 (1.4) × 108
6.8 (1.6) × 108
1.8 (1.3) × 109
2.7 (1.2) × 109
1.0 (2.0) × 108
1.3 (2.2) × 108
2.2 (1.3) × 109
1.1 (1.6) × 109
≤ 108
1.3 (2.5) × 108
≤ 108
≤ 108
2.2 (1.3) × 109
≤ 108
1.2 (1.4) × 109
2.9 (1.8) × 108
2.4 (1.8) × 108
2.2 (1.3) × 109
1.3 (1.4) × 109
2.2 (1.3) × 109
≤ 108
≤ 108
+Cy3 (+)
5'-W W W W X W A C G T-3'
3'-W W W W Z W T G C A-5'
+Cy3 (+)
5'-W W W W W X A C G T-3'
3'-W W W W W Z T G C A-5'
+Cy3 (+)
5'-W W W W W W X C G T-3'
3'-W W W W W W Z G C A-5'
+Cy3 (+)
5'-W W W W W W A X G T-3'
3'-W W W W W W T Z C A-5'
+Cy3 (+)
5'-W W W W W W A C X T-3'
3'-W W W W W W T G Z A-5'
+Cy3 (+)
5'-W W W W W W A C G X-3'
3'-W W W W W W T G C Z-5'
Polyamide 2
 All Ka values are derived from the geometric average of all CSI binding site intensities on the array containing 
a specified sequence, converted to a Ka value using Eq 4, corrected to include an error term ε.  The values in 
parentheses are the geometric standard deviations for each Ka value. X·Z entries marked with a superscripted 
“*” contain averaged intensities below ε.  For these entries, an upper bound on the Ka is estimated based on 
the log-log plot of Ka versus intensity found in Figure 3.9.
Table 3.3 Microarray-derived binding affinities and specificities of all single base pair 
mismatch sites for polyamide 2
  
less specificity than would be predicted for an Im/Py ring pair, binding almost as well to 
A·T as to G·C.1  The polyamide “turn unit,” position 6, confirms a strong preference for 
W over S.1  Through this quantitative study, we observe four strongly encoded binding 
positions, italicized in 5’-WWWCGW-3’.  The discrepancy between the observed sequence 
logo, as found by MEME, and the suggested specificity by a single base pair mutation 
study likely stems from (i) the examination of all sequences in the single base pair mutation 
as compared to only a subset for the sequence logo, (ii) the assumption by the logo of 
independence of base pair-polyamide interaction at each position, and (iii) the examination 
in the single base pair mutation of the average Ka of a group of sequences containing a 
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specified motif.
X·Z
A·T
T·A
C·G
G·C
A·T
T·A
C·G
G·C
A·T
T·A
C·G
G·C
A·T
T·A
C·G
G·C
A·T
T·A
C·G
G·C
A·T
T·A
C·G
G·C
A·T
T·A
C·G
G·C
A·T
T·A
C·G
G·C
A·T
T·A
C·G
G·C
Ka (M-1)
1.6 (2.2) × 108
8.7 (2.0) × 107
4.3 (1.8) × 107
4.7 (1.8) × 107
1.6 (2.2) × 108
7.7 (2.2) × 107
2.1 (1.8) × 107
3.2 (1.9) × 107
1.6 (2.2) × 108
4.3 (1.8) × 107
9.9 (1.9) × 106
7.5 (2.6) × 106
1.6 (2.2) × 108
8.3 (2.2) × 107
9.1 (2.1) × 106
1.1 (2.0) × 107
1.5 (2.1) × 108
5.5 (1.7) × 107
8.5 (1.7) × 107
1.7 (2.3) × 108
1.7 (2.2) × 108
1.5 (2.2) × 108
2.2 (2.2) × 107
2.0 (2.4) × 107
1.6 (2.5) × 108
1.5 (2.0) × 108
3.5 (2.0) × 107
3.9 (2.0) × 107
1.2 (1.9) × 108
1.1 (2.0) × 108
1.1 (1.7) × 108
1.6 (2.2) × 108
1.3 (2.0) × 108
3.5 (1.7) × 107
8.4 (1.6) × 107
2.0 (2.2) × 108
Polyamide 4
5'-X A R A A R W W G-3'
3'-Z T Y T T Y W W C-5'
(+)Cy3
5'-A X R A A R W W G-3'
3'-T Z Y T T Y W W C-5'
(+)Cy3
5'-A A R X A R W W G-3'
3'-T T Y Z T Y W W C-5'
(+)Cy3
5'-A A R A X R W W G-3'
3'-T T Y T Z Y W W C-5'
(+)Cy3
5'-A A R A A X W W G-3'
3'-T T Y T T Z W W C-5'
(+)Cy3
5'-A A R A A R X W G-3'
3'-T T Y T T Y Z W C-5'
(+)Cy3
5'-A A R A A R W X G-3'
3'-T T Y T T Y W Z C-5'
(+)Cy3
5'-A A R A A R W W X-3'
3'-T T Y T T Y W W Z-5'
(+)Cy3
5'-A A X A A R W W G-3'
3'-T T Z T T Y W W C-5'
(+)Cy3
 All Ka values are derived from the geometric average of all CSI binding site intensities on the array containing 
a specified sequence, converted to a Ka value using Equation 3, corrected to include an error term ε.  The 
values in parentheses are the geometric standard deviations for each Ka value.
Table 3.4 Microarray-derived binding affinities and specificities of all single base pair 
mismatch sites for polyamide 4
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3.3 Discussion
In conjunction with the sequence logo for polyamide 2, the CSI array analysis validates 
the sequence specificity programmed by the aromatic amino acid ring pairs.  The extensive 
DNase I footprinting data on eight-ring and six-ring hairpin polyamides, while limited on 
the scale of a CSI microarray, enabled the creation of pairing rules that are remarkably 
general.1  It is evident from the microarray that Im/Py and Py/Im ring pairs offer the greatest 
specificity for a single base pair, while Py/Py, Ct/Py, and the “turn unit” afford general W 
specificity.  While the Ct/Py ring pair conferred minimal specificity for T·A versus A·T, 
its W specificity is likely an improvement over the use of a Py/Py ring pair, which at the 
N-terminus of an eight-ring hairpin polyamide exhibits specificity for A·T, T·A, and G·C 
versus C·G.3c  The sequence specificity of 2 correlates remarkably well with the 5’-ACGT-
3’ specificity of echinomycin,20 also known to affect VEGF expression in cell culture.21 
The examination of polyamide 4 marks the most comprehensive sequence specificity study 
of a linear b-linked polyamide since the original examination of the binding specificity 
for Im-β-Im-Py-β-Im-β-Im-Py-β-Dp.8a,b  In the 5’-A1A2R3A4A5R6W7W8G9-3’ sequence 
(R = G,A; W = A,T), positions 4, 5, and 7, each containing either a Py or a β, exhibit the 
greatest specificity for W over S (S = C,G).  Intriguingly, the β at position 4 prefers A·T 
over T·A, an unexpected specificity.  The sequence logo for polyamide 4 indicates that 
Im has modest preference for G·C or A·T over other base pairings – in this mutational 
study, however, imidazole is generally degenerate. The wide range of Ka values comprising 
each motif (high geometric standard deviation) make the statistical significance of any 
specificities under 4 relatively small.  In general, the geometric standard deviations for 
polyamide 4 were higher than those for polyamide 2, when including only those table 
entries for polyamide 2 in which each Ka value was composed of all instances of the motif. 
One potential source of the increased standard deviation in binding affinities is the single 
variable base flanking the nine base pair binding site for polyamide 4.  Because the minor 
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groove width is a potentially important contributor to binding affinity and specificity for the 
linear β-linked class of polyamides,8c a single variable, flanking base is unlikely to enable 
comprehensive interrogation of the global set of sequence-dependent DNA microstructures. 
As with polyamide 2, the discrepancies observed between the sequence logo of polyamide 
4 and the comprehensive single base pair mutational analysis likely stem from similar 
causes.
With the sequence logo (approximated as 5’-AARAARWWG-3’) as a snapshot of the 
highest affinity binding sites for polyamide 4 (Ka ≈ 5 × 108 to 3.3 × 109 M-1) and the footprint 
titration binding isotherms for determining DNA binding mode, we confirm a preference 
for the 1:1 binding stoichiometry.  Previous data characterizing the linear β-linked 
polyamide Im-β-Im-Py-β-Im-β-Im-Py-β-Dp demonstrated a 30-fold energetic preference 
for the 1:1 versus 2:1 binding stoichiometry, presumably due to the increased entropic 
cost of the 2:1 binding mode.8a  It is remarkable that polyamide 3 exhibited specificity for 
upregulation of the frataxin gene in cell culture,7c since the sequence preference for 4 was 
not overwhelmingly 5’-AAGAAGAAG-3’.  Two possible explanations for this observation 
are (i) that multiple binding events in the genome have marginal effects on transcription 
and that the specificity is amplified by the GAA repeat expansion in Friedreich’s Ataxia, or 
(ii) that many of the sequences described by 5’-AARAARWWG-3’ exist in higher order 
chromosomal structures that cannot be targeted by polyamide 3.
Suggestions for microarray usage
In the case where the free ligand concentration is small relative to the Kd for each 
binding site on the CSI microarray, a linear Ka – intensity relationship is observed.  The 
binding profiles examined for polyamide 2 and for previously studied molecules are 
examples of linear Ka – intensity relationships.  For the highest intensity sites also studied by 
DNase I footprinting (Figure 3.8a), the CSI microarray experiment contains greater 
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resolving power and can differentiate Ka values that are indistinguishable by quantitative 
DNase I footprint titrations.  In this example, as CSI intensity data approach ε, small 
changes in intensity yield large changes in predicted Ka.  Because the characterization of 
DNA-binding ligands is most concerned with defining a perfect match site, this limitation 
is minor.  CSI data for polyamide 2 conservatively enables distinguishing a 50-fold range 
of Ka values, thus encompassing the majority of single base pair mismatch specificities.
In the case where the free ligand concentration is comparable to the Kd, a non-linear 
Ka–intensity relationship is observed.  The binding profile for polyamide 4 marks an 
example of a CSI microarray studied compound that occurs outside the linear range of 
Equation 1.  In this case, closely clustered high-intensity data points can span a broad 
range of Ka values (Figure 3.8b).  The error inherent to the CSI microarray analysis is thus 
amplified when Ka values in this high-CSI-intensity region are interpolated.
Because of the gradual polyamide titration onto the array, it should be possible to 
capture snapshots of both polyamide saturation within the linear Ka–intensity region for 
the highest affinity binding sites on the microarray and binding site saturation enabling 
lower intensity data points to fall within the higher precision linear Ka–intensity region. 
Such titration may enable high-precision Ka data to be extracted from all intensities of the 
microarray.
The sequence logos presented in this paper represent a snapshot of a binding profile for 
the highest affinity binding sites by a dye-labeled ligand.  The polyamide core dictates the 
majority of the binding specificity revealed by CSI microarray analysis – the presence of 
a Cy3 label may reduce affinity to a binding site relative to its unlabeled counterpart but 
does not alter the rank-order of binding preferences.  Complementing the graphical image 
of a sequence logo, the comprehensive single base pair mutational analysis afforded by 
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the extensive microarray data quantitates one’s understanding of the polyamide sequence 
preferences.
Conclusion
Correlating the sequence preference landscape present on the CSI microarray to 
quantitative footprinting enables energetic studies using global binding information.  This 
capacity marks a significant forward step for the field of small molecule·DNA recognition 
and enables the comprehensive interrogation of DNA binding small molecules to be better 
understood.  The elucidation of 5’-WWACGT-3’ as the binding site for 2 confirmed the 
previously established pairing code for hairpin polyamides, and the determination of 
5’-AARAARWWG-3’ for 4 helps explain the specificity it exhibited in cell culture.  The 
correlation between a Cy3-labeled polyamide and an unlabeled polyamide of biological 
interest means that these motifs well approximate the binding profiles for 1 and 3, 
respectively.  DNase I footprinting-calibrated CSI microarrays have been shown to be an 
effective technique for determining the binding affinities of DNA-binding ligands for a 
vastly expanded repertoire of DNA sequences, and we envision them to be a critical tool 
for reliably determining sequence specificity for other ligands in the future.
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3.4 Materials and Methods
Materials 
Boc-β-Ala-Pam resin (0.81 mmol/g), Boc2O and the chiral amino acid 
Fmoc-D-Dab-Boc-OH were purchased from Peptides International. Kaiser oxime resin 
(0.56 mmol/g) was purchased from Novabiochem. Trifluoroacetic acid (TFA) was purchased 
from Halocarbon. All solvents were purchased from Aldrich or EMD Biosciences. 
rac-Dithiothreitol (DTT) was purchased from ICN.  Cy3-NHS ester was purchased 
from Invitrogen. RNase-free DEPC water was purchased from US Biochemicals. Water 
(18.2 MΩ) was purified using a Millipore water purification system.
The pH of buffers was adjusted using a Beckman 340 pH/temp meter. All buffers were 
sterilized by filtration through either a Nalgene 0.2 μm cellulose nitrate filtration device 
or a 0.2 μm Whatman cellulose acetate disposable syringe filter. DNA oligonucleotides 
were ordered PAGE-purified from Integrated DNA Technologies.  [γ-32P] adenosine 
5’-triphosphate (≥ 7000 Ci/mmol) was obtained from MP Biomedicals.  Sonicated, phenol-
extracted calf thymus DNA was from Amersham, and all enzymes and molecular biology 
grade glycogen (20 mg/mL) were purchased from Roche.
Methods 
UV spectra were recorded in water using an Agilent 8453 UV-Vis spectrophotometer 
for polyamide 3.  To solvate polyamides 1, 2, and 4 in water at sufficiently high 
concentrations for DNase I footprinting, 5 mL of DMSO was added to a 20 nmol aliquot 
of polyamide.  The solution was then diluted using RNase-free DEPC water.  UV spectra 
of 1, 2, and 4 were blanked against solutions containing appropriate amounts of DMSO. 
The concentrations of polyamides 1 and 2 were determined using a local λ
max
 of 313 nm, 
ε = 69,500 L·mol–1·cm–1. The concentrations of polyamides 3 and 4 were determined 
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using a local λ
max
 of 288 nm, ε = 43,125 L·mol–1·cm–1. LASER desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS) was performed using an Applied 
Biosystems Voyager DE Pro spectrometer. Analytical and preparative high-pressure 
liquid chromatography (HPLC) were performed with a Beckman Gold system equipped 
with a diode array (analytical) or single-wavelength (preparative) detector as previously 
described.4c,7
i. Polyamide synthesis 
Pyrole and imidazole monomer units (Boc-Py-OBt [(1,2,3-Benzotriazol-1-yl 4-[(tert-
Butoxycarbonyl)amino]-1-methylpyrrole-2-carboxylate) and Boc-Im-OH (4-[(tert-
Butoxycarbonyl)amino]-1-methylimidazole-2-carboxylic acid) respectively) are 
synthesized according to established protocols25  and maintained as general group stock. 
Fmoc-D(Dab)-Boc-OH turn monomer unit  and Boc2O were purchased from Peptides 
International. 
Polyamides 1 and 2 were synthesized on Kaiser oxime resin22 and 3 and 4 were 
synthesized on Boc-β-Ala-PAM resin,23 using previously described methods.4c,7 In a typical 
synthesis, 4 molar equivalents (relative to resin loading for the lot of oxime resin used) 
of monomer unit were activated with 4 equivalents of PyBOP (NovaBiochem)  and 4 
equivalents of diisopropyletheylamine (DIEA) in a solution of dimethylformamide (DMF) 
(solution was approximately 0.3-0.5 M in monomer unit). In a glass peptide synthesis 
vessel, the resin was shaken with this solution for 2-4 hours at room temperature until the 
reaction was complete, as assessed by analytical HPLC of a cleaved sample of resin. Resin 
was deprotected by shaking in a solution of 20% trifluoroacetic acid (TFA) in methylene 
chloride for 20 minutes at room temperature. After completion of synthesis of the oligomer 
the Fmoc protecting group was removed by 10 minute incubation with 20% piperidine in 
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DMF at room temperature. The free amine was subsequently protected by incubation of the 
resin for 1 hour in a solution of Boc2O in DMF.  The polyamide was subsequently cleaved 
from resin by incubation at 55 °C with 3,3-diamino-N-methyl-dipropylamine overnight 
(8-14 hours). The cleavage product was purified by reverse-phase HPLC, frozen in LN2 
and lyophilyzed to dryness. 
To conjugate polyamides to FITC or Cy3 fluorophore, a lyophilized aliquot of 
polyamide was dissolved in DMF to a final concentration ~0.03M, DIEA (100 eq) and 1mg 
FITC isomer 1 isocyanate (polyamide 1) or Cy3-NHS monoester (polyamides 2 and 4) were 
added and the reaction was allowed to shake in darkness for 1 hour at 37 °C. Following 
conjugation the polyamide was precipitated from solution by addition of cold diethyl ether 
and the precipitate was pelleted by centrifugation, the supernatant was removed and the 
pellet was allowed to air-dry. The Boc protecting group was removed by the addition of 
100μL of neat TFA to the pellet. The deprotection proceeded for 10 min at room temperature 
before being diluted with 20% acetonitrile/water (0.1% TFA) followed by purification by 
reverse-phase HPLC. Purities and identities of the polyamides were assessed by HPLC, 
UV-visible spectroscopy, and MALDI-TOF MS.
1: (MALDI-TOF) [M+H]+ calcd for C
77
H
80
ClN22O14S2
+ 1635.5, observed 1635.9
2: (MALDI-TOF) [M+H]+ calcd for C
87
H
105
ClN
23
O16S3
+ 1858.7, observed 1858.7
3: (MALDI-TOF) [M+H]+ calcd for C
41
H
56
N
17
O
8
+ 914.4, observed 914.4
4: (MALDI-TOF) [M+H]+ calcd for C
74
HN20O15S2
+ 1569.7, observed 1569.6
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ii. Plasmid preparation 
Plasmids were constructed by ligating the following hybridized inserts into the 
BamHI / HindIII polycloning site in pUC19:
pKAM3:
 5’-GATCGGAGCTTTTACGTAAGCGGAGGCTTTTACGTAGGCGGAGGCTTTTAC-
GTGAGCGGAGGCTTTTACGGAAGCGGAT-3’
5’-AGCTATCCGCTTCCGTAAAAGCCTCCGCTCACGTAAAAGCCTCCGCCTACG-
TAAAAGCCTCCGCTTACGTAAAAGCTCC-3’
pKAM4:
5’-GATCGGAGCTTTTACGTGAGCGGAGGCAATTTCGTGTGCGGAGGCGCTTTC-
GTCCGCGGAGGCACCTTCGTGAGCGGAT-3’
5’-AGCTATCCGCTCACGAAGGTGCCTCCGCGGACGAAAGCGCCTCCGCACAC-
GAAATTGCCTCCGCTCACGTAAAAGCTCC-3’ 
pJWP17:  
5’-GATCGGAGCAAGAAGAAGTGCGGAGGCAAGAAGTTCAGCGGAGGCAT-
GTTGTTGAGCGGAGGCATGAAGACGAGCGGAT-3’
5’-AGCTATCCGCTCGTCTTCATGCCTCCGCTCAACAACATGCCTCCGCT-
GAACTTCTTGCCTCCGCACTTCTTCTTGCTCC-3.’
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The ligated plasmid was then transformed into JM109 subcompetent cells 
(Promega) by standard methods (30 minute incubation on ice followed by 45 
second heat shock (42 ºC) followed by 1 hour incubation at 37 ºC). Colonies were 
selected for α-complementation on agar plates containing 50 mg/L ampicillin, 
120 mg/L IPTG, and 40 mg/L X-gal after overnight growth at 37 ºC. Cells were harvested 
after 16 h growth at 37 ºC in LB medium containing 50 mg/L ampicillin. Plasmids were 
then purified by mini-prep kits. The presence of the desired inserts was determined by 
capillary electrophoresis dideoxy sequencing methods. 
iii. Preparation of 5’-labeled DNA for DNase I footprinting 
Two primer oligonucleotides, 5’-AATTCGAGCTCGGTACCCGGG-3’ (forward) 
and 5’-CTGGCACGACAGGTTTCCCGA-3’ (reverse) were constructed for PCR 
amplification. The forward primer was radiolabeled using [γ-32P]-dATP and polynucleotide 
kinase, followed by purification using ProbeQuant G-50 spin columns. The desired DNA 
region was amplified as previously described.2  The labeled fragment was loaded onto 
a 7% nondenaturing preparatory polyacrylamide gel (5% cross-link), and the desired 
283 (pKAM3, pKAM4, pJWP17) base-pair band was visualized by autoradiography and 
isolated. Chemical sequencing reactions were performed according to published protocols.26
iv. Quantitative DNase I footprint titrations 
All reactions were carried out in a volume of 400 mL according to published protocols. 
Polyamides were equilibrated with the radiolabeled DNA for 14 h prior to DNase I 
cleavage at 23 ºC. Quantitation by storage phosphor autoradiography and determination of 
equilibrium association constants were as previously described.2
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v.  Microarray procedures  
Microarrays were synthesized by using a Maskless Array Synthesizer 
(NimbleGen Systems, Madison, WI).  Homopolymer (T10) linkers were covalently attached 
to monohydroxysilane glass slides.  Oligonucleotides were then synthesized on the 
homopolymers to create a high-density oligonucleotide microarray.  The array surface was 
derivatized such that the density of oligonucleotides was sufficiently low within the same 
feature so that no one oligonucleotide would hybridize with its neighbors.  Four copies of 
each hairpin containing a unique ten base pair site (5’-GCGC-N1N2N3N4N5N6N7N8N9N10-
GCGC-GGA-GCGC-N10’N9’N8’N7’N6’N5’N4’N3’N2’N1’-GCGC-3’) required a total of 
2,099,200 features, divided among six microarrays.  
vi. Binding assay  
Microarray slides were immersed in 1x PBS and placed in a 90 ºC water bath for 30 
min to induce hairpin formation of the oligonucleotides.  Slides were then transferred to 
a tube of nonstringent wash buffer (saline/sodium phosphate/EDTA buffer, pH 7.5/0.01% 
Tween 20) and scanned to check for low background (<200 intensity).  Microarrays were 
scanned by using an Axon 4000B, and the image files were extracted with GENEPIX PRO 
Version 3.0 (Axon Instruments, Foster City, CA).
vii. Polyamide binding  
Microarrays prepared as above were placed in the microarray hybridization chamber 
and washed twice with nonstringent wash buffer.  Polyamide was diluted to 10 nM (for 2) 
or 175nM (for 4) in Hyb buffer (100 mM Mes/1 M NaCl/20 mM EDTA, pH 7.5/0.01% 
Tween 20).  Polyamide was then added to the hybridization chamber and incubated at room 
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temperature for 1 h.  Finally, the microarrays were washed twice with nonstringent wash 
buffer and scanned.
viii. Data processing  
For each replicate, global mean normalization was used to ensure the mean intensity 
of each microarray was the same.  Local mean normalization24 was then used to ensure 
that the intensity was evenly distributed throughout each sector of the microarray surface. 
Outliers between replicate features were detected by using the Q test at 90% confidence 
and filtered out.  The replicates were then quantile-normalized25 to account for any possible 
nonlinearity between arrays.  Duplicate features were then averaged together.  The median 
of the averaged features was subtracted to account for background.
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Chapter 4
Progress Towards Polyamide Inhibition of  
Myc-Activated Gene Expression by Antagonism 
of the E-box Fragment 5’-WCGWGW-3’
The work outlined in this chapter was performed in collaboration with 
Daniel A. Harki (California Institute of Technology).
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Abstract
Deregulated expression of the Myc transcription factor is a potent and frequently 
encountered defect of human cancer, and a known contributor to cancer pathogenesis 
or disease progression. Inactivation of the myc oncogene or Myc protein represents a 
promising avenue for the development of novel anticancer agents. We describe here the 
synthesis and biochemical characterization of sequence-specific, DNA-binding polyamides 
as antagonists of Myc-activated gene expression. Our goal is to employ DNA-bound 
polyamides to sterically block Myc-activated gene expression in human cancer cells. While 
several of these polyamides showed promising cellular uptake properties in live cells, 
modulation of Myc-regulated gene expression was not observed in MCF-7 (breast cancer) 
or A549 (lung carcinoma) cell lines. We believe that a study of polyamide inhibition of 
Myc-regulated genes has the potential to uncover a novel mechanism for the regulation 
of Myc-overexpressed genes, and we anticipate future developments in polyamide design 
will allow for cellular uptake in other relevent cell lines which may display a different 
genetic response to polyamide treatment.
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4.1 Introduction
The c-Myc (Myc) transcription factor, the protein product of the c-myc (myc) 
proto-oncogene, participates in an array of cellular processes, such as proliferation, growth, 
differentiation, and apoptosis (Figure 4.1).1,2 Unfortunately, deregulated Myc expression 
is a potent and frequently encountered defect of human cancer, and a known contributor 
to cancer pathogenesis or disease progression.1,3 Myc is deregulated and overexpressed in 
most cancer cells, and de-activation of myc in established, Myc-induced transgenic tumors 
triggers proliferative arrest and redifferentiation of tumor cells, resulting in rapid tumor 
regression.4
Myc-Max
Cell Cycle regulation
Apoptosis
Metabolism
Cell adhesion
Cellular differentiation
p19 Arf, cyclin D, cyclin E, CDK4, CUL1
ODC, LDHA, Bax, FasL, PRXII
Enolase, LDHA, PRXII, ODC, CAD
NPM, Nucleolin, JTV-1
Collagen, fibronectin, integrin
5’-CGAGTAGCACGTGCTACTC-3’
3‘-GCTCATCGTGCACGATGAG-5’
Figure 4.1 The Myc-Max transcription factor
The Myc-Max basic-helix-loop-helix leucine zipper heterodimer binds a target DNA site,  known as the 
E-box, having a consensus sequence 5’-CACGTG-3’. c-Myc regulates downstream target genes resulting in 
activation of cell cycle regulation, apoptosis, or inhibition of cell adhesion. Examples of c-Myc target genes 
associated cellular functions are listed.
 
 Structurally, Myc resembles most transcription factors, possessing a helix-loop-helix 
leucine zipper surface for protein dimerization and a basic region that forms contacts with 
DNA surfaces.3,5,6 The active Myc transcription factor exists as a heterodimer with Max 
(Myc associated protein X), which binds DNA and interacts with other distinct proteins.3,5 
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Interestingly, the Myc-Max heterodimer targets different DNA sequences for gene activation 
and suppression. Myc-Max activates gene expression by binding E-box sequences in gene 
promoters (5’-CACGTG-3’) and suppresses gene expression by targeting proximal 
promoter regions (not E-boxes) in other genes.1,3,7-13 Myc also associates with proteins 
involved in chromatin remodeling, transcriptional regulation, and the maintenance of Myc 
stability.13 
Inactivation of the myc oncogene or Myc protein represents a promising avenue for the 
development of novel anticancer agents.3,14 Previous studies directed at the myc oncogene 
have utilized triplex-forming oligonucleotides (TFOs) that target the myc promoter. In 
particular, a TFO conjugated to daunomycin (DNA intercalator) was recently reported 
to reduce Myc promoter activity in prostate and breast cancer cells.15 Similarly, RNAi 
knockdown of myc expression16 and antisense oligodeoxynucleotides targeting myc17 in the 
MCF-7 breast cancer cell line have yielded promising results. Recently, small molecule 
inhibitors of Myc-Max heterodimerization have been identified from library screening18 
and diversity-oriented synthesis,19 and shown to inhibit Myc-dependent proliferation and 
Myc-Max heterodimerization, respectively, in micromolar quantities. 
However, in spite of these encouraging results, Myc is essential for cell growth, 
differentiation, proliferation and, critical for cancer patients, stem cell compartment 
maintenance of regenerative adult tissues such as the gastrointestinal tract, skin and 
bone marrow. Hence, blocking Myc function systemically might trigger devastating and 
irreversible side effects. As Myc functions in cells by both initiating and suppressing gene 
expression as the Myc-Max heterodimer, we hypothesize that cellular abatement of Myc 
will invariably contribute to additional gene deregulation.3 It has been estimated that Myc 
can bind ~25,000 sites in the human genome and regulate a significant number of genes.20 
Hence, decreasing the cellular levels of Myc or disrupting Myc-Max heterodimerization 
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may relinquish control of genes normally repressed by Myc. Furthermore, an autoregulatory 
pathway that monitors Myc protein levels has been proposed as the mechanism by which 
cells regulate Myc gene expression.21 Decreasing intracellular Myc may actually increase 
Myc expression. DNA-binding polyamides offer a new approach for controlling Myc 
overexpression that circumvents such problems—the blocking of Myc-Max heterodimer 
binding to E-box DNA sequences (5’-CACGTG-3’) by a sequence-specific hairpin 
polyamide (Figure 4.2).
5’
5’3’
3’
(a) (b)
(c) (d)
5’
5’3’
3’
5’
5’3’
3’ 5’ 3’
CACGTG
CACGTG CACGTG
GTGCAC
GTGCAC
CACGTG
GTGCAC
gene
expression
+ +R
5’3’ GTGCAC
+ +R
Figure 4.2 Polyamide inhibition of Myc-Max DNA binding
Simplified model of the inhibition of Myc-Max modulated gene expression by a sequence-specific 
DNA-binding polyamide. (a) E-box DNA sequence found in gene promoters 
(b) Myc-Max binds and activates gene expression (c) Polyamide bound to the E-box DNA 
sequence (d) Bound polyamide antagonizing Myc-Max binding and inhibiting gene expression. 
We describe here the synthesis and biochemical characterization of sequence-specific, 
DNA-binding polyamides as antagonists of Myc-activated gene expression. Our goal is 
to employ DNA-bound polyamides to sterically block Myc-activated gene expression 
in human cancer cells. Accordingly, a small library of polyamides targeting the E-box 
(5’-CACGTG-3’) sequence recognized by Myc in gene promoters has been synthesized 
and evaluated biochemically. By antagonizing Myc binding to E-box DNA sequences, as 
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opposed to decreasing cellular levels of Myc protein or disrupting Myc-Max heterodimer 
formation, polyamides may counteract the effects of elevated Myc levels in cells without 
relinquishing control of genes normally repressed by Myc. Importantly, this strategy should 
be relatively specific for inhibiting only the Myc processes associated with gene activation, 
since only a minority of the known Myc-Max binding sites in vivo possess the consensus 
5’-CACGTG-3’ sequence targeted by our proposed polyamide library.20 
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4.2 Experimental Design
I. Design and synthesis of a polyamide library to bind 5’-WCGTGW-3’ 
A small library of polyamides targeting the Myc E-box sequence (5’-CACGTG-3’) 
was synthesized on solid-phase using protocols developed in the Dervan laboratory.22 
Compounds 1-6 possess different modifications to the polyamide skeleton to optimize 
binding affinity and specificity (Figure 4.3). The molecular design of these compounds is 
based upon previous studies in the Dervan laboratory that examined the utility of placing a 
β-alanine unit targeting the G•C base pair proximal to the C•G in the terminal position of 
a polyamide23 and immediately following the chiral turn.24 This initial library consists of 
compounds containing beta-alanine-diaminopropylamine (“Dp”) tails. 
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Figure 4.3 Initial polyamide library.
Compounds 1-6, synthesized by D. Harki and used in initial binding affinity screening studies
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II. Assessment of binding affinities and specificities of initial polyamide library 
Polyamides 1-6 were screened for favorable binding affinities and specificities by melting 
temperature analysis of duplex DNA25 possessing the polyamide match DNA binding site 
(5’-CGTG-3’) or single base pair mismatches. Our interest in determining the specificity 
of the N-terminal pyrrole cap unit led us to design this DNA binding site with a T in place 
of the C normally found in the biologically relevant E-box, thus removing the binding 
ambiguity that would be presented by the palindromic E-box consensus sequence. As 
shown in Table 4.1, polyamides 1 and 2 were found to have the highest DNA duplex 
stabilization. Modifications to polyamide 2, such as introduction of terminal acetamide 
and formamide caps (compounds 3 and 4, respectively), as well as elimination of the first 
β-alanine moiety (5), failed to yield a higher affinity binder. Based on these results, 1 and 
2 were chosen for further biological studies. Eight-ring hairpin 6 failed to yield reliable 
melting temperature curves in this initial screen, and was not further utilized.
Melting temperature studies of duplex DNA (2 nmoles/oligo) treated with polyamides  (2.0-2.4 nmoles). 
Averages and S.D. were calculated from at least four analyses.  Values in brackets represent ∆Tm versus 
untreated DNA duplex. These melting temperature studies were performed by D. Harki.
5'- G G T A X G T G T G G G -3'
3'- C C A T Y C A C A C C C -5'
C-GX-Y: G-C T-A A-T
56.9 ± 0.3DNA only 57.9 ± 0.3 55.2 ± 0.1 55.9 ± 0.5
68.9 ± 0.1 [12.0]++1 65.1 ± 0.1 [7.2] 64.7 ± 0.2 [9.4] 61.3 ± 0.0 [5.4]
71.9 ± 0.2 [15.1]++2 68.2 ± 0.2 [10.3] 66.0 ± 0.1 [10.8] 61.8 ± 0.1 [5.9]
64.1 ± 0.3  [7.2]
++
NH
O
3 60.1 ± 0.2 [2.2] 62.8 ± 0.4 [7.6] 58.5 ± 0.3 [2.6]
70.6 ± 0.4 [13.7]
++
NHH
O
4 67.1 ± 0.4 [9.2] 65.7 ± 0.2 [10.4] 63.2 ± 0.3 [7.3]
69.8 ± 0.3 [12.9]++5 66.4 ± 0.1 [8.4] 65.0 ± 0.2 [9.8] 60.6 ± 0.5 [4.7]
Tm oligo:
Table 4.1 Assessment of binding affinities and specificities of polyamides 1-5 
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III. Design and synthesis of a polyamide library to disrupt Myc-Max DNA binding
Based on the results of the screening, a small library of polyamides derived from 
compounds 1 and 2 was designed to bind the 5’-WCGTGW-3’ sequence of the E-box 
in gene promoters and block Myc-Max-activated gene expression. Over the course of 
experimentation, this library evolved to contain polyamides of several different scaffolds 
and tail substituents, including hairpins containing both diaminopropylamine (“Dp”) as well 
as diamino-N-methyl-dipropyl amine (“triamine”) tails, hairpins containing a β-alanine 
moiety in the tail region, hairpins lacking this β-alanine tail moiety, and even cyclic 
polyamides (Figure 4.4). Polyamides 7-11 contain an isophthalic acid tail modification, a 
modification that has been shown in previous studies by the Dervan laboratory to facilitate 
cellular uptake.26 
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Figure 4.4 Library of compounds synthesized by K. Muzikar and D. Harki for biological studies
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IV. Assessment of binding affinities and specificities of biological polyamide library 
The binding affinities and specificities of polyamides 7 and 8 were rigorously 
characterized by quantitative DNase I footprint titrations as well as thermal melting analysis 
(Figure 4.5).27 These polyamides are analogues of 1 and 2, respectively, and contain the 
isophthalic acid tail modification often noted to encourage positive nuclear localization in 
cell culture. The 5’-terminal base pair was interrogated for specificity since this position 
is often deemed the hardest to obtain specificity. As shown in Figure 4.5, extremely 
high binding affinities for both polyamides were observed. Polyamide 7 bound its match 
DNA sequence with Ka = 4.0 x 10
9 M-1 and polyamide 8 bound the same match site with 
Ka = 1.3 x 10
10 M-1. To our delight, high specificities against binding to the mismatch 
sites was observed for both compounds; with polyamide 8 exhibiting 10-fold preference 
for match site I versus mismatch sites II-IV. Based on these findings we concluded that 
polyamides 7 and 8 are more than sufficient to proceed to biological studies. 
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7 8
I II III IV
pDHKM1 287 bp32PEco RI Pvu II
3'-CTAG TCACC CATGCACA CCCGAGTCACC CATCCACA CCCGAGTCACC CATACACA CCCGAGTCACC CATTCACA CCCGA TCGA -5'
5'-GATC AGTGG GTACGTGT GGGCTCAGTGG GTAGGTGT GGGCTCAGTGG GTATGTGT GGGCTCAGTGG GTAAGTGT GGGCT AGCT -3'     
IPA ++IPA ++
5'- T G G G T A X G T G T G G G -3'
3'- A C C C A T Y C A C A C C C -5'
DNA Tm
7 8
I 63.7 ± 0.3 4.0 (± 0.7) x 10
9
(1.0)
1.3 (± 0.2) x 1010
(1.0) 
70.3 ± 0.2
[6.5]
72.1 ± 0.2
[8.3] 
II 63.0 ± 0.2 2.6 (± 0.9) x 10
8
(0.2)
1.0 (± 0.3) x 109
(0.1)  
65.6 ± 0.2
[2.5]
67.2 ± 0.2
[4.2]
III 61.0 ± 0.1 4.4 (± 0.8) x 10
8
(0.1)
1.0 (± 0.4) x 109
(0.1)  
65.2 ± 0.2
[4.2]
66.2 ± 0.1
[5.1]
IV 62.2 ± 0.2 -- 1.1 (± 0.6) x 10
9
(0.1)  
64.9± 0.1
[2.6]
64.2 ± 0.0
[2.0]
Ka KaΔTm ΔTm
A
B
C
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Figure 4.5 Binding studies of polyamides 7 and 8
 A) Sequence of the pDHKM1 plasmid insert B) Storage phosphor autoradiograms from quantitative DNase 
I footprint titrations of polyamides 7 (left) and 8 (right). Lane 1, intact DNA, lane 2 G reaction, lane 3 A 
reaction, lane 4, DNase control. lanes 5-15: DNase I digestion products in the presence of 1pM, 3pM, 10pM, 
30pM, 100pM, 300pM, 1nM, 3nM, 10nM, 30nM, 100nM polyamide, respectively. C) Summary of binding 
affinities as measured by DNase footprinting and by melting temperature studies of duplex DNA (2 nmoles/
oligo) treated with polyamides  (2.0-2.4 nmoles).  Averages and S.D. were calculated from at least four 
analyses.  Values in brackets represent ∆Tm versus untreated DNA duplex. Values in parenthesis represent Ka 
relative to Ka for match site. Melting temperature experiments were performed by D. Harki.
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V. Evaluation of polyamide uptake and localization in cell culture
In order to assess the ability of the polyamides to traffic across the cell membrane and 
localize to the nucleus of cells, fluorescein isothiocyanate (FITC) conjugates 13-16 were 
synthesized (Figure 4.6 ) so that uptake could be evaluated by confocal microscopy.  
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Figure 4.6 Fluorescein isothiocyanate (FITC) conjugate polyamides synthesized by K. Muzikar and D. Harki
Polyamides 13 and 14 were added at two micromolar concentration to A549 (human 
lung carcinoma), MCF-7 (human breast cancer), LNCaP (human prostate cancer) and 
P493 (human lymphocytes) cells.  For A549, MCF-7, and LnCaP cell lines (Figure 4.7) 
significant amounts of fluorescence was observed in the nucleus when dosed both alone 
and when co-administered with the calcium channel blocker verapamil (25 μM), suggesting 
that both compounds access the nucleus and accumulate to reasonable concentrations in 
these cell lines.  In P493 cells, however, uptake is negligible for both compounds, with 
only small amounts of 13 and 14 localized to the nucleus when co-administered with 
verapamil (25 μM).
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Figure 4.7 Cellular uptake of polyamides 13 and 14
Confocal laser scanning microscopy images of polyamide-fluorescein conjugates 13 and 14 in several 
different cancer cell lines. For each group of pictures, the left images show 2uM polyamide treatment with 
14 hour incubation; the right images show 2μM polyamide and 25μM verapamil treatment with 14 hour 
incubation; top images show fluorescence signal from polyamide; bottom images show  fluorescence signal 
overlaid on visible light image.
 
Figure 4.8 Cellular uptake of polyamides 13-16
Confocal laser scanning microscopy images of polyamide-fluorescein conjugates 13-16  in NCI H82, H60 
cell lines. For each group of pictures, the left images show 2uM polyamide treatment with 14 hour incubation; 
the right images show 2μM polyamide and 25μM verapamil treatment with 14 hour incubation; top images 
show flourescence signal from polyamide; bottom images show  flourescence signal overlaid on visible light 
image.
LnCAPMCF7P493 A549
- + - + - + - +
13
14
- + - + - + - +
H82
H60
++FITC ++FITC +FITC NHAc +FITC NHAc
13 14 15 16
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The favorable uptake of 13 and 14 in the aforementioned three cell lines suggests 
both polyamides have cell permeability properties sufficient for further in vivo 
studies, while studies in P493 cells were not pursued. Additionally, polyamides 13-
16 were added at 2 μM concentration to NCI-H60 (non-small-cell lung cancer) and 
NCI-H82 (small-cell lung cancer) cells (Figure 4.8), which are known to have elevated 
levels of c-myc gene.28 Uptake of all four compounds in these cell lines appears favorable 
both with and without verapamil co-administration, although less so in the NCI-H60 cells. 
Table 4.2 summarizes the uptake properties of compounds 13-14 in the cell lines described 
above.
++FITC
13
++FITC
14
+FITC NHAc
15
+FITC NHAc
16
-
-
+
-
+
25mM
verapamil
+
+
-
H82
++
++
++
+
++
++
++
+
H60
+
+
+
+
-
++
++
++
P493
-
++
-
++
n.d.
n.d.
n.d.
n.d.
MCF-7
++
++
++
++
n.d.
n.d.
n.d.
n.d.
A549
++
++
++
++
n.d.
n.d.
n.d.
n.d.
LnCap
++
++
++
++
n.d.
n.d.
n.d.
n.d.
Table 4.2 Cellular localization of polyamide–dye conjugates in cultured cells
 ++, Nuclear staining exceeds that of the medium; +,nuclear staining less than or equal to that of the 
medium, but still prominent; -, very little nuclear staining, with the most fluorescence seen in the cytoplasm 
and/or medium; --, no nuclear staining. n.d.= not determined.
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VI. Analysis and selection of Myc-inducible gene targets
While it is estimated that ~25,000 genes are regulated in some way by Myc, there is a 
surprising dearth of known primary gene targets of Myc. Identification of Myc-regulated 
genes has generally relied on experimental activation of Myc followed by monitoring 
of changes in mRNA levels.29,30 More than 10 investigative works reported the use of 
high-throughput screening based on cDNA microarrays or the SAGE assay, significantly 
expanding the list of genes that are up- or downregulated by Myc. Based on an updated 
online compilation,31 this list now includes over 1500 genes. It remains unclear, however, 
how many of these genes are direct targets of Myc. In many studies a large fraction of 
Myc-target genes respond weakly, or even fail to respond, to Myc activation, depending on 
the cell type or experimental conditions used. Additionally, lists of genes identified in high-
throughput screens such as RNA microarrays,32 ChIP-screening,33,34 or ChIP-PET35 are only 
partially overlapping, especially between cell lines, and many genes were identified only 
once. Thus, we still possess a fragmentary picture of the loci that are directly targeted by 
Myc, and no accurate estimate of their numbers. 
Table 4.3 E-box and surrounding DNA sequences of several known direct Myc target genes
GCAGGGGACACGTG GTCGCCGAGCGODC GCAACGAGCACGTG GCCTGGGGCGCPT
gene E-box sequence gene E-box sequence
ACTTCGACCACGTG TGACTTGTGTGRCC1 GGGCCTGCCACGTG CACCCCGCCCGcdc25A
TGTGCGGCCACGTG TCGCGAGGCCCODC ACTACAGACACGTG CCACCACACCCcdc25A
TGACTCACCACGTG CATACCTATGGMrDbATATCCGTCACGTG GCCAGAAGCTGeIF4e
TCCCCTCCCACGTG CTCACCCTGGCP53CCATCGGCCACGTG ACCAGTCCTTTeIF4e
GCCGGCCCCACGTG AAGCCCGGAGGRCC1 CTGAGCGCCACGTG TCACTGCACAGECA39
Shown in bold is the six base pair E-box site. Underlined are 5’-WCGWGW-3’ polyamide match sites. Sites 
without an underline present a GC base pair mismatch under the turn moiety.
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Despite this complexity, we have identified a small list of genes that are known direct 
targets of Myc, and whose promoter E-boxes have been rigorously identified (Table 4.3). 
We anticipate that polyamides that bind and interfere with the expression of these genes 
would be useful in then mining the genome for other, perhaps previously unidentified, 
direct targets of Myc. Of the genes identified in Table 4.3, the gene that has by far the 
most relevance to cancer biology is the cap-binding protein eukaryotic translation 
initiation factor 4E (eIF4E). A functional promoter region of eIF4E has been identified 400 
nucleotides upstream of the transcription initiation site with two essential E-box motifs 
in the immediate promoter region. 38 Of these two E-boxes, only one has a full match site 
(5’-ACGTGA-3’) for the polyamide, while the other (5’-ACGTGG-3’) presents a G•C 
base pair under the turn moiety (Figure 4.9)
E-box 2E-box 1 142 bp 68 bp
eIF4E
eIF4E E-box 1
5’-ggcCACGTGacc-3’
3’-ccgGTGCACtgg-5’
IPA ++
eIF4E E-box 2
5’-cgtCACGTGgcc-3’
3’-gcaGTGCACcgg-5’
IPA ++
Figure 4.9 Schematic representation of E-box locations relative to transcription start site of eIF4E
Shown are the sequences of the two E-boxes with a representative polyamide shown bound. Note that while 
there is a full polyamide match binding site in E-box 1, there is a severe mistmatch under the turn moiety of 
the polyamide, it is likely this polyamide has a poor binding affinity for this site.
 
 During initiation of transcription, eIF4E binds the 7-methylguanosine cap of mRNA 
and recruits a transcript to the translational machinery. Increased cap-dependent mRNA 
translation rates are frequently observed in human cancers. Mechanistically, many human 
tumors often overexpress the cap binding protein eukaryotic translation initiation factor 4E 
(eIF4E), leading to enhanced translation of numerous tumor-promoting genes. 
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eIF4E-specific antisense oligonucleotides have been shown to repress expression of 
eIF4E-regulated proteins (e.g., VEGF, cyclin D1, survivin, c-myc) in human cells 
(HeLa, A549, MCF-736) as well as induce apoptosis of the carcinogenic cells. Intravenous 
administration of eIF4E-specific antisense oligonucleotides has been shown to reduce 
eIF4E expression in human tumor xenografts, as well as significantly suppress tumor 
growth.37
VII. Assessment of binding affinities of polyamides towards eIF4E E-box 
The initial thermal melting temperature studies were performed on 12-mer oligos 
that were designed to have an unambiguous polyamide binding site (5’-TACGTGT-3’) 
in order to probe the specificity of the polyamide in the 5’ position  avoiding the palindromic 
sequence 5’-CACGTG-3’. However, it is the second sequence that is relevant within 
the context of the eIF4E E-box, hence we decided to perform a T
m
 analysis on a 12-mer 
oligo containing the sequence 5’CACGTG-3’. Table 4.4 shows that polyamides 7 and 11 
demonstrate essentially the same thermal stabilization energy (∆T
m
 ~4 °C)  as each other 
for the eIF4E duplex. While comparisons cannot be drawn relating ∆T
m
s across different 
DNA oliomers, this is the same general magnitude of stabilization previously seen on the 
5’-TACGTGT-3’ sequence.
Table 4.4 Thermal melting temperature studies of polyamides 7 and 11 on  eIF4e E-box 1 
IPA + NHAc
IPA ++
Duplex 1: eIF4E E-box 1 Duplex 2
5 ' - T G G G T A C G T G T G G G - 3 '
3 ' - A C C C A T G C A C A C C C - 5 '
62.4 ± 0.6DNA only 63.7 ± 0.3
65.6 ± 0.5 [3.2]7 70.3 ± 0.2 [6.5]
66.4 ± 0.5 [4.0]11
Tm oligo:
3 ' - C C G G T G C A C T G G - 5 '
5 ' - G G C C A C G T G A C C - 3 '
n.d.
Melting temperature studies of duplex DNA (2 nmoles/oligo) treated with polyamides  (2.0-2.4 nmoles). 
Averages and S.D. were calculated from at least four analyses.  Values in brackets represent ∆Tm versus 
untreated DNA duplex. n.d.= not determined.
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VIII.  Selection of inducible and endogenously Myc-overexpressed cell lines
Unlike previous transcription factors that have been inhibited by polyamide-DNA 
binding, the Myc-Max transcription factor does not function in response to an antagonist; 
that is, this is not an endogenously inducible system. This gives an added level of 
complexity to the assessment of gene regulatory activity, hence for our initial studies of 
these polyamides in cell culture we intended to use an artificial system that would allow us 
to control cellular Myc levels. Two such cell lines were available from the literature, and 
we requested and received these cell lines. 
P-493 cells:
The P493-6 cell line is a model for cell cycle activation by myc in Burkitt lymphoma 
cells. P493-6 is a human EBV-EBNA1 positive B-cell line in which myc is expressed 
under the control of a tetracycline-regulated promoter. 39 These cells were sent as a gift 
from Professor Dirk Eick (Institute of Clinical Molecular Biology and Tumor Genetics, 
Munich, Germany). Unfortunately, as can been seen in Figure 4.7, cellular localization of 
compounds 13 and 14 was negligible in this cell line and further studies were not pursued. 
MCF-7cl35 cells: 
The Shiu lab at University of Manitoba has developed a clonal MCF-7 human breast 
cancer cell line (MCF-7cl35 ) harboring a stably-transfected human c-myc gene, whose 
expression is controlled by the bacterial reverse tetracycline transcription activator 
protein.40 Expression of endogenous genomic c-myc gene in MCF-7 cells is abolished 
by the potent pure estrogen antagonist, ICI 182,780.  These cells were sent as a gift from 
Professor Robert P.C. Shiu (University of Manitoba, Winnipeg, Manitoba, Canada) and 
were cultured as instructed by the Shiu lab, which is as reported in their papers: in DMEM 
with sodium pyruvate, glutamine (4mM), penicillin-streptomycin (4mM), and 5% FBS.4
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Figure 4.10 Doxycycline-induced Myc and eIF4E expression in MCF7-cl35 cells
A) Myc expression is induced 5-Fold by 12-hour incubation with doxycycline and and repressed by ICI 
inhibitor compound in accordance with literature precident (cell passage number 3). B) Doxycycline time 
course indicates Myc is induced maximally 5-fold at 3 hours doxycyline treatment, while eIF4E is induced 
over 15-fold at this time point (cell passage number 4). C) Doxycycline treatment fails to induce Myc or 
eIF4E over a 1-8 hour range (cell passage number 7).
 Myc induction by doxycycline (a water-soluble version of tetracycline) as well as 
repression of endogenous myc expression by ICI was reproduced when the cell line was 
first received. However, as the cells were passaged over time, the intensity of the myc 
signal induction decreased from 5-fold (passage number three) to less than 2-fold (passage 
number seven). Additionally, while Myc expression was induced, no induced expression of 
the target gene eIF4E was seen in most instances, and what induction is seen for both genes 
is wildly variable. Figure 4.10 shows a compilation of data that represents the irreproducible 
nature of data garnered from this cell line. The large error bars seen in Figure 4.10 were not 
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a one-time occurrence, but were seen in every experiment performed (over 10 independent 
experiments). We hypothesize that the plasmid containing the inducible tet-Myc promoter 
may not be as stably integrated as we expected. There is no additive in the culture medium 
as described by the Shiu group to keep a selective pressure on the cells to maintain the 
plasmid, and it may be that the plasmid does not remain in the cells after several passages. 
While working with an inducible Myc cell line was desirable, we decided to move our 
efforts into an endogenous system.
NCI-H82 cells:
NCI-H82 is a small-cell lung cancer cell line in which c-myc DNA sequences are 
amplified about 25-fold, with a resulting 24-fold increase in c-myc RNA relative to normal 
cells.41 This line grows as aggregates of cells in suspension,  and is available for purchase 
from the American Type Culture Collection (ATCC). In order to establish a baseline for 
comparison for gene repression, Validated Stealth siRNA was purchased from Invitrogen 
and optimized for use with the NCI-H82 cell line. Figure 4.11 shows a representative 
qRT-PCR experiment using the siRNA against Myc in NCI-H82 cells. 
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Figure 4.11 siRNA against Myc in NCI-H82 cells
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IX.  qRT-PCR analysis of Myc-inducible gene expression following polyamide treatment
NCI-H82 cells were dosed with compounds 7-10 at 10 μM concentration for 
48 hours, after which time their mRNA was harvested, reverse transcribed, and analyzed 
by quantitative real-time polymerase chain reaction (qRT-PCR) for the expression levels of 
Myc and eIF4E along with several other genes from Table 4.3  (ODC, RCC1). Unfortunately, 
no appreciable effect on eIF4E gene expression (or ODC or RCC1) is seen following 
1, 5, or 10 μM concentration treatment of compounds 7-10 (data not shown). Figure 4.12 
shows representative results of three independent biological trials, while error bars indicate 
the SD of four technical biological replicates of the given trial. While the levels of the 
actual Myc gene are slightly reduced, no appreciable effect is seen on eIF4E expression 
in excess of that which may be caused by the slight Myc repression. siRNA treatment 
concurrent with these biological trials indicates that reduced levels of expression would 
have likely been detectable if present.
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Figure 4.12 qRT-PCR results in NCI-H82 cells
Representative qRT-PCR results after 48 hours treatment of siRNA or 10 μM concentrations of polyamides 
7-12 in NCI-H82 cells. Error bars represent SD of at least three technical replicates.
X. Enzyme-linked immunosorbent assay (ELISA) 
In collaboration with Summer Undergraduate Research Fellow (SURF) Nickolaus Krall, 
an ELISA assay was developed that would allow us to measure the protein concentration 
of the eIF4e and Myc proteins. In the first step an ELISA42,43 was developed to measure 
eIF4E levels in crude cell lysate. Starting from a design suggested previously44 the optimal 
concentrations of antibodies, buffer compositions, and appropriate incubation conditions 
were determined. To test the hypothesis that the polyamides only affect Myc binding to 
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E-box DNA and hence expression levels of target genes but not Myc protein expression 
itself an ELISA for the measurement of Myc protein levels in crude cell lysate was also 
developed. Due to lack of gene response to polyamide treatment, these assays were 
never used to measure change of protein levels in response to polyamide, but the detailed 
experimental protocol developed can be found in the Materials and Methods section of this 
chapter (Section 4.4, ix).
4.3 Closing Remarks
We have described the development of cell-permeable sequence-specific polyamides 
that bind to the Myc-Max E-box DNA sequence. By antagonizing the discrete binding event 
between Myc-Max and its cognate DNA sequence we hope to regain control of deregulated 
gene expression facilitated by Myc overexpression. A library of matched and mismatched 
polyamides was prepared by solid- and solution-phase synthesis, and their binding affinities 
and specificities for E-box (5’-CACGTG-3’) DNA was determined by quantitative DNase 
I footprinting titration and thermal melting temperature analysis. The favorable cellular 
permeability and intracellular localization properties of the FITC conjugates of the 
compounds was observed by laser-scanning confocal microscopy. However, the ability 
of the polyamides to inhibit Myc-Max binding in vivo was not demonstrated in the cell 
lines and conditions described here.  It is possible that improvements to the uptake of these 
or other E-box-targeted polyamides into alternate cell lines would demonstrate different 
biological effects in those cell lines. We believe that a study of polyamide inhibition of 
Myc-regulated genes has the potential to uncover a novel mechanism for the regulation of 
MYC-overexpressed genes, and we anticipate future developments in polyamide design 
may give this project new direction. 
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4.4 Materials and Methods
i. Polyamide synthesis
Chemicals not otherwise specified are from Sigma-Aldrich.
Synthesis of polyamides 1-6: 
Polyamides 1-6 were synthesized by Dan Harki using pre-loaded Boc-β-Ala-PAM resin 
(50 mg, 0.81 meq/g, Peptides International) according to published manual solid-phase 
synthesis protocols.22,45 The resin was cleaved with neat 3-dimethylamino-1-propylamine 
(1 mL) at 37 °C for 16 h. Products were purified by preparatory reverse-phase HPLC on a 
Beckman Gold system using either a Waters Delta-Pak 25°—100 mm, 15 μm 300 Å C18 
PrepPak Cartridge reverse-phase column or a Varian Dynamax 21.4°—250 mm Microsorb 
8 μm 300 Å C8 reverse-phase column in 0.1% (w/v) TFA with acetonitrile as the eluent. 
The appropriate fractions were lyophilized after characterization by analytical HPLC, 
UV-visible spectroscopy, and MALDI-TOF or ESI mass spectrometry. 
1: (MALDI-TOF) [M+H]+ calcd for C
51
H
70
N21O10
+ 1136.6, observed 1136.6
2: (MALDI-TOF) [M+H]+ calcd for  C
54
H
71
N22O10
+ 1187.6, observed 1187.6
3: (MALDI-TOF) [M+H]+ calcd for C
56
H
74
N
23
O11
+ 1244.6, observed 1244.6
4: (MALDI-TOF) [M+H]+ calcd for C
55
H
72
N
23
O11
+ 1230.6, observed 1230.7
5: (MALDI-TOF) [M+H]+ calcd for C
51
H66N21O9
+ 1116.5, observed 1116.5
6: (MALDI-TOF) [M+H]+ calcd for C
57
H
72
N
23
O10
+ 1238.6, observed 1238.6
Synthesis of polyamides 7-10:
Polyamides 7-10 were synthesized by Katy Muzikar and Dan Harki using 
Boc-β-Ala-PAM resin according to published manual solid-phase synthesis protocols 
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as referenced above. The protected FmocHN-γ-turn amine was deprotected with 20% 
piperidine in DMF and reprotected as the Boc derivative with a solution of Boc2O (Fluka) 
and DIEA in DMF. The Boc-protected resin was cleaved with 1 mL of 3,3’-diamino-
N-methyldipropylamine (triamine) at 37 °C for 16 h. Products were purified by 
preparatory reverse-phase HPLC and the appropriate fractions were lyophilized after 
characterization by analytical HPLC, UV-visible spectroscopy, and MALDI-TOF or ESI 
mass spectrometry. Conjugates were formed by pre-activating isophthalic acid (3.0 equiv) 
with PyBOP (2.9 equiv, Novabiochem) in a solution of DIEA (20 equiv) and DMF at 37 
°C for 30 min, followed by reaction of the activated solution with the polyamide for 1 
h at room temperature. Conjugates were deprotected with neat TFA for 10 min at room 
temperature before purification by preparatory reverse-phase HPLC. Lyophilization of the 
appropriate fractions yielded the polyamide conjugates 7-10, which were characterized as 
described above. Extinction coefficients were calculated according to standard protocols.27 
(i.e., estimating 69,500 cm-1 M-1 for standard 8-ring polyamides leads to an approximation 
of 8,690 cm-1 M-1 per ring for polyamides containing a β-alanine moiety in place of a ring. 
Calculated extinction coefficient was rounded to the nearest hundred, thus the extinction 
coefficient for a 7-ring polyamide is calculated to be 60,800 cm-1 M-1). 
7: (MALDI-TOF) [M+H]+ calcd for C
51
H
70
N21O10
+ 1136.6, observed 1136.6
8: (MALDI-TOF) [M+H]+ calcd for  C
54
H
71
N22O10
+ 1187.6, observed 1187.6
9: (MALDI-TOF) [M+H]+ calcd for C
56
H
74
N
23
O11
+ 1244.6, observed 1244.6
10: (MALDI-TOF) [M+H]+ calcd for C
63
H
80
N22O14
+ 1369.6, observed 1369.9
Synthesis of polyamide 11: 
Polyamide 11 was synthesized by a different route than the rest of the compounds 
owing to the fact that imidazole monomer does not stably load onto oxime resin, and 
synthesis on Boc-β-Ala-Pam resin installs the undesired β-alanine  moiety.
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Scheme 4.1  Synthesis of polyamide 11.
As shown in Scheme 4.1, this necessitated several off-resin synthetic steps. 
Because a β-alanine moiety was desired in the second position from the resin, the 
core of 11 was synthesized according to standard protocols as described above on 
Boc-β-Ala-Pam resin. The core  11a was saponified off the resin via incubation 
with 0.5M lithium hydroxide (LiOH) to provide the carboxylic acid 11b, which was 
purified by preparatory reverse-phase HPLC. This was subsequently coupled with 
4-[(tert-Butoxycarbonyl)amino]-1-methylimidazole-2-carboxylic acid (NH2-Im-OEt)
following established protocols,53 yielding compound 11c, which was purified by 
preparatory reverse-phase HPLC. 11c was saponified in 0.5 M sodium hydroxide (NaOH) 
to yield the carboxylic acid 11d which was purified by preparatory reverse-phase HPLC. 
This was conjugated to 3,3’-diamino-N-methyldipropylamine via PyBOP activation, 
resulting in compound 11e, which was purified by preparatory reverse-phase HPLC. 
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11e was conjugated to IPA, deprotected, and purified by HPLC as described above.
11b: (MALDI-TOF) [M+H]+ calcd for C
43
H
56
N
15
O11
+ 957.4, observed 958.5
11c: (MALDI-TOF) [M+H]+ calcd for C
50
H
65
N
18
O12
+ 1109.5, observed 1109.6
11d: (MALDI-TOF) [M+H]+ calcd for C
48
H61N18O12
+ 1081.4, observed 1037.7    
         ([M-CO2+H]
+)
11e: (MALDI-TOF) [M+H]+ calcd for C
55
H
79
N21O11
+ 1208.6, observed 1208.8
11: (MALDI-TOF) [M+H]+ calcd for C
58
H
74
N21O12
+ 1256.6, observed 1256.8
Synthesis of polyamide 12: 
Cyclic polyamide 12 was synthesized following the methodology established for 
solution-phase cyclic polyamide synthesis.54 Briefly, polyamide half-strands 12a and 12b 
(Scheme 4.2)were synthesized and were conjugated together by solution-phase synthetic 
methods.53 After conjugation of the half-strands, 12c was saponified to 12d, which was 
converted to the pentafluorphenol (Pfp) ester 12e. Each step of this synthesis up to this 
point proceeded in similar yields to those previously published and all intermediates 
were characterized by 1HNMR and analyzed for purity by analytical scale reverse-phase 
HPLC. Each product was >90% pure as assessed by these methods. Pfp ester 12e was 
deprotected and cyclized to form 12f, an insoluble compound that was not characterized. 
The Cbz protecting groups present in 12f were cleaved and the resulting solution purified 
by reverse-phase HPLC to yield compound 12 in trace amounts. This synthesis provided 
the 30 nmols necessary to perform qRT-PCR analysis of its effect in cell culture for one 
biological replicate. Due to the lack of biological activity of cyclic polyamide 12, the 
detailed characterization of these 34 intermediates has been excluded from this thesis.
12: (MALDI-TOF) [M+H]+ calcd for C
58
H
74
N21O12
+ 1256.6, observed 1256.8
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Scheme 4.2  Synthesis of cyclic polyamide 12.
Synthesis of polyamides 13-16: 
Polyamides 13-16 were synthesized by Katy Muzikar and Dan Harki using 
Boc-β-Ala-PAM resin according to published manual solid-phase synthesis protocols 
as referenced above. The protected FmocHN-γ-turn amine was deprotected with 20% 
piperidine in DMF and reprotected as the Boc derivative with a solution of Boc2O (Fluka) 
and DIEA in DMF. The Boc-protected resin was cleaved with 1 mL of 3,3’-diamino-N-
methyldipropylamine (triamine) at 37 °C for 16 h. Products were purified by preparatory 
reverse-phase HPLC and the appropriate fractions were lyophilized after characterization 
by analytical HPLC, UV-visible spectroscopy, and MALDI-TOF or ESI mass spectrometry.
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Conjugates were formed by reacting fluorescein-5-isothiocyanate (FITC, Invitrogen) 
with the polyamide in a solution of DIEA (20 equiv) and DMF for 1 h at room temperature. 
Conjugates were deprotected with neat TFA for 10 min at room temperature before 
purification by preparatory reverse-phase HPLC. Lyophilization of the appropriate fractions 
yielded the polyamide conjugates 13-16, which were characterized as described above. 
Extinction coefficients were calculated according to standard protocols. 
13: (MALDI-TOF) [M+H]+ calcd for C
74
H
86
N
23
O
15
S+ 1568.6, observed 1569.7
14: (MALDI-TOF) [M+H]+ calcd for  C
77
H
87
N
24
O
15
S+ 1619.7, observed 1620.8
15: (MALDI-TOF) [M+H]+ calcd for C
76
H
88
N
23
O16S
+ 1610.7, observed 1611.6
16: (MALDI-TOF) [M+H]+ calcd for C
79
H
89
N
24
O16S
+ 1661.7, observed 1662.6
ii. UV absorption spectrophotometry of of DNA thermal stabilization
Melting temperature analysis was performed on a Varian Cary 100 spectrophotometer 
equipped with a thermo-controlled cell holder possessing a cell path length of 1 cm. An 
aqueous solution of 10 mM sodium cacodylate, 10 mM KCl, 10 mM MgCl2, and 5 mM 
CaCl2 at pH 7.0 was used as analysis buffer. This buffer was degassed under vacuum and 
DNA duplexes and polyamides were added to a final concentration of 2 μM DNA, 3μM 
polyamide for each experiment. Prior to analysis, samples were heated to 90 °C and cooled 
to a starting temperature of 23 °C with a heating rate of 5 °C/min for each ramp. Denaturation 
profiles were recorded at λ = 260 nm from 23 to 90 °C with a heating rate of 0.5 °C/min. 
Each sample was subjected to denaturation in technical duplicate, and the reported numbers 
are the average of at least three experimental replicates. The reported melting temperatures 
were defined as the maximum of the first derivative of the denaturation profile.
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iii. Plasmid preparation
Plasmid pDHKM1 was constructed following standard protocols. The following 
hybridized insert (Integrated DNA Technologies) was ligated into the BamHI/HindIII 
polycloning site in pUC19 Plasmid (Sigma) using a Rapid DNA Ligation Kit (Roche) 
according to the manufacturer’s protocols:
5’-GATC AGTGG GTACGTGT GGGCTCAGTGG GTAGGTGT GGGCTCAGTGG 
GTATGTGT GGGCTCAGTGG GTAAGTGT GGGCT-3’
5’-AGCT AGCCC ACACTTAC CCACTGAGCCC ACACATAC CCACTGAGCCC 
ACACCTAC CCACTGAGCCC ACACGTAC CCACT-3’
The ligated plasmid was then transformed into JM109 subcompetent cells (Promega) 
by standard methods (30 minute incubation on ice followed by 45 second heat shock 
(42 ºC) followed by 1 hour incubation at 37 ºC). Colonies were selected for 
 α-complementation on agar plates containing 50 mg/L ampicillin, 120 mg/L IPTG, and 40 
mg/L X-gal after overnight growth at 37 ºC. Cells were harvested after 16 h growth at 37 ºC 
in LB medium containing 50 mg/L ampicillin. Plasmid was then purified by midi-prep kit 
(Promega). The presence of the desired inserts was determined by capillary electrophoresis 
dideoxy sequencing methods (Laragen).
iv. Preparation of 5’-labeled DNA for DNase I footprinting
Two primer oligonucleotides, 5’-AATTCGAGCTCGGTACCCGGG-3’ 
(forward, corresponding to EcoRI restriction enzyme cut site) and 
5’-CTGGCACGACAGGTTTCCCGA-3’ (reverse, corresponding to the PvuII restriction 
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enzyme cut site) were constructed for PCR amplification. The forward primer was 
radiolabeled using [α-32P]-dATP (MP Biomedicals) and polynucleotide kinase (Roche), 
followed by purification using ProbeQuant G-50 spin columns (GE Healthcare). The 
desired PCR product was generated from the plasmid pDHKM1 using the primer pair 
and Expand High Fidelity PCR Core Kit (Roche) following the manufacturer’s protocol. 
The labeled fragment was purified on a 7% nondenaturing preparatory polyacrylamide gel 
(5% cross-link) and visualized by autoradiography. The radiolabeled band was excised, 
crushed, and soaked overnight (14 hours) in 2 M NaCl. The gel pieces were removed by 
centrifugal filtration and the DNA was precipitated with 2-propanol (1.5 volumes). The 
pellet was washed with 75% ethanol, lyophilized to dryness, and then resuspended in 
1 mL of RNase-free water. Chemical sequencing reactions were performed according to 
published protocols.46,47
v. DNAse I footprint titrations
All reactions were carried out in a volume of 400 uL according to published procedures.27 
Footprinting was performed on 1 pM, 3 pM, 10 pM, 30 pM, 100 pM, 300 pM, 1 nM, 3 nM, 
10 nM, 30 nM, 100 nM solutions of polyamides 7 and 8, where polyamide solutions were 
quantitated at λ=310 nm using  ε=52,100 M-1 cm-1 (compound 7) and  ε=60,800 M-1 cm-1 
(compound 8). Polyamides were equilibrated with the radiolabeled DNA for 14 h prior to 
DNase I cleavage at 23 ºC. DNA was precipitated and subjected to gel electrophoresis as 
previously described. Quantitation by storage phosphor autoradiography and determination 
of equilibrium association constants were as previously described.27
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vi. Cell culture
The human  lung carcinoma cell line NCI-H82 (American Type Culture Collection 
HTB-175) was maintained in RPMI-1640 Medium (ATCC Catalog No. 30-2001) 
supplemented with L-glutamine (4 mM), penicillin/streptomycin (4 mM) and 10% 
fetal bovine serum (Irvine Scientific). Cell growth and morphology were monitored by 
phase-contrast microscopy.
The human  lung carcinoma cell line A549 (ATCC CCL-185) was maintained 
in F-12K Medium, (ATCC Catalog No. 30-2004) supplemented with L-glutamine 
(4 mM), penicillin/streptomycin (4 mM) and 10% fetal bovine serum as 
recommended by the ATCC. Cell growth and morphology were monitored by 
phase-contrast microscopy. 
The human breast adenocarcinoma cell line MCF-7 (American Type Culture 
Collection HTB-22) was maintained in Eagle’s Minimum Essential Medium (ATCC 
Catalog No. 30-2003), supplemented with 0.01 mg/ml bovine insulin; 10% fetal bovine 
serum, as recommended by the ATCC. Cell growth and morphology were monitored by 
phase-contrast microscopy. 
The human prostate adenocarcinoma cell line LnCaP (ATCC CRL-1740) was 
maintained in RPMI-1640 Medium (ATCC Catalog No. 30-2001), supplemented with 10% 
fetal bovine serum, as recommended by the ATCC. Cell growth and morphology were 
monitored by phase-contrast microscopy.
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vii. Confocal microscopy
Cells were trypsinized for 5-10 min at 37°C, centrifuged for 5 min at 2,000 rpm and 
5 °C in a Beckman-Coulter Allegra 6R centrifuge, and resuspended in fresh medium to 
a concentration of 1x106 cells per mL. Incubations were performed by adding 150 μL of 
cells into culture dishes equipped with glass bottoms for direct imaging (MatTek, Ashland, 
MA). The cells were grown in the glass-bottom culture dishes for 24 h. Then 5 μL of a 
60 μM polyamide solution was added and the cells. For verapamil-treated cells, 5 μL 
750 mM verapamil (±)  was added in addition to polyamide. The plates were then incubated in a 
5% CO2 atmosphere at 37 °C for 10-14 h. Imaging was performed with a 40x 
oil-immersion objective lens on a Zeiss LSM 5 Pascal inverted laser scanning microscope. 
Polyamide–fluorescein conjugate fluorescence and visible-light images were obtained 
using standard filter sets for fluorescein.46,47 12-Bit images were analyzed using Zeiss LSM 
and ImageJ software.
viii. Determination of relative mRNA levels via qRT-PCR
siRNA: 
Myc Validated Stealth DuoPak SKU# 12936-50, was purchased from Invitrogen. 
This included Duplex #1 and Duplex #2, of proprietary sequence and concentration. 
Stealth RNAi™ siRNA Negative Control Kit (Invitrogen, Cat. No. 12935-100) 
was purchased and the “Medium GC Duplex #1” was used. siRNA was transfected 
using LipofectamineRNAiMAX (Invitrogen, Cat. No. 13778-075) according to the 
manufacturer’s instructions. The amounts of these reagents used in most assays was 
1 μL Lipofectamine RNAiMax and 1.4 μL of supplied siRNA. 
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Note: at the time of the printing of this thesis, Invitrogen has discontinued the siRNA 
product described. Brief attempts to use the replacement product yielded poor results, but 
a thorough optimization of conditions was not performed.
RNA isolation:  
Cells were plated in 24-well dishes at a density of 40 x 104 cells/mL in 0.5 mL of 
culture medium without antibiotic supplements (which are lethal in combination with 
siRNA treatment) and allowed to attach for 16-20 hours. Polyamides or siRNA were added 
(according to instructions above) and the cells were incubated for 48 hours. The medium 
was removed, cells were washed with ice-cold PBS and immediately lysed with RLT buffer 
from an RNeasy kit (Qiagen). Further RNA isolation was carried out with the RNeasy kit 
as described in the manufacturer’s manual. The isolated total RNA was quantified. The 
yields were 12-15 μg per well. 
Reverse transcription:  
A 2.5 μg sample of total RNA was used to reverse-transcribe cDNA  using 
Superscript II reverse transcriptase (Invitrogen) according to the manufacturer’s protocol. 
Random hexamers were used as primers. The total volume for each RT reaction was 20 μl.
Real-time quantitative RT-PCR:
Analysis was performed using the Myc and eIF4E gene primers described below, 
purchased from Integrated DNA Technologies. Quantitative real-time RTPCR was 
performed using Applied Biosystems SYBR Green RT-PCR master mix according to 
the manufacturer’s instructions. Temperature cycling and detection of the SYBR Green 
emission were performed with an ABI 7300 real-time instrument using Applied Biosystems 
Sequence Detection System version 1.2. Statistical analysis was performed on three 
independent experiments. 
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To amplify the 88-bp fragment from the 3’-translated region of Myc:
Forward primer: 5’-CAGCGACTCTGAGGAGGAAC-3’ 
Reverse primer: 5’-CTCTGACCTTTTGCCAGGAG -3’ 
To amplify the 118-bp fragment from the 3’-translated region of eIF4E:
Forward primer: 5’-TTTTGGGCTCTGTACAACCA-3’ 
Reverse primer: 5’-CTCCCCGTTTGTTTTTCTCA -3’ 
RNA was standardized by quantification of the β-glucuronidase gene as an endogenous 
control,48 Using the following primers:
Forward primer: 5’-CTCATT TGGAATTTTGCCGATT -3’
Reverse primer: 5’- CCGAGTGAAGATCCCCTTTTTA -3’
ix. Determination of relative protein levels via Enzyme-Linked Immunosorbent Assay 
(ELISA) 
In collaboration with Nickolaus Krall, Summer Undergraduate Research Fellow 
(SURF) student, summer 2008:
Cells were incubated at 37 °C, 5% CO2. Cells were induced by the addition of 2 µl of 
1mg/ml doxycyclin (in H2O) to each well at the indicated time point for each experiment. 
At the indicated harvest time point for each experiment the cells were detached from the 
plates by the addition of trypsin. Cells were counted via hemocytometer and subsequently 
pelleted by centrifugation at 130 RCF for 10 minutes. The supernatant was removed and 
the pellet was rinsed twice with PBS and repelleted before the addition of RIPA buffer 
supplemented with protease inhibitor cocktail (PIC) and PMSF. Pellets were agitated by 
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pipetting and left on ice for 20-30 minutes before cell debris was pelleted by centrifugation 
at 1000 RCF for 5 minutes. The supernatant was transferred to a fresh tube and frozen at 
-80°C in an isopropanol slow-freeze bath.
Normalization
Frozen cell lysate was thawed on ice and adjusted to a constant protein or DNA 
concentration prior to determining eIF4E concentrations. Total protein concentration was 
determined with a Bradford assay.19 One ml of Bradford reagent (BioRAD) was added to 
10 µL of crude lysate and 10 µl of water contained in a 1 ml plastic cuvette and mixed 
vigorously. A ready-to-go BSA standard set (BioRAD) was used as a reference. One ml of 
Bradford reagent was added to 10 µl of BSA standard solution and 10 µl of RIPA buffer 
contained in a 1 ml plastic cuvette. The absorbance was measured at 595 nm (A
595
) with 
a UV/Vis Spectrometer (Agilent) and a linear standard curve constructed from the BSA 
reference dilutions. Using this standard curve total protein concentrations in samples were 
calculated from the A
595
. All measurements were carried out in duplicate and the average 
value used to adjust all samples to the same total protein concentration by dilution with 
appropriate amounts of RIPA buffer. For normalization to constant total DNA, DNA was 
extracted from crude cell lysate using a PCR purification kit (Qiagen). DNA content was 
measured with the built in function of a Nano Drop UV/Vis spectrophotometer and samples 
adjusted to the same DNA content with RIPA buffer.
eIF4E ELISA: 
96-well plates (Greiner BioOne Microlon 600) were coated overnight with donkey 
anti-mouse IgG (Jackson, 50µl of 5µg/ml antibody in PBS with 0.05% NaN
3
 per well, 
2-8°C). Plates were subsequently washed (3x 200µl of PBS with 0.05% Tween20 per 
well), then blocked (200 µl of 5% dry milk powder in PBS per well) for 1 h at room 
temperature.  Plates were washed again, then incubated with mouse anti-eIF4E IgG (BD 
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Signal Transduction Laboratories, 50 µl of a 1:450 dilution in antibody buffer [i.e., PBS, 
0.25% BSA and 0.05% Tween20] per well) for 1 h at room temperature. After another wash 
they were incubated with samples (50 µl per well) and standards (Globozymes recombinant 
eIF4E; 50µl of 200, 100, 50, 25, 15, 10, 5, 1 and 0.1 ng/ml in antibody buffer per well) for 1 
h at room temperature. Plates were then washed again and incubated with rabbit anti eIF4E 
(Cell Signaling, 50µl of a 1:1000 dilution in antibody buffer) for 1 h at room temperature, 
followed by another wash step. Plates were subsequently incubated with goat anti-rabbit 
IgG HRP conjugate (Jackson, 50µl of a 1:80,000 dilution in antibody buffer per well for 
1 h at room temperature), washed, and finally developed with TMB substrate (Sigma, 50 µl 
per well) After 30 minutes the reaction was stopped with an equal volume of 1 M HCl. The 
output signal was read as the absorbance at 450 nm (A450) with a Perkin Elmer multiwell 
plate reader. The absorbance of eIF4E standards was fit to a 4-parameter logistic curve17,18 
using Kaleida Graph and used to calculate unknown eIF4E concentrations in samples from 
A450 values.
Myc ELISA: 
The Myc ELISA closely followed the eIF4E ELISA protocol above but differed in 
choice and concentration of antibodies. Coating with donkey anti-IgG was carried out as 
described above. The secondary coating antibody was a monoclonal mouse anti-c-Myc 
IgG (Sigma, clone 9E10, 50 µl of a 1:300 dilution in antibody buffer per well). Incubation 
with samples was as above. The primary detection antibody was a polyclonal antibody 
rabbit anti c-Myc IgG raised against the 262 N-terminal amino acids (Santa Cruz, 50 µl of 
a 1:250 dilution in antibody buffer per well). The secondary detection antibody was a HRP 
conjugated goat anti-rabbit IgG (Jackson, 50 µl of a 1:20,000 dilution in antibody buffer).
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Appendix A
Progress Towards Incorporation of Furan Rings  
into Pyrrole-Imidazole Polyamides
The work outlined in this chapter was performed in collaboration with 
Daniel A. Gubler (California Institute of Technology).
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A.1 Introduction
Lipophilicity plays a role in the pharmacokinetic (PK) properties of lead structures 
for animal studies, including absorption, distribution, clearance, and metabolism. Recent 
in vitro ADMET analysis of a hairpin Py/Im polyamide revealed high levels of plasma 
protein binding characteristic of a highly lipophilic compound.1 As our research program 
using Py-Im polyamides moves from cell culture into small animal models, new monomers 
with comparable DNA-binding affinities to N-methylpyrrole (Py) and N-methylimidazole 
(Im) and decreased lipophilicity/increased water solubility may be desirable. The 
development and incorporation of such monomers into Py-Im polyamides would allow the 
ability to fine-tune the desired lipophilicity of a given polyamide by selectively mixing and 
matching rings.
In this regard, the recently discovered proximicin A-C natural products have drawn 
our attention due to their unique 4-aminofuran-2-carboxlic acid ring system and overall 
similarity to DNA minor groove-binding natural products netropsin (1) and distamycin (2) 
(Figure A.1). Proximicins A-C (3-5) possess dual amide-linked furan amino acids and an 
N-terminal methyl carbamate functionality. C-terminal functionalities consisting of an amide 
(proximicin A, 3), tyramine (proximicin B, 4), or tryptamine (proximicin C, 5) characterize 
each member of the proximicin family.  Evaluations of 3-5 against multiple cancer cell 
lines revealed promising antitumor activities, with GI
50
 values in the low micromolar 
range against gastric adenocarcinoma (AGS), hepatocellular carcinoma (HepG2), and 
breast adenocarcinoma (MCF7) cell lines.  These activities were significantly better than 
netropsin, distamycin, and analogous compounds to 3-5 that possess Py monomers in place 
of both furans.2, 3  
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Figure A.1 DNA-binding molecules with furan heterocycle constituents
Structures of netropsin (1), distamycin (2), proximicin A-C (3-5), and furan analogues of netropsin (6) and 
distamycin (7)
The furan amino acid is identical in shape to Py with the exception of the methylated 
ring nitrogen, which is replaced by oxygen, and this replacement is predicted to increase 
the water solubility of polyamide oligomers. Incorporation of the furan (Fn) monomer 
into polyamides designed to inhibit gene regulation in vivo may provide a polyamide that 
demonstrates a better set of physical properties with regard to efficacy in small animal 
models. Since the N-methyl nitrogen of Py units within a polyamide are positioned away 
from the H-bonding edges of the aromatic amino acid ring pairs, we expect that oxygen 
at this position will be tolerated in terms of minor-groove binding as well as sequence 
recognition.
It is speculated the electronics and overall polarity of the furan amino acid in 
comparison to Py contributes to their enhanced antitumor activities, thus there is even 
stronger reasoning to evaluate this heterocycle as a potential Py replacement in hairpin 
polyamides. Recent efforts by Süssmuth to incorporate the furan heterocycle into netropsin 
and distamycin analogues produced compounds whose binding affinity for DNA has 
been considerably compromised, as assessed by thermal DNA denaturation stabilization 
experiments.3 Süssmuth suggests that the lower stabilizing effect might be due to altered 
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stacking interactions resulting from the different electronic structures of the two heterocyclic 
cores. An additional suggestion for this result is that the N-methyl pyrrole of netropsin or 
distamycin is bulky and nonpolar within the proximity of the anionic backbone of the DNA 
whereas the furan ring’s free electron pair in this same position may lead to a repulsive 
interaction with the DNA backbone. We anticipate that these unfavorable interactions of 
the furan ring will be mitigated by incorporation within the context of a Py-Im polyamide, 
allowing the furan rings to increase polyamide solubility while the Im and Py rings maintain 
high DNA-binding character.
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A.2 Experimental Design
I. Design and partial synthesis of a Py-Im-Fn polyamide library to bind 5’-WGGWCW-3’ 
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Figure A.2 Furan monomers incorporated into 5’-WGGWCW-3’targeted polyamide scaffold 
We designed a library of polyamides targeting the sequence 5’-WGGWCW-3’ (where 
W = A or T) (Figure). This scaffold was chosen because it allows for the assessment of 
several characteristics of the furan amino acid within a series of analogs (Figure A.2). As 
shown in Figure A.3, by altering which position of the parent Py-Im polyamide is altered 
to a furan we can assess the unit’s specificity in all combinations of ring pairs: Im/Fn (2), 
Py/Fn (3), Fn/Im (4), Fn/Py (5) and Fn/Fn (6). Also, by incrementally increasing the number 
of furan rings incorporated into the polyamide (7-9), we can assess the combinatorial effect 
of multiple rings on lipophilicity. 
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Figure A.3 Py-Im-Fn polyamide library designed to test specificity and lipophilicity
Compounds 2-9 are based on the Im-Py scaffold 1. 2-6 allow for the measurement of specificity of Fn rings 
in the context of polyamide pairing rules. 7-9 allow for the measurement of lipophilicity in the context of 
increasing furan monomer content.
The synthesis of the Boc-protected furan monomer unit reported by Süssmuth3 is robust 
and we were able to report similar yields and purity in the synthesis of this monomer unit. 
Unfortunately, incorporation of the Fn monomer unit into Py-Im polyamides by solid-phase 
synthesis on oxime resin was not trivial, as the furan monomer was sensitive to the acidic 
conditions used for Boc removal. Excessive decomposition of the growing polymer chain 
was encountered following each trifluoroacetic acid deprotection. Attempts to use Lewis 
acid deprotection strategies (boron trifluoride diethyl etherate, trimethylsilyl chloride) 
were more successful, however, successive exposure of the oxime resin to the Lewis 
acid conditions appeared to destroy the oxime resin itself and resulted in decomposition 
or loss of the polyamide from the resin. Critically, polyamides containing Fn rings, 
once synthesized, appear to be as stable to light and heat as typical Py-Im polyamides 
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and remain pure by HPLC analysis even after being in solution at room temperature for 
several days. Because compounds 4, 5, and 7 require the least cycles of exposure of the 
furan monomer to acidic conditions, small amounts of these compounds were successfully 
obtained following repeated preparatory HPLC purification of the crude product cleaved 
from resin. These compounds along with the parent compound 1 were analyzed for binding 
affinity and lipophilicity. 
II. Assessment of relative binding affinities and specificities of partial library
Polyamides 1, 4, 5, and 7 were screened for favorable binding affinities and specificities 
by melting temperature analysis of duplex DNA4 containing the sequence 5’-TGGXCA 
-3’ where X was cycled through the four base pair possibilities. On each of the four 
5'- C G A T G G X C A A G C -3'
3'- G C T A C C X G T T C G -5'
A-T T-A G-C C-G
58.0 ± 0.2DNA only 58.2 ± 0.5 59.6 ± 0.1 59.8 ± 0.3
76.2 ± 1.9
[18.2]
1
76.2 ± 2.3
[17.9]
71.2 ± 0.2
[11.7]
72.3 ± 0.3
[12.4]
73.8 ± 0.3
[15.8]
4 75.2 ± 1.5
[17.0]
69.9 ± 0.1
[10.3]
70.0± 0.4
[10.1]
76.6 ± 1.1
[18.6]
5 77.1 ± 0.8
[18.9]
70.8 ± 0.6
[11.9]
72.9 ± 0.3
[13.1]
73.2 ± 1.3
[15.2]
7 74.6 ± 1.0
[16.3]
68.5 ± 0.5
[8.6]
69.1 ± 0.3
[9.3]
+ +
+ +
F
+ +
F
+ +
F F
Table A.1 Assessment of binding affinities and specificities of compounds 1, 4, 5, and 7
Melting temperature studies of duplex DNA (2 nmoles/oligo) treated with polyamides  (2.0-2.4 nmoles). 
Averages and S.D. were calculated from at least three analyses.  Values in brackets represent ∆Tm versus 
untreated DNA duplex.
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duplexes tested, the furan-containing polyamides display similar duplex stabilization to 
the parent compound, indicating that the binding affinity and specificity of the polyamide 
is likely not adversely affected by the incorporation of furan rings. This is particularly 
exciting considering the severe loss of DNA stabilization demonstrated by furan analogs 
of netropsin.3
III. Assessment of relative lipophilicity of partial library as analyzed by LogDoctanol/water at 
pH 7.4.
Small molecule lipophilicity is most commonly described by its octanol/water partition 
coefficient (Logoct/water). The partition coefficient is a ratio of concentrations of un-ionized 
compound between the two solutions. To measure the partition coefficient of ionizable 
solutes, the pH of the aqueous phase is adjusted such that the predominant form of the 
compound is un-ionized. The logarithm of the ratio of the concentrations of the un-ionized 
solute in the solvents is the LogP (Eq 1). 
log P          = 
[solute]
(1)oct/wat log
octanol
[solute]water( (un-ionizedun-ionized
The distribution coefficient is the ratio of the sum of the concentrations of all forms of 
the compound (ionized plus un-ionized) in each of the two phases.. The logarithm of the 
ratio of the sum of concentrations of the solute’s various forms in one solvent, to the sum 
of the concentrations of its forms in the other solvent is called LogD (Eq 2). In addition, 
LogD is pH dependent, hence one must specify the pH at which the LogD was measured. 
log D          = [solute] (2)oct/wat log octanol[solute]water( (un-ionizedun-ionized [solute]octanol[solute]waterionizedionized++
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Lipophilicity, as predicted by LogP and LogD, is an important predictor of oral 
bioavailability for test compounds. Of particular interest in the context of lead structures 
for animal studies is the LogD at pH = 7.4 (the physiological pH of blood serum). A variety 
of protocols have been reported for measuring LogP or LogD both experimentally and 
computationally. (5-7) The LogD and pH 7.4 of compounds 1, 5, and 7 was determined 
via a miniaturized octanol/water shake-flask assay through the commercial services of 
Analiza, Inc. 
For octanol/buffer partitioning, Analiza’s standard two phase system plates were used. 
Octanol in equilibrium with universal buffer adjusted to pH 7.4 were used to prepare 
partitioning plates for the assay. The initial assay was designed to measure the LogD of the 
compounds starting with a 10 mM stock solution, with a final working concentration of 
1 mM. At this concentration, the compounds displayed significant aggregation in the octanol 
layer, a behavior often noted in compounds with higher molecular weights. To compensate, 
the compounds were diluted to 1 mM stock solution, providing a final working concentration 
of 0.1 mM. At this concentration, the compounds were able to be measured with the 
exception of compound 4, which still displayed aggregation. Unexpectedly, the decrease in 
LogD over this series of increasing furan content is quite modest.
LogD LogD*
-0.951 -0.75
n.d.2 n.d.
-0.973 -0.77
-1.014 -0.80
+ +
+ +
F
+ +
F
+ +
F F
Table A.2 LogD at pH 7.4 of compounds 1, 4, 5, and 7 at 0.1 mM concentration
LogD* values have been corrected for DMSO background
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A.3 Future Directions
The binding measurements of the compounds synthesized show promise, however 
the modest decrease in lipophilicity observed is dissapointing. It may be that compound 
containing a large percentage of furans will show more promise, thus the remaining 
compounds of the library should be synthesized. Considering the instability of the furan 
monomer unit to the acid conditions required by Boc peptide chemistry, a promising 
route is to instead utilize Fmoc-based peptide chemistry. This alternate protecting group 
methodology has been successfully utilized in synthesizing Py-Im polyamides and we 
suspect will be much milder on the furan monomer during synthesis.8 Once the entire 
library has been synthesized, lipophilicity measurements will be performed and, following 
this, the compounds will be tested in a protein-binding assay to determine if this alteration 
has the desired effect of decreasing the protein binding characteristic of Py-Im polyamides.
A.4 Synthetic Efforts
At the beginning of this project, the synthesis of furan amino acid F had not been 
reported. Accordingly, we set out to synthesize this monomer; a summary of our progress 
is shown in Scheme 2. The synthesis, developed by D. Gubler, began from commercially 
available 4-bromo-2-furaldehyde 16 and converted to carbamate 17 in three steps. The 
key step of this sequence, and of the entire synthesis, was a copper-catalyzed coupling of 
the 4-bromofuran intermediate with Boc carbamate. Unfortunately, the copper-catalyzed 
coupling reaction did not work on starting material 16 or its carboxylic acid derivative. 
Consequently, the coupling reaction was performed at the alcohol oxidation state, which, 
unfortunately, required two steps for reduction and protection of the alcohol followed by 
two steps for oxidation to give aldehyde 18. 
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Scheme A.1 Attempted synthesis by D. Gubler of furan monomer Fn.
O
Br
CHO
1. NaBH4, MeOH, 94%
2. TBSOTf, Et3N, DMAP, 98%
3.CuI, ligand, K2CO3, BocNH2, 80%
O
BocHN
OTBS
1. TBAF, 89%
2. TPAP, NMO, 76% O
BocHN
CHO
[O]
O
BocHN
CO2H
14
15 16
17
About the same time we obtained aldehyde 18, the synthesis of 4-aminofuran-
2-carboxylic acid F was reported by Süssmuth along with the total synthesis of the 
proximicins.3 This synthesis of Fn proved to be more amendable for rapid, gram scale 
synthesis than our route.
In addition to the furan monomer analog of Py, 4-amino-1,3-oxazole-2-carboxylic acid 
(Ox) has been proposed as a more hydrophilic analogue of Im. D. Gubler developed a 
synthetic route to the oxazole amino acid monomer which is very robust and can be done 
on multi-gram scale. The synthesis of oxazole monomer 22 starts from known oxazole 18.9 
Saponification of oxazole 18 followed by Curtius rearrangement gave Boc carbamate 19 
in 65% yield. Dihydroxylation of Boc carbamate 19 using osmium tetroxide followed by 
cleavage of the resultant diol with sodium periodate furnished aldehyde 20 in 73% yield 
for the two steps. Oxidation of aldehyde 20 with manganese dioxide and sodium cyanide 
provided methyl ester 21. Saponification of ester 21 smoothly furnished oxazole monomer 
22 in good yield.
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N
EtO2C
Ph
1. LiOH, THF/H2O, 99%
2. EtO2CCl, Et3N, NaN3
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Scheme A.2 Synthesis of oxazole monomer Ox by D. Gubler
 
 Unfortunately, initial attempts to couple oxazole monomer 22 into Py/Im polyamides 
has not been successful to date. Decomposition is seen in the coupling step under the stan-
dard coupling conditions of either PyBop/DIEA or EDCI/DMAP. Although initial forays 
into this area have been discouraging, more effort is needed for an accurate assessment of 
the feasibility of working with this monomer. 
A.5 Materials and Methods
Materials
Unless otherwise stated, DNA oligonucleotides were ordered HPLC-purified from 
Integrated DNA Technologies. Unless otherwise stated, reagents were purchased 
from Sigma-Aldrich. All solvents were purchased from Aldrich or EMD Biosciences. 
Commercially obtained reagents were used as received. Reaction temperatures were 
controlled by an IKAmag temperature modulator. Thin-layer chromatography (TLC) was 
performed using E. Merck silica gel 60 F254 precoated plates (0.25 mm) and visualized by 
UV fluorescence quenching. ICN Silica gel (particle size 0.032-0.063 mm) was used for 
flash column chromatography. 
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Methods
UV spectra were recorded using an Agilent 8453 UV-Vis spectrophotometer. 
Polyamide concentrations were measured as a solution in water at λ=310 nm using 
an estimated extinction coefficient of ε=69,500 M-1 cm-1 for 8-ring polyamides.39 
LASER desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) 
was performed using an Applied Biosystems Voyager DE Pro spectrometer. Analytical 
and preparative high-pressure liquid chromatography (HPLC) were performed with a 
Beckman Gold system equipped with a diode array (analytical) or single-wavelength 
(preparative) detector. 1H NMR spectra were recorded on a Varian Mercury 300 (at 300 
MHz) or a Varian Inova 500 (at 500 MHz) and are reported relative to solvent peak. Data 
for  1H NMR spectra are reported as follows: chemical shift (ppm) (multiplicity, integration, 
coupling constant (Hz)). 13C NMR spectra were recorded on a Varian Inova 500 (at 125 
MHz) and are reported relative to solvent peak. Data for 13C NMR spectra are reported in 
terms of chemical shift. High-resolution mass spectra were obtained from the California 
Institute of Technology Mass Spectral Facility.
i. Furan monomer synthesis
O
OHC morpholine, n-BuLi
s-Buli, MeOCOCl
O CO2Me
Pinnick
Oxidation
O
HO2C
CO2Me
DPPA
t-BuOH O
BocHN
CO2Me
0.1 N LiOH
O
BocHN
CO2H
OHC
10 11 12
13 14
Scheme A.3 Synthesis of Boc-protected Fn monomer as reported by Süssmuth.
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Synthesis of furan monomer was performed exactly as described by the literature 
procedure3:
4-Formyl-furan-2-carboxylic acid methyl ester (11). Morpholine (952 mg, 10.93 
mmol, 1.05 eq) was dissolved in THF (75 mL) and cooled to -78 °C under argon. To 
this solution n-BuLi (6.830 mL, 1.6 M in hexane, 1.05 eq) was added dropwise and the 
resulting slightly yellow solution was stirred for further 20 min and then 3-furaldehyde 
(10, 1000 mg, 10.41 mmol, 1.0 eq) dissolved in THF (2 mL) was added dropwise. 
After another 20 min s-BuLi (8.406 mL, 1.3 M in cyclohexane, 1.05 eq) was added 
dropwise. The resulting suspension was stirred at -78 C for 2.5 h. Methyl chloroformate 
(1082 mg, 11.45 mmol, 1.1 eq) was dissolved in THF (2 mL) and added dropwise and 
the reaction mixture was stirred for 45 min at this temperature an additional 40 min at 
room temperature. The solution was poured into ice cold 10 % HCl and the layers were 
separated and the aqueous phase was extracted with Et2O (4 x 50 mL). The combined 
organic phases were dried over MgSO
4
, filtered, and concentrated under reduced 
pressure to give the crude product, which was purified by column chromatography 
(silica gel, hexanes/EtOAc 7/1) to yield 460 mg (30%) of the desired compound. 
1H NMR δH (300 MHz; CDCl
3
) 3.93 (s, 3H), 7.49 (d, 1H, J=0.6), 8.17 (d, 1H, J=0.8), 9.96 
(s, 1H).
O
OHC morpholine, n-BuLi
s-Buli, MeOCOCl
O CO2Me
OHC
10 11
168
O CO2Me
Pinnick
Oxidation
O
HO2C
CO2Me
OHC
11 12
Furan-2,4-dicarboxylic acid 2-methyl ester (12). Compound 11 (860 mg, 5.58 mmol, 1.0 
eq) was dissolved in t-BuOH (138 mL) and 2-methyl-2-butene (34 mL). 80 % NaClO2 
(5.93 g, 52.45 mmol, 9.4 eq) and NaH2PO4•2H2O (6.094g, 39.06 mmol, 7.0 eq) were dis-
solved in H2O (54 ml) and slowly added to a stirring solution of the aldehyde. The reaction 
was stirred for 50 min at room temperature. Then 2-methyl-2-butene and t-BuOH were 
removed under reduced pressure and the residue was diluted with water and extracted with 
hexane (3 x 50 mL). The aqueous phase was acidified to pH 2 with 10 % HCl and extracted 
with EtOAc (3 x 50 mL). The organic phases were combined and dried over Na2SO4, fil-
tered and concentrated under reduced pressure. This slightly yellow solid was washed with 
CHCl
3
, yielding the title compound as a colorless solid (710 mg, 75 %). 
1H NMR δH (300 MHz; DMSO-d6) 3.82 (s, 1H), 7.40 (d, 2H, J=), 8.54 (d, 2H, J=0.83), 
13.10 (brs, 1H).
O
HO2C
CO2Me
DPPA
t-BuOH O
BocHN
CO2Me
12
13
 
 4-tert-Butoxycarbonylamino-furan-2-carboxylic acid methyl ester (13). To a solution 
of the acid 12 (1.3 g, 7.68 mmol, 1.0 eq) in CH
3
CN (1 mL/mmol) were added sequentially 
triethylamine (1.069 mL, 7.68 mmol, 1.0 eq) and DPPA (1.657 mL, 7.68 mmol, 1.0 eq). 
This solution was stirred at RT for 3.5 h. Then t-BuOH (0.95 mL/mmol) was added in one 
portion and the resulting mixture was stirred under reflux for 24 h. The mixture was cooled 
to room temperature, poured into saturated NaHCO
3
 (50 mL), and extracted with Et2O (3 x 
50 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated 
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under reduced pressure. The crude product was purified by flash chromatography (silica 
gel, 7/1, hexane/EtOAc), yielding the title compound as a slightly yellow 
solid (1.4 g, 78 %).1H NMR δH (300 MHz; CDCl
3
) 1.49 (s, 9H), 3.87 (s, 3H), 6.36 (brs, 
1H), 7.00 (s, 1H), 7.88 (brs, 1H).
O
BocHN
CO2Me
0.1 N LiOH
O
BocHN
CO2H
13 14
 4-tert-Butoxycarbonylamino-furan-2-carboxylic acid (14). To a solution of ester 13 
(374 mg, 1.55 mmol, 1.0 eq) in THF (78 mL), LiOH (186 mg, 7.75, 5.0 eq) dissolved in 
H2O (78 mL) was added dropwise. After stirring for 1.5 h at room temperature the reaction 
mixture was concentrated under reduced pressure and diluted with water. The solution was 
acidified to pH 3 by adding 10% HCl and extracted with EtOAc (3 x 40 mL). The com-
bined organic phases were dried over Na2SO4, filtered, and the solvent was removed under 
reduced pressure, yielding the title compound as a yellow solid (345 mg, quant. yield). 
1H NMR δH (500 MHz; DMSO-d6) 1.44 (s, 9H), 6.97 (s, 1H), 7.85 (s, 1H), 9.43 (s, 1H), 
13.08 (brs, 1H). 13C NMR δC (125 MHz; DMSO-d6) 28.46, 79.92, 111.47, 127.71, 133.60, 
143.32, 153.00, 159.58. EI-HRMS m/z 227.0791 [M+•, C10H13O5N1 requires 241.0794].
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ii. Polyamide synthesis  
Pyrole and imidazole monomer units [Boc-Py-OBt (1,2,3-Benzotriazol-1-yl 4-[(tert-
Butoxycarbonyl)amino]-1-methylpyrrole-2-carboxylate) and Boc-Im-OH (4-[(tert-
Butoxycarbonyl)amino]-1-methylimidazole-2-carboxylic acid) respectively] are 
synthesized according to established protocols10 and maintained as general group stock. 
Fmoc-D(Dab)-Boc-OH turn monomer unit  was purchased from Peptides International. 
Polyamides 1, 4, 5, and 7 were synthesized by solid-phase methods on Kaiser oxime 
resin (Nova Biochem, Darmstadt, Germany) following established protocols,11 with the 
exception of the Boc deprotection step. In a typical synthesis, 4 molar equivalents (relative 
to resin loading for the lot of oxime resin used) of monomer unit were activated with 
4 equivalents of PyBOP (NovaBiochem) and 4 equivalents of diisopropyletheylamine 
(DIEA) in a solution of dimethylformamide (DMF) (solution was approximately 0.3-0.5 M 
in monomer unit). In a glass peptide synthesis vessel, the resin was shaken with this solution 
for 2-4 hours at room temperature until the reaction was complete, as assessed by analytical 
HPLC of a cleaved sample of resin. Resin was deprotected by shaking in a solution of 
5 equivalents boron trifluoride diethyl etheraate (BF
3
•Et2O) in methylene chloride for 5 
minutes at room temperature. After completion of synthesis the polyamide was cleaved by 
incubation in neat 3-dimethylamino-1-propylamine (0.3 mL) at 37 °C for 16 h. Products 
were purified by preparatory reverse-phase HPLC on a Beckman Gold system using either 
a Waters Delta-Pak 25°—100 mm, 15 μm 300 Å C18 PrepPak Cartridge reverse-phase 
column or a Varian Dynamax 21.4°—250 mm Microsorb 8 μm 300 Å C8 reverse-phase 
column in 0.1% (w/v) TFA with acetonitrile as the eluent. The appropriate fractions were 
lyophilized after characterization by analytical HPLC, UV-visible spectroscopy, and 
MALDI-TOF mass spectrometry. 
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1: (MALDI-TOF) [M+H]+ calcd for C
54
H
67
N22O9
+ 1167.6, observed 1167.6
4: (MALDI-TOF) [M+H]+ calcd for  C
53
H
64
N21O10
+ 1154.5, observed 1154.6
5: (MALDI-TOF) [M+H]+ calcd for C
53
H
64
N21O10
+ 1154.5, observed 1154.6
7: (MALDI-TOF) [M+H]+ calcd for C
52
H61N20O11
+ 1141.5, observed 1141.7
iii. UV Absorption Spectrophotometry of of DNA thermal stabilization
Melting temperature analysis was performed on a Varian Cary 100 spectrophotometer 
equipped with a thermo-controlled cell holder possessing a cell path length of 1 cm. An 
aqueous solution of 10 mM sodium cacodylate, 10 mM KCl, 10 mM MgCl2, and 5 mM 
CaCl2 at pH 7.0 was used as analysis buffer. This buffer was degassed under vacuum and 
DNA duplexes and polyamides were added to a final concentration of 2 μM DNA, 3μM 
polyamide for each experiment. Prior to analysis, samples were heated to 90 °C and cooled 
to a starting temperature of 23 °C with a heating rate of 5 °C/min for each ramp. Denaturation 
profiles were recorded at λ = 260 nm from 23 to 90 °C with a heating rate of 0.5 °C/min. 
Each sample was subjected to denaturation in technical duplicate, and the reported numbers 
are the average of at least three experimental replicates. The reported melting temperatures 
were defined as the maximum of the first derivative of the denaturation profile.
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iv. LogD Analysis
LogD analysis was performed by Analiza, Inc., information can be found at 
http://www.analiza.com. The following description regarding experimental protocol was 
provided by the company.
Sample Preparation:
The DMSO stock solutions were sonicated in a 40°C water bath to facilitate dissolution. 
Following sonication all of the samples appeared to be fully dissolved. Due to aggregation 
in the two phase system, the compounds were diluted to 1mM from the original 10mM 
DMSO stock and analyzed further. Note that for compounds 5 and 7, some material 
accumulated at the interface of the octanol/water partition even at the diluted range.
Partitioning:
For octanol/buffer partitioning, Analiza’s standard two phase system plates were used. 
Octanol in equilibrium with universal buffer (composed of 0.15 M NaCl and 0.01 M each 
of phosphoric, boric, and acetic acids, adjusted to pH 7.4 with NaOH) were used to prepare 
partitioning plates for the assay. This buffer provides uniform ionic composition across 
a wide pH range. DMSO stock solutions (25μL) were added to each partitioning plate to 
a final concentration of 10% DMSO. The plates were sealed, vortexed on our specially 
designed deep well plate mixer, and centrifuged to aid in phase settling. The assay was 
conducted on the ADW workstation using chemiluminescent nitrogen detection.
Three separate on-board performance indicating standards were assayed with the 
Caltech supplied compounds and all results were within the acceptable range.
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Calculation of Results:
The equimolar nitrogen response of the detector is calibrated using standards which 
span the dynamic range of the instrument from 0.08 to 4500 μg/ml nitrogen. Both the top 
and bottom phases were quantitated with respect to this calibration curve and the logarithm 
of the ratio of the concentration in the top phase to the concentration in the bottom phase 
is calculated as the partition coefficient. In addition to reporting the directly observed Log 
D value, the observed Log D value was adjusted to a corrected Log D* based upon our 
previous work correlating Log D in the presence and absence of a fixed amount of DMSO 
in the partitioning system.
The calculated Log D and Log D* values are corrected for any background nitrogen 
in the DMSO. The Log D results presented assume that the samples were free of nitrogen 
containing impurities and are stable under the assay conditions.
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